[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnOE0mncstQh8xm6G0BrrCy7ssNuTx0a4-gQxksgNpQ0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Radboud University Medical Center",[4],971,false,130,57,572490,599,[13,16,19,22,24,27,29,32],{"name":14,"count":15},"Parkinson Disease",22,{"name":17,"count":18},"Endotoxemia",18,{"name":20,"count":21},"Cancer",15,{"name":23,"count":21},"Colorectal Cancer",{"name":25,"count":26},"HIV Infections",14,{"name":28,"count":26},"Prostate Cancer",{"name":30,"count":31},"Breast Cancer",13,{"name":33,"count":31},"Sepsis",[35,40,45,50,55,59,63,68,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05387655","Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases","2023-05-15","BCG",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT01792934","Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases","2025-01","XELOX regimen according to standard procedures",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04751786","Dose Escalation Study of Immunomodulatory Nanoparticles","2025-07","PRECIOUS-01",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06624436","Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia","2025-09","Dexamethasone",{"nctId":56,"briefTitle":57,"date":53,"intervention":58},"NCT06422494","The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II","hyperinsulinaemic hypoglycaemic clamp",{"nctId":60,"briefTitle":61,"date":53,"intervention":62},"NCT05513365","Phase II Dutasteride in Combination With CAB vs CAB in SDC","Goserelin 10.8 mg",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05917275","Multi-Omics to Predict the Blood Pressure Response to Antihypertensives","2025-10","Amlodipine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06218069","Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor","2025-12","Sasanlimab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05986968","Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage","2025-12-01","Ticagrelor",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05162742","Colchicine and Inflammation in Aortic Stenosis","2025-12-22","Colchicine",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,135,175,211,236,264,282,308,326,344,369,397,415,433,451,477,560,626,665,691,717,735,761,787,813,831,857,879,897,925,951,977,995,1019,1062,1087,1113,1138,1162,1180,1198,1225,1245,1270,1288,1313,1331,1376,1421,1451,1478,1508,1534,1552,1570,1588,1606,1632,1710,1762,1812,1856,1905,1946,1981,2015,2047,2078,2112,2138,2161,2189,2213,2231,2256,2280,2298,2323,2341,2359,2382,2407,2425,2454,2472,2490,2523,2541,2559,2577,2595,2613,2631,2655,2679,2703,2721,2743,2770,2788,2814,2832,2856,2874,2892,2919,2937,2955,2979,3004,3022,3048,3066,3084,3112,3130,3155,3173,3191,3209,3227,3251,3269,3293,3317,3340,3358,3384,3402,3420,3450,3468,3486,3504,3522,3546,3573,3591,3615,3633,3651,3669,3687,3712,3730,3754,3772,3799,3827,3845,3882,3916,3953,3982,4004,4029,4054,4072,4090,4114,4139,4157,4175,4200,4225,4249,4267,4292,4316,4340,4364,4387,4405,4427,4454,4477,4495,4520,4538,4556,4579,4613,4649,4681,4713,4744,4779,4806,4846,4881,4911,4944,4970,4994,5018,5036,5054,5076,5102,5126,5150,5168,5193,5211,5237,5261,5286,5304,5322,5345,5373,5391,5409,5430,5456,5474,5496,5517,5539,5561,5586,5609,5632,5650,5673,5696,5714,5738,5756,5781,5799,5817,5839,5861,5884,5907,5934,5958,5976,6002,6026,6048,6066,6084,6107,6133,6158,6182,6204,6226,6244,6269,6287,6305,6328,6354,6376,6400,6425,6448,6474,6498,6523,6548,6575,6599,6617,6643,6661,6684,6708,6732,6756,6777,6801,6824,6847,6865,6886,6909,6927,6950,6972,6998,7020,7043,7061,7084,7108,7129,7150,7168,7190,7208,7230,7254,7278,7299,7322,7345,7370,7388,7406,7424,7445,7463,7487,7511,7534,7557,7575,7593,7611,7633,7651,7674,7701,7726,7744,7762,7783,7805,7823,7841,7859,7882,7905,7923,7947,7971,7989,8046,8105,8154,8198,8232,8275,8311,8351,8387,8420,8454,8484,8510,8548,8585,8611,8637,8659,8681,8703,8725,8749,8775,8813,8845,8876,8898,8926,8948,8975,9006,9041,9066,9102,9126,9144,9162,9180,9205,9223,9241,9259,9277,9295,9321,9339,9361,9384,9402,9420,9438,9456,9479,9507,9530,9553,9571,9593,9616,9643,9661,9679,9697,9719,9737,9760,9778,9796,9819,9841,9863,9888,9906,9927,9950,9975,10002,10020,10042,10065,10088,10112,10130,10148,10172,10190,10208,10232,10250,10272,10290,10316,10334,10357,10375,10398,10419,10437,10458,10480,10498,10516,10538,10556,10574,10598,10616,10634,10652,10670,10688,10706,10724,10742,10766,10787,10805,10823,10841,10859,10877,10895,10917,10942,10967,10993,11014,11032,11050,11068,11086,11104,11122,11140,11158,11176,11200,11224,11242,11263,11285,11303,11324,11342,11360,11386,11404,11422],{"intervention":92,"totalTrials":93,"cells":94},"Cobicistat",2,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":133},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":111},"NCT02565888","A Drug-drug Interaction Study Between Daclatasvir and Atazanavir\u002FRitonavir or Atazanavir\u002FCobicistat","COMPLETED",[85],"2016-01","2015-11",16,[109,110],"Hepatitis C","HIV",[112,113,114,92],"Daclatasvir","Atazanavir","Ritonavir",{"trials":116,"activeCount":97},[],{"trials":118,"activeCount":97},[],{"trials":120,"activeCount":132,"soonestReadout":126},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT05078671","Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness","RECRUITING",[88],"2025-12-31","2021-12-15",160,[20],[131,92],"Olaparib",1,{"trials":134,"activeCount":97},[],{"intervention":54,"totalTrials":93,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":173},{"trials":138,"activeCount":97},[],{"trials":140,"activeCount":97},[],{"trials":142,"activeCount":97},[],{"trials":144,"activeCount":97},[],{"trials":146,"activeCount":132,"soonestReadout":53},[147,158],{"nctId":51,"briefTitle":52,"status":124,"phases":148,"primaryCompletion":53,"completion":71,"start":149,"enrollment":150,"conditions":151,"interventions":156},[88],"2024-10-24",52,[33,152,153,17,154,54,155],"Neuroinflammatory Response","Immunosuppresion","Anakinra","Tocilizumab",[54,155,154,157],"LPS",{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT03017391","Treatment Algorithm for Nausea and Vomiting in the Palliative Phase","UNKNOWN",[88],"2018-04","2017-01",20,[167,168,20],"Nausea","Vomiting",[170,171,54,172],"metoclopramide","granisetron","Granisetron 2Mg",{"trials":174,"activeCount":97},[],{"intervention":176,"totalTrials":93,"cells":177},"Hydrochlorothiazide",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":209},{"trials":179,"activeCount":97},[],{"trials":181,"activeCount":97},[],{"trials":183,"activeCount":97},[],{"trials":185,"activeCount":97},[],{"trials":187,"activeCount":132,"soonestReadout":66},[188,197],{"nctId":64,"briefTitle":65,"status":124,"phases":189,"primaryCompletion":66,"completion":66,"start":190,"enrollment":191,"conditions":192,"interventions":194},[88],"2024-04-04",96,[193],"Primary Hypertension",[67,195,176,196],"Olmesartan","Amlodipine\u002FOlmesartan",{"nctId":198,"briefTitle":199,"status":103,"phases":200,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":206},"NCT00457483","Nijmegen Antihypertensive Management Improvement Study",[88],"2010-12","2011-03","2007-08",120,[193],[207,208],"hydrochlorothiazide","valsartan, 80 mg once-a-day",{"trials":210,"activeCount":97},[],{"intervention":212,"totalTrials":132,"cells":213},"botulinum toxin",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":234},{"trials":215,"activeCount":97},[],{"trials":217,"activeCount":97},[],{"trials":219,"activeCount":97},[],{"trials":221,"activeCount":97},[],{"trials":223,"activeCount":132,"soonestReadout":228},[224],{"nctId":225,"briefTitle":226,"status":124,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT06411028","Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia",[88],"2027-05-30","2025-01-01",60,[232],"Dystonic Tremor Syndrome",[212],{"trials":235,"activeCount":97},[],{"intervention":237,"totalTrials":132,"cells":238},"levosimendan",{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":262},{"trials":240,"activeCount":97},[],{"trials":242,"activeCount":97},[],{"trials":244,"activeCount":97},[],{"trials":246,"activeCount":97},[],{"trials":248,"activeCount":132,"soonestReadout":253},[249],{"nctId":250,"briefTitle":251,"status":124,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":260},"NCT07105202","Shorter Weaning From Invasive Ventilation With Levosimendan",[88],"2027-08-01","2028-08-01","2025-09-17",250,[258,259],"Mechanical Ventilation","Weaning Failure",[237,261],"Soluvit",{"trials":263,"activeCount":97},[],{"intervention":261,"totalTrials":132,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":97},[],{"trials":269,"activeCount":97},[],{"trials":271,"activeCount":97},[],{"trials":273,"activeCount":97},[],{"trials":275,"activeCount":132,"soonestReadout":253},[276],{"nctId":250,"briefTitle":251,"status":124,"phases":277,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":278,"interventions":279},[88],[258,259],[237,261],{"trials":281,"activeCount":97},[],{"intervention":283,"totalTrials":132,"cells":284},"Methylphenidate Hydrochloride",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":306},{"trials":286,"activeCount":97},[],{"trials":288,"activeCount":97},[],{"trials":290,"activeCount":97},[],{"trials":292,"activeCount":97},[],{"trials":294,"activeCount":132,"soonestReadout":299},[295],{"nctId":296,"briefTitle":297,"status":124,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":21,"conditions":302,"interventions":305},"NCT06465641","Methylphenidate in KBG Syndrome: N-of-1 Series",[88],"2027-01-01","2027-10-01","2024-11-13",[303,304],"Kbg Syndrome","ADHD - Combined Type",[283],{"trials":307,"activeCount":97},[],{"intervention":131,"totalTrials":132,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":324},{"trials":311,"activeCount":97},[],{"trials":313,"activeCount":97},[],{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":132,"soonestReadout":126},[320],{"nctId":122,"briefTitle":123,"status":124,"phases":321,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":322,"interventions":323},[88],[20],[131,92],{"trials":325,"activeCount":97},[],{"intervention":155,"totalTrials":132,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":342},{"trials":329,"activeCount":97},[],{"trials":331,"activeCount":97},[],{"trials":333,"activeCount":97},[],{"trials":335,"activeCount":97},[],{"trials":337,"activeCount":132,"soonestReadout":53},[338],{"nctId":51,"briefTitle":52,"status":124,"phases":339,"primaryCompletion":53,"completion":71,"start":149,"enrollment":150,"conditions":340,"interventions":341},[88],[33,152,153,17,154,54,155],[54,155,154,157],{"trials":343,"activeCount":97},[],{"intervention":345,"totalTrials":132,"cells":346},"Nitrofurantoin",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":367},{"trials":348,"activeCount":97},[],{"trials":350,"activeCount":97},[],{"trials":352,"activeCount":97},[],{"trials":354,"activeCount":97},[],{"trials":356,"activeCount":132,"soonestReadout":361},[357],{"nctId":358,"briefTitle":359,"status":124,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":366},"NCT05652374","Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study",[88],"2027-10","2022-10-20",100,[365],"Recurrent Urinary Tract Infection",[345],{"trials":368,"activeCount":97},[],{"intervention":370,"totalTrials":132,"cells":371},"Hydroxychloroquin",{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":395},{"trials":373,"activeCount":97},[],{"trials":375,"activeCount":97},[],{"trials":377,"activeCount":97},[],{"trials":379,"activeCount":97},[],{"trials":381,"activeCount":132,"soonestReadout":387},[382],{"nctId":383,"briefTitle":384,"status":385,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT07230028","Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study.","NOT_YET_RECRUITING",[88],"2026-11-01","2027-11-01","2026-03-01",50,[392],"Lyme Borreliosis, Nervous System",[370,394],"Doxycycline",{"trials":396,"activeCount":97},[],{"intervention":67,"totalTrials":132,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":413},{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"trials":404,"activeCount":97},[],{"trials":406,"activeCount":97},[],{"trials":408,"activeCount":132,"soonestReadout":66},[409],{"nctId":64,"briefTitle":65,"status":124,"phases":410,"primaryCompletion":66,"completion":66,"start":190,"enrollment":191,"conditions":411,"interventions":412},[88],[193],[67,195,176,196],{"trials":414,"activeCount":97},[],{"intervention":195,"totalTrials":132,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":431},{"trials":418,"activeCount":97},[],{"trials":420,"activeCount":97},[],{"trials":422,"activeCount":97},[],{"trials":424,"activeCount":97},[],{"trials":426,"activeCount":132,"soonestReadout":66},[427],{"nctId":64,"briefTitle":65,"status":124,"phases":428,"primaryCompletion":66,"completion":66,"start":190,"enrollment":191,"conditions":429,"interventions":430},[88],[193],[67,195,176,196],{"trials":432,"activeCount":97},[],{"intervention":196,"totalTrials":132,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":449},{"trials":436,"activeCount":97},[],{"trials":438,"activeCount":97},[],{"trials":440,"activeCount":97},[],{"trials":442,"activeCount":97},[],{"trials":444,"activeCount":132,"soonestReadout":66},[445],{"nctId":64,"briefTitle":65,"status":124,"phases":446,"primaryCompletion":66,"completion":66,"start":190,"enrollment":191,"conditions":447,"interventions":448},[88],[193],[67,195,176,196],{"trials":450,"activeCount":97},[],{"intervention":452,"totalTrials":132,"cells":453},"Teicoplanin",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":475},{"trials":455,"activeCount":97},[],{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":97},[],{"trials":463,"activeCount":132,"soonestReadout":469},[464],{"nctId":465,"briefTitle":466,"status":467,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":474},"NCT05914467","TDM-optimized Teicoplanin Dosing Versus Standard of Care","ACTIVE_NOT_RECRUITING",[88],"2026-04-30","2023-08-01",74,[473],"Bacterial Infections",[452],{"trials":476,"activeCount":97},[],{"intervention":154,"totalTrials":478,"cells":479},7,{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":528,"PHASE4":540,"NA":546},{"trials":481,"activeCount":97},[],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":97},[486,495,505,517],{"nctId":487,"briefTitle":488,"status":161,"phases":489,"primaryCompletion":53,"completion":71,"start":490,"enrollment":491,"conditions":492,"interventions":494},"NCT04834388","Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke",[86],"2022-08-10",75,[493],"Intracerebral Hemorrhage",[154],{"nctId":496,"briefTitle":497,"status":103,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":504},"NCT03233776","Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT",[86],"2020-04-02","2017-08-21",9,[503],"Multiple Myeloma",[154],{"nctId":506,"briefTitle":507,"status":161,"phases":508,"primaryCompletion":509,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":516},"NCT00928876","Interleukin-1 Receptor Antagonist and Insulin Sensitivity",[86],"2010-03","2010-07","2009-06",12,[514,515],"Diabetes Mellitus, Type 2","Insulin Resistance",[154],{"nctId":518,"briefTitle":519,"status":103,"phases":520,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT04099901","Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial",[86],"2023-03-14","2024-02-26","2019-11-04",88,[503],[154,527],"Placebos",{"trials":529,"activeCount":97},[530],{"nctId":531,"briefTitle":532,"status":103,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":390,"conditions":537,"interventions":539},"NCT02108210","Cytokine Inhibition in Chronic Fatigue Syndrome Patients",[86,87],"2015-12","2016-05","2014-06",[538],"Chronic Fatigue Syndrome",[154],{"trials":541,"activeCount":132,"soonestReadout":53},[542],{"nctId":51,"briefTitle":52,"status":124,"phases":543,"primaryCompletion":53,"completion":71,"start":149,"enrollment":150,"conditions":544,"interventions":545},[88],[33,152,153,17,154,54,155],[54,155,154,157],{"trials":547,"activeCount":97},[548],{"nctId":549,"briefTitle":550,"status":161,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":107,"conditions":555,"interventions":559},"NCT01285232","The Effect of Anakinra on Insulin Secretion",[89],"2012-03","2012-12","2011-01",[556,557,558],"Glucose Intolerance","Impaired Insulin Secretion","Diabetes Mellitus Type 2",[154],{"intervention":394,"totalTrials":561,"cells":562},4,{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":602},{"trials":564,"activeCount":97},[],{"trials":566,"activeCount":97},[],{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":132,"soonestReadout":387},[573,585,589],{"nctId":574,"briefTitle":575,"status":103,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":584},"NCT01318356","The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment",[88],"2015-09","2011-04",156,[581,582,583],"Q Fever","Fatigue Syndrome, Chronic","Coxiella Infection",[394],{"nctId":383,"briefTitle":384,"status":385,"phases":586,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":587,"interventions":588},[88],[392],[370,394],{"nctId":590,"briefTitle":591,"status":103,"phases":592,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":600},"NCT01207739","Persistent Lyme Empiric Antibiotic Study Europe",[88],"2013-10","2014-10","2010-09",280,[598,599],"Lyme Disease","Borrelia Infection",[394,601],"Clarithromycin and hydroxychloroquine",{"trials":603,"activeCount":97},[604],{"nctId":605,"briefTitle":606,"status":607,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":615},"NCT03173053","S. Aureus Decolonization in HPN Patients.","TERMINATED",[89],"2021-10-14","2018-02-08",63,[613,614],"Staphylococcus Aureus","Motility Disorder",[394,616,617,618,619,620,621,622,623,624,625],"Trimethoprim","Sulfamethoxazole\u002Ftrimethoprim","Clindamycin","Clarithromycin","Ciprofloxacin","Fusidic Acid","Rifampin","Chlorhexidine","Mupirocin","Betadine",{"intervention":157,"totalTrials":627,"cells":628},3,{"EARLY_PHASE1":629,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":654},{"trials":630,"activeCount":97},[631],{"nctId":632,"briefTitle":633,"status":103,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":641},"NCT02602977","the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia",[84],"2016-03","2015-10",30,[639,640],"Autoimmune Diseases","Infection",[157],{"trials":643,"activeCount":97},[],{"trials":645,"activeCount":97},[],{"trials":647,"activeCount":97},[],{"trials":649,"activeCount":132,"soonestReadout":53},[650],{"nctId":51,"briefTitle":52,"status":124,"phases":651,"primaryCompletion":53,"completion":71,"start":149,"enrollment":150,"conditions":652,"interventions":653},[88],[33,152,153,17,154,54,155],[54,155,154,157],{"trials":655,"activeCount":97},[656],{"nctId":657,"briefTitle":658,"status":103,"phases":659,"primaryCompletion":660,"completion":660,"start":661,"enrollment":512,"conditions":662,"interventions":664},"NCT05570643","The Effects of Human Endotoxemia on Functional Capacity of Hematopoietic Stem and Progenitor Cells",[89],"2018-06-28","2018-01-05",[663],"Sepsis, Endotoxemia, Immunosuppression",[157],{"intervention":666,"totalTrials":132,"cells":667},"Endothelin Receptor Antagonist",{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":687,"NA":689},{"trials":669,"activeCount":97},[],{"trials":671,"activeCount":97},[],{"trials":673,"activeCount":97},[],{"trials":675,"activeCount":132,"soonestReadout":681},[676],{"nctId":677,"briefTitle":678,"status":679,"phases":680,"primaryCompletion":681,"completion":682,"start":683,"enrollment":363,"conditions":684,"interventions":686},"NCT06432452","Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm","ENROLLING_BY_INVITATION",[86,87],"2026-06-15","2026-07-01","2024-11-11",[685],"Coronary Spasm",[666],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":97},[],{"intervention":692,"totalTrials":132,"cells":693},"Arm A: DC vaccination",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":713,"NA":715},{"trials":695,"activeCount":97},[],{"trials":697,"activeCount":97},[],{"trials":699,"activeCount":97},[],{"trials":701,"activeCount":132,"soonestReadout":706},[702],{"nctId":703,"briefTitle":704,"status":385,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},"NCT07609901","Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers",[87],"2032-10-01","2026-10-01",372,[710],"Lynch Syndrome",[692,712],"Arm B: Placebo vaccination",{"trials":714,"activeCount":97},[],{"trials":716,"activeCount":97},[],{"intervention":712,"totalTrials":132,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":731,"NA":733},{"trials":720,"activeCount":97},[],{"trials":722,"activeCount":97},[],{"trials":724,"activeCount":97},[],{"trials":726,"activeCount":132,"soonestReadout":706},[727],{"nctId":703,"briefTitle":704,"status":385,"phases":728,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":729,"interventions":730},[87],[710],[692,712],{"trials":732,"activeCount":97},[],{"trials":734,"activeCount":97},[],{"intervention":82,"totalTrials":132,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":757,"NA":759},{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[],{"trials":742,"activeCount":97},[],{"trials":744,"activeCount":132,"soonestReadout":81},[745],{"nctId":79,"briefTitle":80,"status":467,"phases":746,"primaryCompletion":81,"completion":81,"start":747,"enrollment":748,"conditions":749,"interventions":756},[87],"2022-12-22",150,[750,751,752,753,754,755],"Aortic Valve Disease","Aortic Valve Stenosis","Aortic Valve Calcification","Inflammation","Calcification","Cardiovascular Diseases",[82],{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"intervention":762,"totalTrials":132,"cells":763},"SDD",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":783,"NA":785},{"trials":765,"activeCount":97},[],{"trials":767,"activeCount":97},[],{"trials":769,"activeCount":97},[],{"trials":771,"activeCount":132,"soonestReadout":776},[772],{"nctId":773,"briefTitle":774,"status":124,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT05865743","Perioperative SDD to Prevent Infectious Complications After Esophagectomy",[87],"2027-12-31","2028-06-30","2024-10-21",854,[781],"Esophageal Cancer",[762],{"trials":784,"activeCount":97},[],{"trials":786,"activeCount":97},[],{"intervention":788,"totalTrials":132,"cells":789},"Intranasal insulin-40U",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":809,"NA":811},{"trials":791,"activeCount":97},[],{"trials":793,"activeCount":97},[],{"trials":795,"activeCount":97},[],{"trials":797,"activeCount":132,"soonestReadout":802},[798],{"nctId":799,"briefTitle":800,"status":385,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":637,"conditions":805,"interventions":807},"NCT07532577","Intranasal Insulin to Prevent Intensive Care Unit Delirium",[86,87],"2026-07-15","2026-08-15","2026-04-15",[806],"Delirium - Postoperative",[788,808],"Intranasal sodium chloride 0.9%",{"trials":810,"activeCount":97},[],{"trials":812,"activeCount":97},[],{"intervention":808,"totalTrials":132,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":827,"NA":829},{"trials":816,"activeCount":97},[],{"trials":818,"activeCount":97},[],{"trials":820,"activeCount":97},[],{"trials":822,"activeCount":132,"soonestReadout":802},[823],{"nctId":799,"briefTitle":800,"status":385,"phases":824,"primaryCompletion":802,"completion":803,"start":804,"enrollment":637,"conditions":825,"interventions":826},[86,87],[806],[788,808],{"trials":828,"activeCount":97},[],{"trials":830,"activeCount":97},[],{"intervention":832,"totalTrials":132,"cells":833},"Modafinil",{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":840,"PHASE4":853,"NA":855},{"trials":835,"activeCount":97},[],{"trials":837,"activeCount":97},[],{"trials":839,"activeCount":97},[],{"trials":841,"activeCount":132,"soonestReadout":846},[842],{"nctId":843,"briefTitle":844,"status":385,"phases":845,"primaryCompletion":846,"completion":847,"start":848,"enrollment":230,"conditions":849,"interventions":852},"NCT07582458","Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)",[86,87],"2027-02-01","2027-06","2026-06-01",[850,851],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)","Chronic Fatigue",[832],{"trials":854,"activeCount":97},[],{"trials":856,"activeCount":97},[],{"intervention":72,"totalTrials":132,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":875,"NA":877},{"trials":860,"activeCount":97},[],{"trials":862,"activeCount":97},[],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":132,"soonestReadout":71},[867],{"nctId":69,"briefTitle":70,"status":385,"phases":868,"primaryCompletion":71,"completion":869,"start":870,"enrollment":165,"conditions":871,"interventions":873},[86,87],"2027-03","2025-02",[872],"NSCLC",[72,874],"[89Zr]Zr-crefmirlimab berdoxam",{"trials":876,"activeCount":97},[],{"trials":878,"activeCount":97},[],{"intervention":874,"totalTrials":132,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":893,"NA":895},{"trials":882,"activeCount":97},[],{"trials":884,"activeCount":97},[],{"trials":886,"activeCount":97},[],{"trials":888,"activeCount":132,"soonestReadout":71},[889],{"nctId":69,"briefTitle":70,"status":385,"phases":890,"primaryCompletion":71,"completion":869,"start":870,"enrollment":165,"conditions":891,"interventions":892},[86,87],[872],[72,874],{"trials":894,"activeCount":97},[],{"trials":896,"activeCount":97},[],{"intervention":898,"totalTrials":132,"cells":899},"Diltiazem Hydrochloride",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":921,"NA":923},{"trials":901,"activeCount":97},[],{"trials":903,"activeCount":97},[],{"trials":905,"activeCount":97},[],{"trials":907,"activeCount":132,"soonestReadout":912},[908],{"nctId":909,"briefTitle":910,"status":467,"phases":911,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":920},"NCT04777045","Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial",[87],"2026-07","2026-12","2019-10-25",85,[917,918,919],"Microvascular Angina","Coronary Vasospasm","Microvascular Ischemia of Myocardium",[898],{"trials":922,"activeCount":97},[],{"trials":924,"activeCount":97},[],{"intervention":926,"totalTrials":132,"cells":927},"Atomoxetine",{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":947,"NA":949},{"trials":929,"activeCount":97},[],{"trials":931,"activeCount":97},[],{"trials":933,"activeCount":97},[],{"trials":935,"activeCount":132,"soonestReadout":940},[936],{"nctId":937,"briefTitle":938,"status":124,"phases":939,"primaryCompletion":940,"completion":776,"start":941,"enrollment":230,"conditions":942,"interventions":946},"NCT07316296","Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach",[87],"2027-07-01","2026-01-01",[943,944,945],"Parkinson's Disease (PD)","Freezing of Gait","Freezing of Gait Symptoms in Parkinson Disease",[926],{"trials":948,"activeCount":97},[],{"trials":950,"activeCount":97},[],{"intervention":952,"totalTrials":132,"cells":953},"Optimised dose rifampicin",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":973,"NA":975},{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":97},[],{"trials":959,"activeCount":97},[],{"trials":961,"activeCount":132,"soonestReadout":966},[962],{"nctId":963,"briefTitle":964,"status":124,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT06057519","Pragmatic Optimized Rifampicin Trial",[87],"2026-12-31","2024-01-16",164,[970],"Tuberculosis, Pulmonary",[952,972],"Standard dose rifampicin",{"trials":974,"activeCount":97},[],{"trials":976,"activeCount":97},[],{"intervention":972,"totalTrials":132,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":991,"NA":993},{"trials":980,"activeCount":97},[],{"trials":982,"activeCount":97},[],{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":132,"soonestReadout":966},[987],{"nctId":963,"briefTitle":964,"status":124,"phases":988,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":989,"interventions":990},[87],[970],[952,972],{"trials":992,"activeCount":97},[],{"trials":994,"activeCount":97},[],{"intervention":996,"totalTrials":132,"cells":997},"Obinutuzumab administration",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1015,"NA":1017},{"trials":999,"activeCount":97},[],{"trials":1001,"activeCount":97},[],{"trials":1003,"activeCount":97},[],{"trials":1005,"activeCount":132,"soonestReadout":1010},[1006],{"nctId":1007,"briefTitle":1008,"status":124,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":165,"conditions":1012,"interventions":1014},"NCT07163611","Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study",[86,87],"2028-04-01","2025-10-01",[1013],"Membranous Nephropathy - PLA2R Induced",[996],{"trials":1016,"activeCount":97},[],{"trials":1018,"activeCount":97},[],{"intervention":1020,"totalTrials":627,"cells":1021},"DC vaccination",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1023,"activeCount":97},[],{"trials":1025,"activeCount":97},[],{"trials":1027,"activeCount":132,"soonestReadout":1051},[1028,1037,1047],{"nctId":1029,"briefTitle":1030,"status":161,"phases":1031,"primaryCompletion":1032,"completion":53,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1036},"NCT01885702","Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI",[85,86],"2016-04","2010-10",25,[23],[1020],{"nctId":1038,"briefTitle":1039,"status":103,"phases":1040,"primaryCompletion":636,"completion":1032,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT02285413","Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients",[86],"2011-02",54,[1044],"Melanoma",[1020,1046],"DC vaccination with cisplatinum",{"nctId":1048,"briefTitle":1049,"status":385,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":31,"conditions":1054,"interventions":1055},"NCT07412197","Preventive Dendritic Cell Vaccination for Lynch Syndrome",[85,86],"2029-12","2036-06","2026-08",[710],[1020],{"trials":1057,"activeCount":97},[],{"trials":1059,"activeCount":97},[],{"trials":1061,"activeCount":97},[],{"intervention":1063,"totalTrials":132,"cells":1064},"LSD tartrate",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1066,"activeCount":97},[],{"trials":1068,"activeCount":97},[],{"trials":1070,"activeCount":132,"soonestReadout":1075},[1071],{"nctId":1072,"briefTitle":1073,"status":124,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1080},"NCT05477459","LSD to Improve Cluster Headache Impact Trial",[86],"2027-04","2025-04-16",65,[1079],"Chronic Cluster Headache",[1063],{"trials":1082,"activeCount":97},[],{"trials":1084,"activeCount":97},[],{"trials":1086,"activeCount":97},[],{"intervention":1088,"totalTrials":132,"cells":1089},"XP-DC vaccinations",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1091,"activeCount":97},[],{"trials":1093,"activeCount":97},[],{"trials":1095,"activeCount":132,"soonestReadout":1100},[1096],{"nctId":1097,"briefTitle":1098,"status":124,"phases":1099,"primaryCompletion":1100,"completion":966,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1106},"NCT05773859","NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer",[85,86],"2026-03","2023-03-17",10,[1104,1105],"Epithelial Ovarian Cancer","Ovarian Carcinoma",[1088],{"trials":1108,"activeCount":97},[],{"trials":1110,"activeCount":97},[],{"trials":1112,"activeCount":97},[],{"intervention":1114,"totalTrials":132,"cells":1115},"Interferon Gamma-1B",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":132,"soonestReadout":1126},[1122],{"nctId":1123,"briefTitle":1124,"status":467,"phases":1125,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1131},"NCT04979052","Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia",[86],"2026-04-23","2022-03-31",200,[1130],"Candidemia",[1114],{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":97},[],{"trials":1137,"activeCount":97},[],{"intervention":62,"totalTrials":132,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1141,"activeCount":97},[],{"trials":1143,"activeCount":97},[],{"trials":1145,"activeCount":132,"soonestReadout":53},[1146],{"nctId":60,"briefTitle":61,"status":124,"phases":1147,"primaryCompletion":53,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1153},[86],"2027-09","2022-09-27",26,[1152],"Salivary Duct Carcinoma",[62,1154,1155],"Bicalutamide 50 mg","Dutasteride 0.5 mg",{"trials":1157,"activeCount":97},[],{"trials":1159,"activeCount":97},[],{"trials":1161,"activeCount":97},[],{"intervention":1154,"totalTrials":132,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1165,"activeCount":97},[],{"trials":1167,"activeCount":97},[],{"trials":1169,"activeCount":132,"soonestReadout":53},[1170],{"nctId":60,"briefTitle":61,"status":124,"phases":1171,"primaryCompletion":53,"completion":1148,"start":1149,"enrollment":1150,"conditions":1172,"interventions":1173},[86],[1152],[62,1154,1155],{"trials":1175,"activeCount":97},[],{"trials":1177,"activeCount":97},[],{"trials":1179,"activeCount":97},[],{"intervention":1155,"totalTrials":132,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1183,"activeCount":97},[],{"trials":1185,"activeCount":97},[],{"trials":1187,"activeCount":132,"soonestReadout":53},[1188],{"nctId":60,"briefTitle":61,"status":124,"phases":1189,"primaryCompletion":53,"completion":1148,"start":1149,"enrollment":1150,"conditions":1190,"interventions":1191},[86],[1152],[62,1154,1155],{"trials":1193,"activeCount":97},[],{"trials":1195,"activeCount":97},[],{"trials":1197,"activeCount":97},[],{"intervention":1199,"totalTrials":132,"cells":1200},"Personalised treatment",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1202,"activeCount":97},[],{"trials":1204,"activeCount":132,"soonestReadout":1209},[1205],{"nctId":1206,"briefTitle":1207,"status":385,"phases":1208,"primaryCompletion":1209,"completion":1210,"start":848,"enrollment":1102,"conditions":1211,"interventions":1216},"NCT07485569","Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial",[85],"2027-06-01","2027-09-01",[1212,1213,1214,1215],"Thyroid Cancer Stage IV","Anaplastic Thyroid Cancer","Differentiated Thyroid Cancer","Poorly Differentiated Thyroid Carcinoma",[1199],{"trials":1218,"activeCount":97},[],{"trials":1220,"activeCount":97},[],{"trials":1222,"activeCount":97},[],{"trials":1224,"activeCount":97},[],{"intervention":49,"totalTrials":132,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1243},{"trials":1228,"activeCount":97},[],{"trials":1230,"activeCount":132,"soonestReadout":48},[1231],{"nctId":46,"briefTitle":47,"status":467,"phases":1232,"primaryCompletion":48,"completion":71,"start":1233,"enrollment":21,"conditions":1234,"interventions":1236},[85],"2021-01-11",[1235],"Advanced Solid Tumor",[49],{"trials":1238,"activeCount":97},[],{"trials":1240,"activeCount":97},[],{"trials":1242,"activeCount":97},[],{"trials":1244,"activeCount":97},[],{"intervention":1246,"totalTrials":132,"cells":1247},"12 mg of nebulised 99mTc-liposomal amphotericin B",{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1249,"activeCount":97},[],{"trials":1251,"activeCount":132,"soonestReadout":1256},[1252],{"nctId":1253,"briefTitle":1254,"status":385,"phases":1255,"primaryCompletion":1256,"completion":1209,"start":1257,"enrollment":18,"conditions":1258,"interventions":1260},"NCT07530263","Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)",[85],"2027-05-01","2026-05-01",[1259],"Chronic Pulmonary Aspergillosis",[1246,1261],"24 mg of nebulised 99mTc-liposomal amphotericin B",{"trials":1263,"activeCount":97},[],{"trials":1265,"activeCount":97},[],{"trials":1267,"activeCount":97},[],{"trials":1269,"activeCount":97},[],{"intervention":1261,"totalTrials":132,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1273,"activeCount":97},[],{"trials":1275,"activeCount":132,"soonestReadout":1256},[1276],{"nctId":1253,"briefTitle":1254,"status":385,"phases":1277,"primaryCompletion":1256,"completion":1209,"start":1257,"enrollment":18,"conditions":1278,"interventions":1279},[85],[1259],[1246,1261],{"trials":1281,"activeCount":97},[],{"trials":1283,"activeCount":97},[],{"trials":1285,"activeCount":97},[],{"trials":1287,"activeCount":97},[],{"intervention":1289,"totalTrials":132,"cells":1290},"[111In]In-DOTA-TCO-trastuzumab",{"EARLY_PHASE1":1291,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1311},{"trials":1292,"activeCount":132,"soonestReadout":913},[1293],{"nctId":1294,"briefTitle":1295,"status":124,"phases":1296,"primaryCompletion":913,"completion":913,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT07009184","TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.",[84],"2025-12-10",19,[1300],"HER2 Positive Solid Tumor",[1289,1302],"Small molecule tetrazine trigger component",{"trials":1304,"activeCount":97},[],{"trials":1306,"activeCount":97},[],{"trials":1308,"activeCount":97},[],{"trials":1310,"activeCount":97},[],{"trials":1312,"activeCount":97},[],{"intervention":1302,"totalTrials":132,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1316,"activeCount":132,"soonestReadout":913},[1317],{"nctId":1294,"briefTitle":1295,"status":124,"phases":1318,"primaryCompletion":913,"completion":913,"start":1297,"enrollment":1298,"conditions":1319,"interventions":1320},[84],[1300],[1289,1302],{"trials":1322,"activeCount":97},[],{"trials":1324,"activeCount":97},[],{"trials":1326,"activeCount":97},[],{"trials":1328,"activeCount":97},[],{"trials":1330,"activeCount":97},[],{"intervention":1332,"totalTrials":627,"cells":1333},"Bevacizumab",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1335,"activeCount":97},[],{"trials":1337,"activeCount":97},[],{"trials":1339,"activeCount":97},[],{"trials":1341,"activeCount":97},[],{"trials":1343,"activeCount":97},[],{"trials":1345,"activeCount":132,"soonestReadout":43},[1346,1355,1369],{"nctId":41,"briefTitle":42,"status":467,"phases":1347,"primaryCompletion":43,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1353},[89],"2027-07","2013-05",478,[1352],"Multi-organ Metastatic Colorectal Cancer",[44,1354,1332],"FOLFOX regimen according to standard procedures",{"nctId":1356,"briefTitle":1357,"status":103,"phases":1358,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1366},"NCT01125943","Bevacizumab and Endothelium Dependent Vasodilation",[89],"2011-10","2011-11","2010-06",24,[1364,20,1365],"Hypertension","Endothelial Dysfunction",[1367,1368,1332],"Acetylcholine","Nitroprusside",{"nctId":1370,"briefTitle":1371,"status":103,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":511,"enrollment":1102,"conditions":1374,"interventions":1375},"NCT00929058","Bevacizumab and Vasoconstriction",[89],"2009-11",[1364,20],[1332],{"intervention":39,"totalTrials":627,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1397,"NA":1399},{"trials":1379,"activeCount":97},[],{"trials":1381,"activeCount":97},[],{"trials":1383,"activeCount":97},[],{"trials":1385,"activeCount":97},[1386],{"nctId":1387,"briefTitle":1388,"status":103,"phases":1389,"primaryCompletion":1390,"completion":1390,"start":1391,"enrollment":1392,"conditions":1393,"interventions":1396},"NCT02114255","Effects of BCG on Influenza Induced Immune Response",[86,87],"2014-09","2014-05",40,[1394,1395],"Influenza Virus Infection","Trained Immunity",[39],{"trials":1398,"activeCount":97},[],{"trials":1400,"activeCount":132,"soonestReadout":38},[1401,1411],{"nctId":1402,"briefTitle":1403,"status":103,"phases":1404,"primaryCompletion":1405,"completion":106,"start":1406,"enrollment":637,"conditions":1407,"interventions":1409},"NCT02175420","Role of BCG as Booster Vaccination",[89],"2015-04","2012-07",[1408],"BCG Vaccination",[39,1410],"TFV",{"nctId":36,"briefTitle":37,"status":467,"phases":1412,"primaryCompletion":38,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1420},[],"2027-06-20","2022-05-20",4292,[1417,1418,753,1419],"BCG Vaccination Reaction","Infections","COVID-19",[39],{"intervention":77,"totalTrials":93,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1424,"activeCount":97},[],{"trials":1426,"activeCount":97},[],{"trials":1428,"activeCount":97},[],{"trials":1430,"activeCount":97},[],{"trials":1432,"activeCount":97},[],{"trials":1434,"activeCount":132,"soonestReadout":76},[1435,1442],{"nctId":74,"briefTitle":75,"status":124,"phases":1436,"primaryCompletion":76,"completion":76,"start":1437,"enrollment":1128,"conditions":1438,"interventions":1440},[89],"2023-07-06",[1439],"ST Elevation Myocardial Infarction",[77,1441],"Aspirin",{"nctId":1443,"briefTitle":1444,"status":103,"phases":1445,"primaryCompletion":534,"completion":534,"start":636,"enrollment":1392,"conditions":1446,"interventions":1447},"NCT02612480","Ticagrelor in Human Endotoxemia Response to Human Endotoxemia",[89],[17],[1448,1449,1450],"ticagrelor","Clopidogrel","Acetylsalicylic acid lysinate",{"intervention":1441,"totalTrials":93,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1459,"PHASE4":1461,"NA":1463},{"trials":1454,"activeCount":97},[],{"trials":1456,"activeCount":97},[],{"trials":1458,"activeCount":97},[],{"trials":1460,"activeCount":97},[],{"trials":1462,"activeCount":97},[],{"trials":1464,"activeCount":132,"soonestReadout":76},[1465,1469],{"nctId":74,"briefTitle":75,"status":124,"phases":1466,"primaryCompletion":76,"completion":76,"start":1437,"enrollment":1128,"conditions":1467,"interventions":1468},[89],[1439],[77,1441],{"nctId":1470,"briefTitle":1471,"status":103,"phases":1472,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":637,"conditions":1476,"interventions":1477},"NCT02922673","The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia",[89],"2016-12","2017-09","2016-09",[17],[1441],{"intervention":1479,"totalTrials":93,"cells":1480},"Phentolamine",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1482,"activeCount":97},[],{"trials":1484,"activeCount":97},[],{"trials":1486,"activeCount":97},[],{"trials":1488,"activeCount":97},[],{"trials":1490,"activeCount":97},[],{"trials":1492,"activeCount":132,"soonestReadout":53},[1493,1499],{"nctId":56,"briefTitle":57,"status":467,"phases":1494,"primaryCompletion":53,"completion":66,"start":229,"enrollment":1362,"conditions":1495,"interventions":1497},[89],[1496,753],"Diabetes Mellitus, Type 1",[58,1498,1479],"Propranolol Hydrochloride 1 MG\u002FML",{"nctId":1500,"briefTitle":1501,"status":161,"phases":1502,"start":1503,"conditions":1504,"interventions":1506},"NCT00132106","The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure",[89],"2005-08",[1505],"Heart Failure, Congestive",[1507],"phentolamine",{"intervention":1509,"totalTrials":132,"cells":1510},"Tirzepatide",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1512,"activeCount":97},[],{"trials":1514,"activeCount":97},[],{"trials":1516,"activeCount":97},[],{"trials":1518,"activeCount":97},[],{"trials":1520,"activeCount":97},[],{"trials":1522,"activeCount":132,"soonestReadout":682},[1523],{"nctId":1524,"briefTitle":1525,"status":385,"phases":1526,"primaryCompletion":682,"completion":1527,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1533},"NCT07504172","Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity",[],"2026-08-01","2026-04-01",1700,[1531,1532],"Overweight , Obesity","Obesity (Disorder)",[1509],{"intervention":44,"totalTrials":132,"cells":1535},{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1537,"activeCount":97},[],{"trials":1539,"activeCount":97},[],{"trials":1541,"activeCount":97},[],{"trials":1543,"activeCount":97},[],{"trials":1545,"activeCount":97},[],{"trials":1547,"activeCount":132,"soonestReadout":43},[1548],{"nctId":41,"briefTitle":42,"status":467,"phases":1549,"primaryCompletion":43,"completion":1348,"start":1349,"enrollment":1350,"conditions":1550,"interventions":1551},[89],[1352],[44,1354,1332],{"intervention":1354,"totalTrials":132,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1555,"activeCount":97},[],{"trials":1557,"activeCount":97},[],{"trials":1559,"activeCount":97},[],{"trials":1561,"activeCount":97},[],{"trials":1563,"activeCount":97},[],{"trials":1565,"activeCount":132,"soonestReadout":43},[1566],{"nctId":41,"briefTitle":42,"status":467,"phases":1567,"primaryCompletion":43,"completion":1348,"start":1349,"enrollment":1350,"conditions":1568,"interventions":1569},[89],[1352],[44,1354,1332],{"intervention":58,"totalTrials":132,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1573,"activeCount":97},[],{"trials":1575,"activeCount":97},[],{"trials":1577,"activeCount":97},[],{"trials":1579,"activeCount":97},[],{"trials":1581,"activeCount":97},[],{"trials":1583,"activeCount":132,"soonestReadout":53},[1584],{"nctId":56,"briefTitle":57,"status":467,"phases":1585,"primaryCompletion":53,"completion":66,"start":229,"enrollment":1362,"conditions":1586,"interventions":1587},[89],[1496,753],[58,1498,1479],{"intervention":1498,"totalTrials":132,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[],{"trials":1595,"activeCount":97},[],{"trials":1597,"activeCount":97},[],{"trials":1599,"activeCount":97},[],{"trials":1601,"activeCount":132,"soonestReadout":53},[1602],{"nctId":56,"briefTitle":57,"status":467,"phases":1603,"primaryCompletion":53,"completion":66,"start":229,"enrollment":1362,"conditions":1604,"interventions":1605},[89],[1496,753],[58,1498,1479],{"intervention":1607,"totalTrials":132,"cells":1608},"Hormonal Antineoplastics",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1617,"NA":1619},{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":97},[],{"trials":1614,"activeCount":97},[],{"trials":1616,"activeCount":97},[],{"trials":1618,"activeCount":97},[],{"trials":1620,"activeCount":132,"soonestReadout":1625},[1621],{"nctId":1622,"briefTitle":1623,"status":124,"phases":1624,"primaryCompletion":1625,"completion":1210,"start":1626,"enrollment":748,"conditions":1627,"interventions":1631},"NCT03621904","PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer",[],"2026-10-15","2022-10-15",[1628,1629,1630],"Endometrial Cancer Stage III","Endometrial Cancer Stage IV","Endometrial Cancer Recurrent",[1607],{"intervention":1633,"totalTrials":1634,"cells":1635},"Raltegravir",6,{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1692,"PHASE3":1694,"PHASE4":1696,"NA":1708},{"trials":1637,"activeCount":97},[],{"trials":1639,"activeCount":97},[1640,1651,1662,1673,1683],{"nctId":1641,"briefTitle":1642,"status":103,"phases":1643,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1362,"conditions":1647,"interventions":1648},"NCT00665717","The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)",[85],"2008-09","2008-10","2008-05",[25],[1649,1633,1650],"Pravastatin","Pravastatin and raltegravir",{"nctId":1652,"briefTitle":1653,"status":103,"phases":1654,"primaryCompletion":1655,"completion":1655,"start":1656,"enrollment":1362,"conditions":1657,"interventions":1659},"NCT01978782","Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).",[85],"2014-04","2014-01",[110,1658],"Depression",[1660,1661],"raltegravir","citalopram",{"nctId":1663,"briefTitle":1664,"status":103,"phases":1665,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1362,"conditions":1669,"interventions":1671},"NCT01779687","Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.",[85],"2013-07","2013-08","2013-03",[110,1670],"Hypercholesterolaemia",[1660,1672],"Atorvastatin",{"nctId":1674,"briefTitle":1675,"status":103,"phases":1676,"primaryCompletion":1360,"completion":1677,"start":1678,"enrollment":1362,"conditions":1679,"interventions":1681},"NCT01288417","Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir",[85],"2011-12","2011-08",[25,1680],"HCV Infections",[1682,1660],"boceprevir",{"nctId":1684,"briefTitle":1685,"status":103,"phases":1686,"primaryCompletion":1645,"completion":1645,"start":1687,"enrollment":1362,"conditions":1688,"interventions":1690},"NCT00618241","Pharmacokinetic Study on Raltegravir and Lamotrigine",[85],"2008-02",[1689],"HIV Infection",[1691,1633],"lamotrigine",{"trials":1693,"activeCount":97},[],{"trials":1695,"activeCount":97},[],{"trials":1697,"activeCount":97},[1698],{"nctId":1699,"briefTitle":1700,"status":103,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1392,"conditions":1705,"interventions":1706},"NCT02383355","Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation",[88],"2016-03-31","2017-07-01","2015-03-01",[110],[1633,1707],"Continuation of own regimen",{"trials":1709,"activeCount":97},[],{"intervention":1711,"totalTrials":561,"cells":1712},"Metformin",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1760},{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[1717],{"nctId":1718,"briefTitle":1719,"status":103,"phases":1720,"primaryCompletion":635,"completion":1032,"start":105,"enrollment":165,"conditions":1721,"interventions":1723},"NCT02565862","A Drug-drug Interaction Study Between Daclatasvir and Metformin",[85],[109,1722,515],"Diabetes Mellitus",[112,1711],{"trials":1725,"activeCount":97},[],{"trials":1727,"activeCount":97},[],{"trials":1729,"activeCount":97},[1730,1739,1748],{"nctId":1731,"briefTitle":1732,"status":103,"phases":1733,"primaryCompletion":1406,"completion":1406,"start":1734,"enrollment":18,"conditions":1735,"interventions":1737},"NCT01613755","Metformin-Dipyridamole Interaction Trial",[88],"2012-04",[1736],"Diabetes",[1738,1711],"Metformin, dipyridamole",{"nctId":1740,"briefTitle":1741,"status":103,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":1360,"enrollment":363,"conditions":1744,"interventions":1747},"NCT01438723","The Metformin in Coronary Artery Bypass Graft (CABG) (MetCAB) Trial",[88],"2014-07",[1745,1746],"Cardiovascular Disease","Ischemic Heart Disease",[1711],{"nctId":1749,"briefTitle":1750,"status":103,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1150,"conditions":1754,"interventions":1757},"NCT01610401","The Metformin-FMD Trial",[88],"2013-01","2012-05",[1755,1756],"Ischemia Reperfusion Injury","Endothelial Function",[1711,1758,1759],"Pretreatment with metformin in combination of infusion of caffeine.","No pretreatment with metformin in combination with infusion of caffeine",{"trials":1761,"activeCount":97},[],{"intervention":1763,"totalTrials":627,"cells":1764},"posaconazole",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1781,"PHASE3":1792,"PHASE4":1794,"NA":1810},{"trials":1766,"activeCount":97},[],{"trials":1768,"activeCount":97},[1769],{"nctId":1770,"briefTitle":1771,"status":103,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1362,"conditions":1776,"interventions":1778},"NCT00817765","Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir",[85],"2009-07","2009-10","2009-01",[1689,1777],"Fungal Infection",[1779,1780,114],"Posaconazole","Fosamprenavir",{"trials":1782,"activeCount":97},[1783],{"nctId":1784,"briefTitle":1785,"status":103,"phases":1786,"primaryCompletion":510,"completion":1787,"start":1788,"enrollment":512,"conditions":1789,"interventions":1791},"NCT00799071","Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)",[86],"2010-08","2009-02",[1790],"Chronic Granulomatous Disease",[1763],{"trials":1793,"activeCount":97},[],{"trials":1795,"activeCount":97},[1796],{"nctId":1797,"briefTitle":1798,"status":103,"phases":1799,"primaryCompletion":1800,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1809},"NCT02805946","Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections",[88],"2019-07-26","2019-09-07","2017-04-28",21,[1805,1806,1807,1808],"Allogeneic Stem Cell Transplant","Acute Graft Versus Host Disease","Acute Myeloid Leucaemia","Myelo Dysplastic Syndrome",[1763],{"trials":1811,"activeCount":97},[],{"intervention":1813,"totalTrials":627,"cells":1814},"BCG vaccine",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1832,"NA":1854},{"trials":1816,"activeCount":97},[],{"trials":1818,"activeCount":97},[],{"trials":1820,"activeCount":97},[],{"trials":1822,"activeCount":97},[1823],{"nctId":1824,"briefTitle":1825,"status":103,"phases":1826,"primaryCompletion":594,"completion":1827,"start":1828,"enrollment":165,"conditions":1829,"interventions":1830},"NCT02085590","Effects of BCG on Immune Response",[86,87],"2014-11","2014-03",[33],[1813,1831],"Lipopolysaccharide (LPS) E. Coli 1 ng\u002Fkg intravenously",{"trials":1833,"activeCount":97},[1834,1845],{"nctId":1835,"briefTitle":1836,"status":161,"phases":1837,"primaryCompletion":1838,"completion":1839,"start":1840,"enrollment":491,"conditions":1841,"interventions":1843},"NCT02771782","Influence of BCG on TDaP-IPV Vaccination",[88],"2016-07","2017-04","2015-01",[1842],"Whooping Cough",[1813,1844],"TDaP-IPV vaccine",{"nctId":1846,"briefTitle":1847,"status":161,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1853},"NCT04417335","Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination",[88],"2021-05","2020-04-16",2014,[1419],[1813],{"trials":1855,"activeCount":97},[],{"intervention":1857,"totalTrials":627,"cells":1858},"Rocuronium Bromide",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1865,"PHASE4":1867,"NA":1903},{"trials":1860,"activeCount":97},[],{"trials":1862,"activeCount":97},[],{"trials":1864,"activeCount":97},[],{"trials":1866,"activeCount":97},[],{"trials":1868,"activeCount":97},[1869,1883,1892],{"nctId":1870,"briefTitle":1871,"status":103,"phases":1872,"primaryCompletion":1873,"completion":1874,"start":1875,"enrollment":363,"conditions":1876,"interventions":1881},"NCT03572413","The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.",[88],"2020-08-31","2020-12-01","2018-10-24",[1877,1878,1879,1880],"Pneumoperitoneum","Neuromuscular Blockade","Surgery","Immune Suppression",[1882],"Rocuronium bromide",{"nctId":1884,"briefTitle":1885,"status":103,"phases":1886,"primaryCompletion":1887,"completion":1888,"start":1875,"enrollment":1889,"conditions":1890,"interventions":1891},"NCT03608436","The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery",[88],"2021-03-03","2021-06-03",178,[1877,1878,1879],[1857],{"nctId":1893,"briefTitle":1894,"status":103,"phases":1895,"primaryCompletion":1896,"completion":1896,"start":1897,"enrollment":363,"conditions":1898,"interventions":1902},"NCT05562999","Impact of Deep Neuromuscular Blockade During Total Hip Replacement Surgery on Postoperative Recovery and Immune Function",[88],"2024-08-29","2022-11-18",[1878,1899,1900,1901],"Innate Inflammatory Response","Quality of Life","Postoperative Complications",[1857,1857],{"trials":1904,"activeCount":97},[],{"intervention":1672,"totalTrials":627,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1915,"PHASE3":1917,"PHASE4":1919,"NA":1944},{"trials":1908,"activeCount":97},[],{"trials":1910,"activeCount":97},[1911],{"nctId":1663,"briefTitle":1664,"status":103,"phases":1912,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1362,"conditions":1913,"interventions":1914},[85],[110,1670],[1660,1672],{"trials":1916,"activeCount":97},[],{"trials":1918,"activeCount":97},[],{"trials":1920,"activeCount":97},[1921,1935],{"nctId":1922,"briefTitle":1923,"status":103,"phases":1924,"completion":1925,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1933},"NCT00449410","Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients",[88],"2006-10","2005-05",35,[1929,1930,1931,753,1932],"Atrial Fibrillation","Neuropsychology","Magnetic Resonance Imaging","Hemostasis",[1672,1934],"ezetimibe",{"nctId":1936,"briefTitle":1937,"status":103,"phases":1938,"primaryCompletion":1788,"completion":1939,"start":1940,"enrollment":637,"conditions":1941,"interventions":1942},"NCT00441597","Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?",[88],"2009-03","2007-02",[1755,1745],[1943],"atorvastatin",{"trials":1945,"activeCount":97},[],{"intervention":1947,"totalTrials":93,"cells":1948},"Rivaroxaban 2.5 Mg Oral",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1979},{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":97},[1959,1969],{"nctId":1960,"briefTitle":1961,"status":103,"phases":1962,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1968},"NCT04218656","DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease",[88],"2021-12-31","2020-06-08",159,[1967],"Peripheral Artery Disease",[1947],{"nctId":1970,"briefTitle":1971,"status":161,"phases":1972,"primaryCompletion":1973,"completion":1974,"start":1975,"enrollment":165,"conditions":1976,"interventions":1978},"NCT05210725","Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease",[88],"2022-04-15","2022-07-01","2022-03-01",[1977],"Coronary Artery Disease",[1947],{"trials":1980,"activeCount":97},[],{"intervention":1982,"totalTrials":93,"cells":1983},"Dolutegravir",{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1999,"PHASE4":2001,"NA":2013},{"trials":1985,"activeCount":97},[],{"trials":1987,"activeCount":97},[],{"trials":1989,"activeCount":97},[1990],{"nctId":1991,"briefTitle":1992,"status":607,"phases":1993,"primaryCompletion":1473,"completion":1473,"start":1994,"enrollment":501,"conditions":1995,"interventions":1997},"NCT02566707","Pharmacokinetics of Atazanavir \u002FDolutegravir\u002FLamivudine Regimen as Maintenance Regimen",[86],"2015-08",[1996],"HIV-1 Infection",[113,1982,1998],"Lamivudine",{"trials":2000,"activeCount":97},[],{"trials":2002,"activeCount":97},[2003],{"nctId":2004,"briefTitle":2005,"status":2006,"phases":2007,"primaryCompletion":1963,"completion":1963,"start":2008,"enrollment":97,"conditions":2009,"interventions":2012},"NCT03813979","Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.","WITHDRAWN",[88],"2020-11-15",[2010,2011],"HIV-1-infection","Hepatic Impairment",[1982],{"trials":2014,"activeCount":97},[],{"intervention":2016,"totalTrials":93,"cells":2017},"Aprepitant",{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2045},{"trials":2019,"activeCount":97},[],{"trials":2021,"activeCount":97},[],{"trials":2023,"activeCount":97},[],{"trials":2025,"activeCount":97},[],{"trials":2027,"activeCount":97},[2028,2034],{"nctId":2029,"briefTitle":2030,"status":2006,"phases":2031,"completion":1644,"enrollment":97,"conditions":2032,"interventions":2033},"NCT00429754","Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)",[88],[167,168],[2016],{"nctId":2035,"briefTitle":2036,"status":607,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":165,"conditions":2040,"interventions":2042},"NCT00588835","Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients",[88],"2010-01","2008-03",[2041],"Tumor",[2043,2044],"aprepitant","Dexamethasone and Ondansetron during CE-treatment",{"trials":2046,"activeCount":97},[],{"intervention":2048,"totalTrials":93,"cells":2049},"Bosentan",{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2056,"PHASE4":2058,"NA":2076},{"trials":2051,"activeCount":97},[],{"trials":2053,"activeCount":97},[],{"trials":2055,"activeCount":97},[],{"trials":2057,"activeCount":97},[],{"trials":2059,"activeCount":97},[2060,2069],{"nctId":2061,"briefTitle":2062,"status":103,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":15,"conditions":2066,"interventions":2068},"NCT01779596","ET-blockade and Exercise Induced Blood Flow in T2DM",[88],"2013-12","2011-05",[2067],"Type 2 Diabetes Mellitus",[2048],{"nctId":2070,"briefTitle":2071,"status":103,"phases":2072,"primaryCompletion":2064,"completion":2064,"start":2073,"enrollment":1298,"conditions":2074,"interventions":2075},"NCT01779609","ET-blockade and Exercise-induced Vascular Adaptations in T2DM",[88],"2010-04",[2067],[2048],{"trials":2077,"activeCount":97},[],{"intervention":2079,"totalTrials":93,"cells":2080},"Pemetrexed",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2110},{"trials":2082,"activeCount":97},[],{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[],{"trials":2090,"activeCount":97},[2091,2102],{"nctId":2092,"briefTitle":2093,"status":103,"phases":2094,"primaryCompletion":2095,"completion":2096,"start":2097,"enrollment":1102,"conditions":2098,"interventions":2101},"NCT03655834","Dose Individualization of Pemetrexed - IMPROVE-III",[88],"2020-09-20","2021-08-01","2019-02-01",[2099,2100],"Non Small Cell Lung Cancer","Mesothelioma",[2079],{"nctId":2103,"briefTitle":2104,"status":607,"phases":2105,"primaryCompletion":2106,"completion":2106,"start":2097,"enrollment":2107,"conditions":2108,"interventions":2109},"NCT03655821","Dose Individualization of Pemetrexed - IMPROVE-II",[88],"2021-05-11",81,[2099,2100],[2079],{"trials":2111,"activeCount":97},[],{"intervention":2113,"totalTrials":132,"cells":2114},"TCA treatment",{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2121,"PHASE4":2123,"NA":2136},{"trials":2116,"activeCount":97},[],{"trials":2118,"activeCount":97},[],{"trials":2120,"activeCount":97},[],{"trials":2122,"activeCount":97},[],{"trials":2124,"activeCount":97},[2125],{"nctId":2126,"briefTitle":2127,"status":103,"phases":2128,"primaryCompletion":2129,"completion":2130,"start":2131,"enrollment":2132,"conditions":2133,"interventions":2135},"NCT03548675","Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)",[88],"2022-02-02","2022-07-13","2018-05-23",125,[2134],"Depressive Disorder, Major",[2113],{"trials":2137,"activeCount":97},[],{"intervention":2139,"totalTrials":132,"cells":2140},"Somatuline",{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2149,"NA":2159},{"trials":2142,"activeCount":97},[],{"trials":2144,"activeCount":97},[],{"trials":2146,"activeCount":97},[],{"trials":2148,"activeCount":97},[],{"trials":2150,"activeCount":97},[2151],{"nctId":2152,"briefTitle":2153,"status":161,"phases":2154,"start":2155,"conditions":2156,"interventions":2158},"NCT00543179","Treatment of the Dumping Syndrome With Lanreotide Autogel®",[88],"2007-10",[2157],"Dumping Syndrome",[2139],{"trials":2160,"activeCount":97},[],{"intervention":2162,"totalTrials":132,"cells":2163},"Valsartan",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2187},{"trials":2165,"activeCount":97},[],{"trials":2167,"activeCount":97},[],{"trials":2169,"activeCount":97},[],{"trials":2171,"activeCount":97},[],{"trials":2173,"activeCount":97},[2174],{"nctId":2175,"briefTitle":2176,"status":607,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":2179,"enrollment":2180,"conditions":2181,"interventions":2186},"NCT04335786","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease",[88],"2021-05-25","2020-04-17",23,[2182,2183,2184,1419,2185],"Acute Respiratory Distress Syndrome","SARS-CoV-2","COVID","Severe Acute Respiratory Syndrome",[2162],{"trials":2188,"activeCount":97},[],{"intervention":2190,"totalTrials":132,"cells":2191},"Omegaven 10%",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2198,"PHASE4":2200,"NA":2211},{"trials":2193,"activeCount":97},[],{"trials":2195,"activeCount":97},[],{"trials":2197,"activeCount":97},[],{"trials":2199,"activeCount":97},[],{"trials":2201,"activeCount":97},[2202],{"nctId":2203,"briefTitle":2204,"status":103,"phases":2205,"primaryCompletion":2206,"completion":577,"start":1656,"enrollment":1634,"conditions":2207,"interventions":2209},"NCT02349594","Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease",[88],"2015-05",[2208],"Crohn Disease",[2190,2210],"Intralipid 20%",{"trials":2212,"activeCount":97},[],{"intervention":2210,"totalTrials":132,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2229},{"trials":2216,"activeCount":97},[],{"trials":2218,"activeCount":97},[],{"trials":2220,"activeCount":97},[],{"trials":2222,"activeCount":97},[],{"trials":2224,"activeCount":97},[2225],{"nctId":2203,"briefTitle":2204,"status":103,"phases":2226,"primaryCompletion":2206,"completion":577,"start":1656,"enrollment":1634,"conditions":2227,"interventions":2228},[88],[2208],[2190,2210],{"trials":2230,"activeCount":97},[],{"intervention":2232,"totalTrials":132,"cells":2233},"Oralgen",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2242,"NA":2254},{"trials":2235,"activeCount":97},[],{"trials":2237,"activeCount":97},[],{"trials":2239,"activeCount":97},[],{"trials":2241,"activeCount":97},[],{"trials":2243,"activeCount":97},[2244],{"nctId":2245,"briefTitle":2246,"status":103,"phases":2247,"completion":2248,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2253},"NCT00150514","Effects of Sublingual Immunotherapy on Grasspollen Allergy",[88],"2006-12","2002-01",38,[2252],"Hayfever",[2232],{"trials":2255,"activeCount":97},[],{"intervention":2257,"totalTrials":132,"cells":2258},"Sugammadex",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2267,"NA":2278},{"trials":2260,"activeCount":97},[],{"trials":2262,"activeCount":97},[],{"trials":2264,"activeCount":97},[],{"trials":2266,"activeCount":97},[],{"trials":2268,"activeCount":97},[2269],{"nctId":2270,"briefTitle":2271,"status":161,"phases":2272,"primaryCompletion":2273,"completion":2273,"start":1359,"enrollment":637,"conditions":2274,"interventions":2276},"NCT01453530","Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade",[88],"2012-09",[2275],"Anesthesia Recovery Period",[2257,2277],"Neostigmine\u002FGlycopyrrolate",{"trials":2279,"activeCount":97},[],{"intervention":2277,"totalTrials":132,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2290,"NA":2296},{"trials":2283,"activeCount":97},[],{"trials":2285,"activeCount":97},[],{"trials":2287,"activeCount":97},[],{"trials":2289,"activeCount":97},[],{"trials":2291,"activeCount":97},[2292],{"nctId":2270,"briefTitle":2271,"status":161,"phases":2293,"primaryCompletion":2273,"completion":2273,"start":1359,"enrollment":637,"conditions":2294,"interventions":2295},[88],[2275],[2257,2277],{"trials":2297,"activeCount":97},[],{"intervention":2299,"totalTrials":132,"cells":2300},"usage oral angiogenesis inhibitor",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2321},{"trials":2302,"activeCount":97},[],{"trials":2304,"activeCount":97},[],{"trials":2306,"activeCount":97},[],{"trials":2308,"activeCount":97},[],{"trials":2310,"activeCount":97},[2311],{"nctId":2312,"briefTitle":2313,"status":161,"phases":2314,"primaryCompletion":2315,"completion":1734,"start":1645,"enrollment":637,"conditions":2316,"interventions":2319},"NCT00777504","Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors",[88],"2012-01",[2317,2318],"Renal Cell Carcinoma","Gastrointestinal Stromal Tumor",[2299,2320],"stop oral angiogenesis inhibitor",{"trials":2322,"activeCount":97},[],{"intervention":2320,"totalTrials":132,"cells":2324},{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2339},{"trials":2326,"activeCount":97},[],{"trials":2328,"activeCount":97},[],{"trials":2330,"activeCount":97},[],{"trials":2332,"activeCount":97},[],{"trials":2334,"activeCount":97},[2335],{"nctId":2312,"briefTitle":2313,"status":161,"phases":2336,"primaryCompletion":2315,"completion":1734,"start":1645,"enrollment":637,"conditions":2337,"interventions":2338},[88],[2317,2318],[2299,2320],{"trials":2340,"activeCount":97},[],{"intervention":1844,"totalTrials":132,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2357},{"trials":2344,"activeCount":97},[],{"trials":2346,"activeCount":97},[],{"trials":2348,"activeCount":97},[],{"trials":2350,"activeCount":97},[],{"trials":2352,"activeCount":97},[2353],{"nctId":1835,"briefTitle":1836,"status":161,"phases":2354,"primaryCompletion":1838,"completion":1839,"start":1840,"enrollment":491,"conditions":2355,"interventions":2356},[88],[1842],[1813,1844],{"trials":2358,"activeCount":97},[],{"intervention":2360,"totalTrials":132,"cells":2361},"Pemetrexed + oral folinic acid rescue",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2368,"PHASE4":2370,"NA":2380},{"trials":2363,"activeCount":97},[],{"trials":2365,"activeCount":97},[],{"trials":2367,"activeCount":97},[],{"trials":2369,"activeCount":97},[],{"trials":2371,"activeCount":97},[2372],{"nctId":2373,"briefTitle":2374,"status":103,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2097,"enrollment":1634,"conditions":2378,"interventions":2379},"NCT03656549","Dose Individualization of Pemetrexed - IMPROVE-I",[88],"2023-12-01","2023-12-29",[2099,2100],[2360],{"trials":2381,"activeCount":97},[],{"intervention":2383,"totalTrials":132,"cells":2384},"sofosbuvir\u002Fvelpatasvir",{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2405},{"trials":2386,"activeCount":97},[],{"trials":2388,"activeCount":97},[],{"trials":2390,"activeCount":97},[],{"trials":2392,"activeCount":97},[],{"trials":2394,"activeCount":97},[2395],{"nctId":2396,"briefTitle":2397,"status":2006,"phases":2398,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":97,"conditions":2401,"interventions":2403},"NCT03389061","Bioequivalence Study of Crushed Sofosbuvir\u002FVelpatasvir Compared to the Whole Tablet",[88],"2019-03-22","2018-04-01",[2402],"HCV",[2383,2404],"sofosbuvir\u002Fvelpatasvir crushed",{"trials":2406,"activeCount":97},[],{"intervention":2404,"totalTrials":132,"cells":2408},{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2417,"NA":2423},{"trials":2410,"activeCount":97},[],{"trials":2412,"activeCount":97},[],{"trials":2414,"activeCount":97},[],{"trials":2416,"activeCount":97},[],{"trials":2418,"activeCount":97},[2419],{"nctId":2396,"briefTitle":2397,"status":2006,"phases":2420,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":97,"conditions":2421,"interventions":2422},[88],[2402],[2383,2404],{"trials":2424,"activeCount":97},[],{"intervention":2426,"totalTrials":132,"cells":2427},"sampling blood",{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2452},{"trials":2429,"activeCount":97},[],{"trials":2431,"activeCount":97},[],{"trials":2433,"activeCount":97},[],{"trials":2435,"activeCount":97},[],{"trials":2437,"activeCount":97},[2438],{"nctId":2439,"briefTitle":2440,"status":161,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":637,"conditions":2445,"interventions":2449},"NCT05421312","Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip",[88],"2023-09","2023-12","2022-09",[2446,2447,2448],"PJI","Bone and Joint Infection","Pharmacokinetics",[2426,2450,2451],"Sampling synovial fluid","Sampling bone tissue",{"trials":2453,"activeCount":97},[],{"intervention":2450,"totalTrials":132,"cells":2455},{"EARLY_PHASE1":2456,"PHASE1":2458,"PHASE2":2460,"PHASE3":2462,"PHASE4":2464,"NA":2470},{"trials":2457,"activeCount":97},[],{"trials":2459,"activeCount":97},[],{"trials":2461,"activeCount":97},[],{"trials":2463,"activeCount":97},[],{"trials":2465,"activeCount":97},[2466],{"nctId":2439,"briefTitle":2440,"status":161,"phases":2467,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":637,"conditions":2468,"interventions":2469},[88],[2446,2447,2448],[2426,2450,2451],{"trials":2471,"activeCount":97},[],{"intervention":2451,"totalTrials":132,"cells":2473},{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2480,"PHASE4":2482,"NA":2488},{"trials":2475,"activeCount":97},[],{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"trials":2483,"activeCount":97},[2484],{"nctId":2439,"briefTitle":2440,"status":161,"phases":2485,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":637,"conditions":2486,"interventions":2487},[88],[2446,2447,2448],[2426,2450,2451],{"trials":2489,"activeCount":97},[],{"intervention":2491,"totalTrials":132,"cells":2492},"Secukinumab",{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2521},{"trials":2494,"activeCount":97},[],{"trials":2496,"activeCount":97},[],{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":97},[2503],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2506,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2511,"interventions":2514},"NCT04340076","Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis",[88],"2025-01-30","2025-01-31","2020-08-20",244,[2512,2513],"Psoriasis","Psoriasis Vulgaris",[2491,2515,2516,2517,2518,2519,2520],"Ixekizumab","Brodalumab","Guselkumab","Risankizumab","Tildrakizumab","Bimekizumab",{"trials":2522,"activeCount":97},[],{"intervention":2515,"totalTrials":132,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2539},{"trials":2526,"activeCount":97},[],{"trials":2528,"activeCount":97},[],{"trials":2530,"activeCount":97},[],{"trials":2532,"activeCount":97},[],{"trials":2534,"activeCount":97},[2535],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2536,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2537,"interventions":2538},[88],[2512,2513],[2491,2515,2516,2517,2518,2519,2520],{"trials":2540,"activeCount":97},[],{"intervention":2516,"totalTrials":132,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2549,"PHASE4":2551,"NA":2557},{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[],{"trials":2550,"activeCount":97},[],{"trials":2552,"activeCount":97},[2553],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2554,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2555,"interventions":2556},[88],[2512,2513],[2491,2515,2516,2517,2518,2519,2520],{"trials":2558,"activeCount":97},[],{"intervention":2517,"totalTrials":132,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2575},{"trials":2562,"activeCount":97},[],{"trials":2564,"activeCount":97},[],{"trials":2566,"activeCount":97},[],{"trials":2568,"activeCount":97},[],{"trials":2570,"activeCount":97},[2571],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2572,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2573,"interventions":2574},[88],[2512,2513],[2491,2515,2516,2517,2518,2519,2520],{"trials":2576,"activeCount":97},[],{"intervention":2518,"totalTrials":132,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2593},{"trials":2580,"activeCount":97},[],{"trials":2582,"activeCount":97},[],{"trials":2584,"activeCount":97},[],{"trials":2586,"activeCount":97},[],{"trials":2588,"activeCount":97},[2589],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2590,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2591,"interventions":2592},[88],[2512,2513],[2491,2515,2516,2517,2518,2519,2520],{"trials":2594,"activeCount":97},[],{"intervention":2519,"totalTrials":132,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2605,"NA":2611},{"trials":2598,"activeCount":97},[],{"trials":2600,"activeCount":97},[],{"trials":2602,"activeCount":97},[],{"trials":2604,"activeCount":97},[],{"trials":2606,"activeCount":97},[2607],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2608,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2609,"interventions":2610},[88],[2512,2513],[2491,2515,2516,2517,2518,2519,2520],{"trials":2612,"activeCount":97},[],{"intervention":2520,"totalTrials":132,"cells":2614},{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2629},{"trials":2616,"activeCount":97},[],{"trials":2618,"activeCount":97},[],{"trials":2620,"activeCount":97},[],{"trials":2622,"activeCount":97},[],{"trials":2624,"activeCount":97},[2625],{"nctId":2504,"briefTitle":2505,"status":103,"phases":2626,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2627,"interventions":2628},[88],[2512,2513],[2491,2515,2516,2517,2518,2519,2520],{"trials":2630,"activeCount":97},[],{"intervention":2632,"totalTrials":132,"cells":2633},"Anidulafungin 100mg single dose iv",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2640,"PHASE4":2642,"NA":2653},{"trials":2635,"activeCount":97},[],{"trials":2637,"activeCount":97},[],{"trials":2639,"activeCount":97},[],{"trials":2641,"activeCount":97},[],{"trials":2643,"activeCount":97},[2644],{"nctId":2645,"briefTitle":2646,"status":103,"phases":2647,"primaryCompletion":594,"completion":594,"start":2648,"enrollment":2649,"conditions":2650,"interventions":2652},"NCT02021123","Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)",[88],"2014-08",8,[2651],"Obesity Morbid",[2632],{"trials":2654,"activeCount":97},[],{"intervention":2656,"totalTrials":132,"cells":2657},"Acetyl cysteine",{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2677},{"trials":2659,"activeCount":97},[],{"trials":2661,"activeCount":97},[],{"trials":2663,"activeCount":97},[],{"trials":2665,"activeCount":97},[],{"trials":2667,"activeCount":97},[2668],{"nctId":2669,"briefTitle":2670,"status":103,"phases":2671,"primaryCompletion":2672,"completion":2672,"start":2673,"enrollment":230,"conditions":2674,"interventions":2676},"NCT03354572","Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine",[88],"2018-10-29","2017-10-20",[2675],"Postoperative Pain",[2656,527],{"trials":2678,"activeCount":97},[],{"intervention":2680,"totalTrials":132,"cells":2681},"Ticagrelor 180 mg single dose",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2701},{"trials":2683,"activeCount":97},[],{"trials":2685,"activeCount":97},[],{"trials":2687,"activeCount":97},[],{"trials":2689,"activeCount":97},[],{"trials":2691,"activeCount":97},[2692],{"nctId":2693,"briefTitle":2694,"status":103,"phases":2695,"primaryCompletion":2696,"completion":2064,"start":2697,"enrollment":26,"conditions":2698,"interventions":2700},"NCT01996735","Ticagrelor and Adenosine",[88],"2013-11","2013-04",[2699],"Healthy",[2680],{"trials":2702,"activeCount":97},[],{"intervention":1738,"totalTrials":132,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2719},{"trials":2706,"activeCount":97},[],{"trials":2708,"activeCount":97},[],{"trials":2710,"activeCount":97},[],{"trials":2712,"activeCount":97},[],{"trials":2714,"activeCount":97},[2715],{"nctId":1731,"briefTitle":1732,"status":103,"phases":2716,"primaryCompletion":1406,"completion":1406,"start":1734,"enrollment":18,"conditions":2717,"interventions":2718},[88],[1736],[1738,1711],{"trials":2720,"activeCount":97},[],{"intervention":2722,"totalTrials":132,"cells":2723},"anti-hypertensive medication",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2730,"PHASE4":2732,"NA":2741},{"trials":2725,"activeCount":97},[],{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"trials":2733,"activeCount":97},[2734],{"nctId":2735,"briefTitle":2736,"status":161,"phases":2737,"primaryCompletion":2064,"completion":2064,"start":2738,"enrollment":230,"conditions":2739,"interventions":2740},"NCT00966199","The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population",[88],"2009-09",[1364],[2722],{"trials":2742,"activeCount":97},[],{"intervention":2744,"totalTrials":132,"cells":2745},"Mifepristone",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2768},{"trials":2747,"activeCount":97},[],{"trials":2749,"activeCount":97},[],{"trials":2751,"activeCount":97},[],{"trials":2753,"activeCount":97},[],{"trials":2755,"activeCount":97},[2756],{"nctId":2757,"briefTitle":2758,"status":607,"phases":2759,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":2763,"conditions":2764,"interventions":2766},"NCT03212352","Comparing Two Medical Treatments for Early Pregnancy Failure.",[88],"2020-01-23","2020-03-16","2018-06-27",342,[2765],"Early Pregnancy Failure",[2744,2767],"Misoprostol",{"trials":2769,"activeCount":97},[],{"intervention":2767,"totalTrials":132,"cells":2771},{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2778,"PHASE4":2780,"NA":2786},{"trials":2773,"activeCount":97},[],{"trials":2775,"activeCount":97},[],{"trials":2777,"activeCount":97},[],{"trials":2779,"activeCount":97},[],{"trials":2781,"activeCount":97},[2782],{"nctId":2757,"briefTitle":2758,"status":607,"phases":2783,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":2763,"conditions":2784,"interventions":2785},[88],[2765],[2744,2767],{"trials":2787,"activeCount":97},[],{"intervention":2789,"totalTrials":132,"cells":2790},"Haloperidol 1 mg\u002Fq8h",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2797,"PHASE4":2799,"NA":2812},{"trials":2792,"activeCount":97},[],{"trials":2794,"activeCount":97},[],{"trials":2796,"activeCount":97},[],{"trials":2798,"activeCount":97},[],{"trials":2800,"activeCount":97},[2801],{"nctId":2802,"briefTitle":2803,"status":103,"phases":2804,"primaryCompletion":1473,"completion":2805,"start":2806,"enrollment":2807,"conditions":2808,"interventions":2810},"NCT01785290","pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium",[88],"2017-03","2013-06",1800,[2809],"Delirium",[2789,2811],"Haloperidol 2 mg\u002Fq8h",{"trials":2813,"activeCount":97},[],{"intervention":2811,"totalTrials":132,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2830},{"trials":2817,"activeCount":97},[],{"trials":2819,"activeCount":97},[],{"trials":2821,"activeCount":97},[],{"trials":2823,"activeCount":97},[],{"trials":2825,"activeCount":97},[2826],{"nctId":2802,"briefTitle":2803,"status":103,"phases":2827,"primaryCompletion":1473,"completion":2805,"start":2806,"enrollment":2807,"conditions":2828,"interventions":2829},[88],[2809],[2789,2811],{"trials":2831,"activeCount":97},[],{"intervention":2833,"totalTrials":132,"cells":2834},"Norepinephrine",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2843,"NA":2854},{"trials":2836,"activeCount":97},[],{"trials":2838,"activeCount":97},[],{"trials":2840,"activeCount":97},[],{"trials":2842,"activeCount":97},[],{"trials":2844,"activeCount":97},[2845],{"nctId":2846,"briefTitle":2847,"status":103,"phases":2848,"primaryCompletion":1838,"completion":2849,"start":105,"enrollment":1392,"conditions":2850,"interventions":2851},"NCT02675868","Effects of Vasopressors on Immune Response",[88],"2016-10",[17],[2833,2852,2853],"Phenylephrine","Vasopressins",{"trials":2855,"activeCount":97},[],{"intervention":2852,"totalTrials":132,"cells":2857},{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2864,"PHASE4":2866,"NA":2872},{"trials":2859,"activeCount":97},[],{"trials":2861,"activeCount":97},[],{"trials":2863,"activeCount":97},[],{"trials":2865,"activeCount":97},[],{"trials":2867,"activeCount":97},[2868],{"nctId":2846,"briefTitle":2847,"status":103,"phases":2869,"primaryCompletion":1838,"completion":2849,"start":105,"enrollment":1392,"conditions":2870,"interventions":2871},[88],[17],[2833,2852,2853],{"trials":2873,"activeCount":97},[],{"intervention":2853,"totalTrials":132,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2882,"PHASE4":2884,"NA":2890},{"trials":2877,"activeCount":97},[],{"trials":2879,"activeCount":97},[],{"trials":2881,"activeCount":97},[],{"trials":2883,"activeCount":97},[],{"trials":2885,"activeCount":97},[2886],{"nctId":2846,"briefTitle":2847,"status":103,"phases":2887,"primaryCompletion":1838,"completion":2849,"start":105,"enrollment":1392,"conditions":2888,"interventions":2889},[88],[17],[2833,2852,2853],{"trials":2891,"activeCount":97},[],{"intervention":2893,"totalTrials":132,"cells":2894},"Trimethoprim\u002FSulfamethoxazole",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2903,"NA":2917},{"trials":2896,"activeCount":97},[],{"trials":2898,"activeCount":97},[],{"trials":2900,"activeCount":97},[],{"trials":2902,"activeCount":97},[],{"trials":2904,"activeCount":97},[2905],{"nctId":2906,"briefTitle":2907,"status":103,"phases":2908,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":2912,"interventions":2914},"NCT03228108","Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.",[88],"2021-09-26","2018-04-03",1538,[2913,640,28],"Complication",[620,2893,2915,2916],"Fosfomycin","Pivmecillinam\u002Faugmentin",{"trials":2918,"activeCount":97},[],{"intervention":2915,"totalTrials":132,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2935},{"trials":2922,"activeCount":97},[],{"trials":2924,"activeCount":97},[],{"trials":2926,"activeCount":97},[],{"trials":2928,"activeCount":97},[],{"trials":2930,"activeCount":97},[2931],{"nctId":2906,"briefTitle":2907,"status":103,"phases":2932,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":2933,"interventions":2934},[88],[2913,640,28],[620,2893,2915,2916],{"trials":2936,"activeCount":97},[],{"intervention":2916,"totalTrials":132,"cells":2938},{"EARLY_PHASE1":2939,"PHASE1":2941,"PHASE2":2943,"PHASE3":2945,"PHASE4":2947,"NA":2953},{"trials":2940,"activeCount":97},[],{"trials":2942,"activeCount":97},[],{"trials":2944,"activeCount":97},[],{"trials":2946,"activeCount":97},[],{"trials":2948,"activeCount":97},[2949],{"nctId":2906,"briefTitle":2907,"status":103,"phases":2950,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":2951,"interventions":2952},[88],[2913,640,28],[620,2893,2915,2916],{"trials":2954,"activeCount":97},[],{"intervention":2956,"totalTrials":132,"cells":2957},"Etoricoxib",{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2964,"PHASE4":2966,"NA":2977},{"trials":2959,"activeCount":97},[],{"trials":2961,"activeCount":97},[],{"trials":2963,"activeCount":97},[],{"trials":2965,"activeCount":97},[],{"trials":2967,"activeCount":97},[2968],{"nctId":2969,"briefTitle":2970,"status":103,"phases":2971,"primaryCompletion":1359,"completion":1359,"start":2972,"enrollment":2973,"conditions":2974,"interventions":2976},"NCT01022190","Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement",[88],"2009-12",42,[2975],"Ossification, Heterotopic",[2956],{"trials":2978,"activeCount":97},[],{"intervention":2980,"totalTrials":132,"cells":2981},"Medroxyprogesterone Acetate 10 MG",{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2988,"PHASE4":2990,"NA":3002},{"trials":2983,"activeCount":97},[],{"trials":2985,"activeCount":97},[],{"trials":2987,"activeCount":97},[],{"trials":2989,"activeCount":97},[],{"trials":2991,"activeCount":97},[2992],{"nctId":2993,"briefTitle":2994,"status":103,"phases":2995,"primaryCompletion":2996,"completion":2997,"start":2998,"enrollment":2973,"conditions":2999,"interventions":3001},"NCT03309176","\"Stair Step Study\"",[88],"2017-11-30","2018-05-31","2016-06-21",[3000],"Ovulation Disorder",[2980],{"trials":3003,"activeCount":97},[],{"intervention":2044,"totalTrials":132,"cells":3005},{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3012,"PHASE4":3014,"NA":3020},{"trials":3007,"activeCount":97},[],{"trials":3009,"activeCount":97},[],{"trials":3011,"activeCount":97},[],{"trials":3013,"activeCount":97},[],{"trials":3015,"activeCount":97},[3016],{"nctId":2035,"briefTitle":2036,"status":607,"phases":3017,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":165,"conditions":3018,"interventions":3019},[88],[2041],[2043,2044],{"trials":3021,"activeCount":97},[],{"intervention":3023,"totalTrials":132,"cells":3024},"atorvastatin 3 days",{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3029,"PHASE3":3031,"PHASE4":3033,"NA":3046},{"trials":3026,"activeCount":97},[],{"trials":3028,"activeCount":97},[],{"trials":3030,"activeCount":97},[],{"trials":3032,"activeCount":97},[],{"trials":3034,"activeCount":97},[3035],{"nctId":3036,"briefTitle":3037,"status":103,"phases":3038,"primaryCompletion":3039,"completion":509,"start":2738,"enrollment":3040,"conditions":3041,"interventions":3042},"NCT00987974","Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury",[88],"2010-02",48,[1755,1365],[3043,3023,3044,3045],"rosuvastatin","rosuvastatin 7 days","atorvastatin 7 days",{"trials":3047,"activeCount":97},[],{"intervention":3044,"totalTrials":132,"cells":3049},{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3056,"PHASE4":3058,"NA":3064},{"trials":3051,"activeCount":97},[],{"trials":3053,"activeCount":97},[],{"trials":3055,"activeCount":97},[],{"trials":3057,"activeCount":97},[],{"trials":3059,"activeCount":97},[3060],{"nctId":3036,"briefTitle":3037,"status":103,"phases":3061,"primaryCompletion":3039,"completion":509,"start":2738,"enrollment":3040,"conditions":3062,"interventions":3063},[88],[1755,1365],[3043,3023,3044,3045],{"trials":3065,"activeCount":97},[],{"intervention":3045,"totalTrials":132,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3074,"PHASE4":3076,"NA":3082},{"trials":3069,"activeCount":97},[],{"trials":3071,"activeCount":97},[],{"trials":3073,"activeCount":97},[],{"trials":3075,"activeCount":97},[],{"trials":3077,"activeCount":97},[3078],{"nctId":3036,"briefTitle":3037,"status":103,"phases":3079,"primaryCompletion":3039,"completion":509,"start":2738,"enrollment":3040,"conditions":3080,"interventions":3081},[88],[1755,1365],[3043,3023,3044,3045],{"trials":3083,"activeCount":97},[],{"intervention":3085,"totalTrials":132,"cells":3086},"N-acetylcysteine",{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3093,"PHASE4":3095,"NA":3110},{"trials":3088,"activeCount":97},[],{"trials":3090,"activeCount":97},[],{"trials":3092,"activeCount":97},[],{"trials":3094,"activeCount":97},[],{"trials":3096,"activeCount":97},[3097],{"nctId":3098,"briefTitle":3099,"status":103,"phases":3100,"completion":3101,"start":3102,"enrollment":3103,"conditions":3104,"interventions":3108},"NCT00184977","COPD on Primary Care Treatment (COOPT)",[88],"2003-01","1998-12",270,[3105,3106,3107],"Pulmonary Disease, Chronic Obstructive","Lung Diseases, Obstructive","Bronchitis, Chronic",[3085,3109],"fluticasone propionate",{"trials":3111,"activeCount":97},[],{"intervention":3109,"totalTrials":132,"cells":3113},{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3128},{"trials":3115,"activeCount":97},[],{"trials":3117,"activeCount":97},[],{"trials":3119,"activeCount":97},[],{"trials":3121,"activeCount":97},[],{"trials":3123,"activeCount":97},[3124],{"nctId":3098,"briefTitle":3099,"status":103,"phases":3125,"completion":3101,"start":3102,"enrollment":3103,"conditions":3126,"interventions":3127},[88],[3105,3106,3107],[3085,3109],{"trials":3129,"activeCount":97},[],{"intervention":3131,"totalTrials":132,"cells":3132},"Mycophenolate mofetil",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3153},{"trials":3134,"activeCount":97},[],{"trials":3136,"activeCount":97},[],{"trials":3138,"activeCount":97},[],{"trials":3140,"activeCount":97},[],{"trials":3142,"activeCount":97},[3143],{"nctId":3144,"briefTitle":3145,"status":161,"phases":3146,"primaryCompletion":3147,"completion":3147,"start":164,"enrollment":3148,"conditions":3149,"interventions":3151},"NCT02900443","Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis",[88],"2023-06",70,[3150],"Autoimmune Hepatitis",[3131,3152],"Azathioprine",{"trials":3154,"activeCount":97},[],{"intervention":3152,"totalTrials":132,"cells":3156},{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3165,"NA":3171},{"trials":3158,"activeCount":97},[],{"trials":3160,"activeCount":97},[],{"trials":3162,"activeCount":97},[],{"trials":3164,"activeCount":97},[],{"trials":3166,"activeCount":97},[3167],{"nctId":3144,"briefTitle":3145,"status":161,"phases":3168,"primaryCompletion":3147,"completion":3147,"start":164,"enrollment":3148,"conditions":3169,"interventions":3170},[88],[3150],[3131,3152],{"trials":3172,"activeCount":97},[],{"intervention":1934,"totalTrials":132,"cells":3174},{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3179,"PHASE3":3181,"PHASE4":3183,"NA":3189},{"trials":3176,"activeCount":97},[],{"trials":3178,"activeCount":97},[],{"trials":3180,"activeCount":97},[],{"trials":3182,"activeCount":97},[],{"trials":3184,"activeCount":97},[3185],{"nctId":1922,"briefTitle":1923,"status":103,"phases":3186,"completion":1925,"start":1926,"enrollment":1927,"conditions":3187,"interventions":3188},[88],[1929,1930,1931,753,1932],[1672,1934],{"trials":3190,"activeCount":97},[],{"intervention":1758,"totalTrials":132,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3199,"PHASE4":3201,"NA":3207},{"trials":3194,"activeCount":97},[],{"trials":3196,"activeCount":97},[],{"trials":3198,"activeCount":97},[],{"trials":3200,"activeCount":97},[],{"trials":3202,"activeCount":97},[3203],{"nctId":1749,"briefTitle":1750,"status":103,"phases":3204,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1150,"conditions":3205,"interventions":3206},[88],[1755,1756],[1711,1758,1759],{"trials":3208,"activeCount":97},[],{"intervention":1759,"totalTrials":132,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3217,"PHASE4":3219,"NA":3225},{"trials":3212,"activeCount":97},[],{"trials":3214,"activeCount":97},[],{"trials":3216,"activeCount":97},[],{"trials":3218,"activeCount":97},[],{"trials":3220,"activeCount":97},[3221],{"nctId":1749,"briefTitle":1750,"status":103,"phases":3222,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1150,"conditions":3223,"interventions":3224},[88],[1755,1756],[1711,1758,1759],{"trials":3226,"activeCount":97},[],{"intervention":3228,"totalTrials":132,"cells":3229},"alpha methyldopa",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3238,"NA":3249},{"trials":3231,"activeCount":97},[],{"trials":3233,"activeCount":97},[],{"trials":3235,"activeCount":97},[],{"trials":3237,"activeCount":97},[],{"trials":3239,"activeCount":97},[3240],{"nctId":3241,"briefTitle":3242,"status":161,"phases":3243,"completion":3244,"start":3245,"enrollment":1927,"conditions":3246,"interventions":3248},"NCT00117546","Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia",[88],"2008-12","2005-09",[3247],"Preeclampsia",[3228],{"trials":3250,"activeCount":97},[],{"intervention":1707,"totalTrials":132,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3255,"PHASE2":3257,"PHASE3":3259,"PHASE4":3261,"NA":3267},{"trials":3254,"activeCount":97},[],{"trials":3256,"activeCount":97},[],{"trials":3258,"activeCount":97},[],{"trials":3260,"activeCount":97},[],{"trials":3262,"activeCount":97},[3263],{"nctId":1699,"briefTitle":1700,"status":103,"phases":3264,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1392,"conditions":3265,"interventions":3266},[88],[110],[1633,1707],{"trials":3268,"activeCount":97},[],{"intervention":3270,"totalTrials":132,"cells":3271},"Enzalutamide",{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3278,"PHASE4":3280,"NA":3291},{"trials":3273,"activeCount":97},[],{"trials":3275,"activeCount":97},[],{"trials":3277,"activeCount":97},[],{"trials":3279,"activeCount":97},[],{"trials":3281,"activeCount":97},[3282],{"nctId":3283,"briefTitle":3284,"status":103,"phases":3285,"primaryCompletion":3286,"completion":3286,"start":3287,"enrollment":9,"conditions":3288,"interventions":3290},"NCT03927391","Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects",[88],"2024-01-08","2019-05-30",[3289],"Prostatic Neoplasms, Castration-Resistant",[3270],{"trials":3292,"activeCount":97},[],{"intervention":3294,"totalTrials":132,"cells":3295},"Atovaquone \u002F Proguanil",{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3300,"PHASE3":3302,"PHASE4":3304,"NA":3315},{"trials":3297,"activeCount":97},[],{"trials":3299,"activeCount":97},[],{"trials":3301,"activeCount":97},[],{"trials":3303,"activeCount":97},[],{"trials":3305,"activeCount":97},[3306],{"nctId":3307,"briefTitle":3308,"status":103,"phases":3309,"primaryCompletion":3244,"completion":3244,"start":3310,"enrollment":3311,"conditions":3312,"interventions":3314},"NCT00421473","Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients",[88],"2007-03",79,[25,3313],"Malaria",[3294],{"trials":3316,"activeCount":97},[],{"intervention":3318,"totalTrials":132,"cells":3319},"L-arginine + heme arginate",{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3324,"PHASE3":3326,"PHASE4":3328,"NA":3338},{"trials":3321,"activeCount":97},[],{"trials":3323,"activeCount":97},[],{"trials":3325,"activeCount":97},[],{"trials":3327,"activeCount":97},[],{"trials":3329,"activeCount":97},[3330],{"nctId":3331,"briefTitle":3332,"status":607,"phases":3333,"start":1939,"enrollment":1634,"conditions":3334,"interventions":3336},"NCT00856817","Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation",[88],[3335],"Atherosclerotic Cardiovascular Disease",[3318,3337],"Heme arginate + L-arginine",{"trials":3339,"activeCount":97},[],{"intervention":3337,"totalTrials":132,"cells":3341},{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3348,"PHASE4":3350,"NA":3356},{"trials":3343,"activeCount":97},[],{"trials":3345,"activeCount":97},[],{"trials":3347,"activeCount":97},[],{"trials":3349,"activeCount":97},[],{"trials":3351,"activeCount":97},[3352],{"nctId":3331,"briefTitle":3332,"status":607,"phases":3353,"start":1939,"enrollment":1634,"conditions":3354,"interventions":3355},[88],[3335],[3318,3337],{"trials":3357,"activeCount":97},[],{"intervention":3359,"totalTrials":132,"cells":3360},"Doravirine 100Mg Tab",{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3365,"PHASE3":3367,"PHASE4":3369,"NA":3382},{"trials":3362,"activeCount":97},[],{"trials":3364,"activeCount":97},[],{"trials":3366,"activeCount":97},[],{"trials":3368,"activeCount":97},[],{"trials":3370,"activeCount":97},[3371],{"nctId":3372,"briefTitle":3373,"status":103,"phases":3374,"primaryCompletion":3375,"completion":3376,"start":3377,"enrollment":165,"conditions":3378,"interventions":3380},"NCT05648201","Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers",[88],"2024-11-01","2025-04-28","2023-03-01",[3379],"Hiv",[3359,3381],"Biktarvy 50\u002F200\u002F25 Tab",{"trials":3383,"activeCount":97},[],{"intervention":3381,"totalTrials":132,"cells":3385},{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3392,"PHASE4":3394,"NA":3400},{"trials":3387,"activeCount":97},[],{"trials":3389,"activeCount":97},[],{"trials":3391,"activeCount":97},[],{"trials":3393,"activeCount":97},[],{"trials":3395,"activeCount":97},[3396],{"nctId":3372,"briefTitle":3373,"status":103,"phases":3397,"primaryCompletion":3375,"completion":3376,"start":3377,"enrollment":165,"conditions":3398,"interventions":3399},[88],[3379],[3359,3381],{"trials":3401,"activeCount":97},[],{"intervention":601,"totalTrials":132,"cells":3403},{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3410,"PHASE4":3412,"NA":3418},{"trials":3405,"activeCount":97},[],{"trials":3407,"activeCount":97},[],{"trials":3409,"activeCount":97},[],{"trials":3411,"activeCount":97},[],{"trials":3413,"activeCount":97},[3414],{"nctId":590,"briefTitle":591,"status":103,"phases":3415,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":3416,"interventions":3417},[88],[598,599],[394,601],{"trials":3419,"activeCount":97},[],{"intervention":3421,"totalTrials":132,"cells":3422},"Direct CYP2C19 genotyping",{"EARLY_PHASE1":3423,"PHASE1":3425,"PHASE2":3427,"PHASE3":3429,"PHASE4":3431,"NA":3448},{"trials":3424,"activeCount":97},[],{"trials":3426,"activeCount":97},[],{"trials":3428,"activeCount":97},[],{"trials":3430,"activeCount":97},[],{"trials":3432,"activeCount":97},[3433],{"nctId":3434,"briefTitle":3435,"status":161,"phases":3436,"primaryCompletion":3437,"completion":3438,"start":3439,"enrollment":3440,"conditions":3441,"interventions":3443},"NCT04619927","Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.",[88],"2024-06-30","2024-12-31","2021-03-01",2276,[3442],"Peripheral Arterial Disease",[3421,3444,3445,3446,3447],"CYP2C19 genotyping at the end of the study","Poor metabolisers","Intermediate metabolisers","Normal metabolisers and unknown metaboliser state",{"trials":3449,"activeCount":97},[],{"intervention":3444,"totalTrials":132,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3466},{"trials":3453,"activeCount":97},[],{"trials":3455,"activeCount":97},[],{"trials":3457,"activeCount":97},[],{"trials":3459,"activeCount":97},[],{"trials":3461,"activeCount":97},[3462],{"nctId":3434,"briefTitle":3435,"status":161,"phases":3463,"primaryCompletion":3437,"completion":3438,"start":3439,"enrollment":3440,"conditions":3464,"interventions":3465},[88],[3442],[3421,3444,3445,3446,3447],{"trials":3467,"activeCount":97},[],{"intervention":3445,"totalTrials":132,"cells":3469},{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3476,"PHASE4":3478,"NA":3484},{"trials":3471,"activeCount":97},[],{"trials":3473,"activeCount":97},[],{"trials":3475,"activeCount":97},[],{"trials":3477,"activeCount":97},[],{"trials":3479,"activeCount":97},[3480],{"nctId":3434,"briefTitle":3435,"status":161,"phases":3481,"primaryCompletion":3437,"completion":3438,"start":3439,"enrollment":3440,"conditions":3482,"interventions":3483},[88],[3442],[3421,3444,3445,3446,3447],{"trials":3485,"activeCount":97},[],{"intervention":3446,"totalTrials":132,"cells":3487},{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3494,"PHASE4":3496,"NA":3502},{"trials":3489,"activeCount":97},[],{"trials":3491,"activeCount":97},[],{"trials":3493,"activeCount":97},[],{"trials":3495,"activeCount":97},[],{"trials":3497,"activeCount":97},[3498],{"nctId":3434,"briefTitle":3435,"status":161,"phases":3499,"primaryCompletion":3437,"completion":3438,"start":3439,"enrollment":3440,"conditions":3500,"interventions":3501},[88],[3442],[3421,3444,3445,3446,3447],{"trials":3503,"activeCount":97},[],{"intervention":3447,"totalTrials":132,"cells":3505},{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3510,"PHASE3":3512,"PHASE4":3514,"NA":3520},{"trials":3507,"activeCount":97},[],{"trials":3509,"activeCount":97},[],{"trials":3511,"activeCount":97},[],{"trials":3513,"activeCount":97},[],{"trials":3515,"activeCount":97},[3516],{"nctId":3434,"briefTitle":3435,"status":161,"phases":3517,"primaryCompletion":3437,"completion":3438,"start":3439,"enrollment":3440,"conditions":3518,"interventions":3519},[88],[3442],[3421,3444,3445,3446,3447],{"trials":3521,"activeCount":97},[],{"intervention":3523,"totalTrials":132,"cells":3524},"Administration of study drug",{"EARLY_PHASE1":3525,"PHASE1":3527,"PHASE2":3529,"PHASE3":3531,"PHASE4":3533,"NA":3544},{"trials":3526,"activeCount":97},[],{"trials":3528,"activeCount":97},[],{"trials":3530,"activeCount":97},[],{"trials":3532,"activeCount":97},[],{"trials":3534,"activeCount":97},[3535],{"nctId":3536,"briefTitle":3537,"status":103,"phases":3538,"primaryCompletion":3539,"completion":3539,"start":3540,"enrollment":107,"conditions":3541,"interventions":3543},"NCT02320604","Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)",[88],"2018-11-03","2018-03-22",[3542],"Morbid Obesity",[3523],{"trials":3545,"activeCount":97},[],{"intervention":3547,"totalTrials":132,"cells":3548},"Topical coal tar",{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3571},{"trials":3550,"activeCount":97},[],{"trials":3552,"activeCount":97},[],{"trials":3554,"activeCount":97},[],{"trials":3556,"activeCount":97},[],{"trials":3558,"activeCount":97},[3559],{"nctId":3560,"briefTitle":3561,"status":161,"phases":3562,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":3567,"interventions":3569},"NCT03461302","Efficacy of Topical Coal Tar in Children With Atopic Dermatitis",[88],"2019-08-01","2019-09-01","2018-02-01",80,[3568],"Atopic Dermatitis",[3547,3570],"Topical corticosteroids",{"trials":3572,"activeCount":97},[],{"intervention":3570,"totalTrials":132,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3581,"PHASE4":3583,"NA":3589},{"trials":3576,"activeCount":97},[],{"trials":3578,"activeCount":97},[],{"trials":3580,"activeCount":97},[],{"trials":3582,"activeCount":97},[],{"trials":3584,"activeCount":97},[3585],{"nctId":3560,"briefTitle":3561,"status":161,"phases":3586,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":3587,"interventions":3588},[88],[3568],[3547,3570],{"trials":3590,"activeCount":97},[],{"intervention":3592,"totalTrials":132,"cells":3593},"Posaconazole Injection [Noxafil] 300mg",{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3600,"PHASE4":3602,"NA":3613},{"trials":3595,"activeCount":97},[],{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":97},[],{"trials":3603,"activeCount":97},[3604],{"nctId":3605,"briefTitle":3606,"status":103,"phases":3607,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":1362,"conditions":3610,"interventions":3611},"NCT03246386","Dosing Obese With Noxafil® Under a Trial (DONUT)",[88],"2018-09-01","2017-11-05",[3542],[3592,3612],"Posaconazole Injection [Noxafil] 400mg",{"trials":3614,"activeCount":97},[],{"intervention":3612,"totalTrials":132,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3623,"PHASE4":3625,"NA":3631},{"trials":3618,"activeCount":97},[],{"trials":3620,"activeCount":97},[],{"trials":3622,"activeCount":97},[],{"trials":3624,"activeCount":97},[],{"trials":3626,"activeCount":97},[3627],{"nctId":3605,"briefTitle":3606,"status":103,"phases":3628,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":1362,"conditions":3629,"interventions":3630},[88],[3542],[3592,3612],{"trials":3632,"activeCount":97},[],{"intervention":170,"totalTrials":132,"cells":3634},{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3641,"PHASE4":3643,"NA":3649},{"trials":3636,"activeCount":97},[],{"trials":3638,"activeCount":97},[],{"trials":3640,"activeCount":97},[],{"trials":3642,"activeCount":97},[],{"trials":3644,"activeCount":97},[3645],{"nctId":159,"briefTitle":160,"status":161,"phases":3646,"primaryCompletion":163,"start":164,"enrollment":165,"conditions":3647,"interventions":3648},[88],[167,168,20],[170,171,54,172],{"trials":3650,"activeCount":97},[],{"intervention":171,"totalTrials":132,"cells":3652},{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3659,"PHASE4":3661,"NA":3667},{"trials":3654,"activeCount":97},[],{"trials":3656,"activeCount":97},[],{"trials":3658,"activeCount":97},[],{"trials":3660,"activeCount":97},[],{"trials":3662,"activeCount":97},[3663],{"nctId":159,"briefTitle":160,"status":161,"phases":3664,"primaryCompletion":163,"start":164,"enrollment":165,"conditions":3665,"interventions":3666},[88],[167,168,20],[170,171,54,172],{"trials":3668,"activeCount":97},[],{"intervention":172,"totalTrials":132,"cells":3670},{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3677,"PHASE4":3679,"NA":3685},{"trials":3672,"activeCount":97},[],{"trials":3674,"activeCount":97},[],{"trials":3676,"activeCount":97},[],{"trials":3678,"activeCount":97},[],{"trials":3680,"activeCount":97},[3681],{"nctId":159,"briefTitle":160,"status":161,"phases":3682,"primaryCompletion":163,"start":164,"enrollment":165,"conditions":3683,"interventions":3684},[88],[167,168,20],[170,171,54,172],{"trials":3686,"activeCount":97},[],{"intervention":3688,"totalTrials":132,"cells":3689},"Rivaroxaban 20mg",{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3710},{"trials":3691,"activeCount":97},[],{"trials":3693,"activeCount":97},[],{"trials":3695,"activeCount":97},[],{"trials":3697,"activeCount":97},[],{"trials":3699,"activeCount":97},[3700],{"nctId":3701,"briefTitle":3702,"status":103,"phases":3703,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":1803,"conditions":3706,"interventions":3708},"NCT06314763","Rivaroxaban Sotorasib Interaction Study",[88],"2024-03-21","2023-11-09",[3707],"Drug Drug Interaction Study",[3688,3709],"Sotorasib 960mg",{"trials":3711,"activeCount":97},[],{"intervention":3709,"totalTrials":132,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3720,"PHASE4":3722,"NA":3728},{"trials":3715,"activeCount":97},[],{"trials":3717,"activeCount":97},[],{"trials":3719,"activeCount":97},[],{"trials":3721,"activeCount":97},[],{"trials":3723,"activeCount":97},[3724],{"nctId":3701,"briefTitle":3702,"status":103,"phases":3725,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":1803,"conditions":3726,"interventions":3727},[88],[3707],[3688,3709],{"trials":3729,"activeCount":97},[],{"intervention":3731,"totalTrials":132,"cells":3732},"everolimus dose escalation",{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3752},{"trials":3734,"activeCount":97},[],{"trials":3736,"activeCount":97},[],{"trials":3738,"activeCount":97},[],{"trials":3740,"activeCount":97},[],{"trials":3742,"activeCount":97},[3743],{"nctId":3744,"briefTitle":3745,"status":103,"phases":3746,"primaryCompletion":3747,"completion":3747,"start":1667,"enrollment":3748,"conditions":3749,"interventions":3751},"NCT01948960","Influence of Exceptional Patient Characteristics on Everolimus Exposure",[88],"2018-01-15",56,[3750],"Breast Neoplasms",[3731],{"trials":3753,"activeCount":97},[],{"intervention":208,"totalTrials":132,"cells":3755},{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3764,"NA":3770},{"trials":3757,"activeCount":97},[],{"trials":3759,"activeCount":97},[],{"trials":3761,"activeCount":97},[],{"trials":3763,"activeCount":97},[],{"trials":3765,"activeCount":97},[3766],{"nctId":198,"briefTitle":199,"status":103,"phases":3767,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":3768,"interventions":3769},[88],[193],[207,208],{"trials":3771,"activeCount":97},[],{"intervention":3773,"totalTrials":132,"cells":3774},"BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331",{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3797},{"trials":3776,"activeCount":97},[],{"trials":3778,"activeCount":97},[],{"trials":3780,"activeCount":97},[],{"trials":3782,"activeCount":97},[],{"trials":3784,"activeCount":97},[3785],{"nctId":3786,"briefTitle":3787,"status":161,"phases":3788,"primaryCompletion":3789,"completion":3790,"start":3791,"enrollment":3792,"conditions":3793,"interventions":3796},"NCT05766345","BCG-induced Epigenetic Modifications in the NEXT Generation",[88],"2024-08","2024-10","2023-10-02",36,[1395,3794,3795],"BCG Vaccine","Epigenetics",[3773],{"trials":3798,"activeCount":97},[],{"intervention":3800,"totalTrials":132,"cells":3801},"Fluconazole 200mg tab",{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3808,"PHASE4":3810,"NA":3825},{"trials":3803,"activeCount":97},[],{"trials":3805,"activeCount":97},[],{"trials":3807,"activeCount":97},[],{"trials":3809,"activeCount":97},[],{"trials":3811,"activeCount":97},[3812],{"nctId":3813,"briefTitle":3814,"status":103,"phases":3815,"primaryCompletion":3816,"completion":3816,"start":3817,"enrollment":1034,"conditions":3818,"interventions":3823},"NCT04122560","Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration",[88],"2021-03-23","2019-11-30",[3819,3820,3821,3822],"Fluconazole","Candidiasis","Invasive Fungal Infections","Obesity",[3800,3824],"Fluconazole 2 MG\u002FML",{"trials":3826,"activeCount":97},[],{"intervention":3824,"totalTrials":132,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3833,"PHASE3":3835,"PHASE4":3837,"NA":3843},{"trials":3830,"activeCount":97},[],{"trials":3832,"activeCount":97},[],{"trials":3834,"activeCount":97},[],{"trials":3836,"activeCount":97},[],{"trials":3838,"activeCount":97},[3839],{"nctId":3813,"briefTitle":3814,"status":103,"phases":3840,"primaryCompletion":3816,"completion":3816,"start":3817,"enrollment":1034,"conditions":3841,"interventions":3842},[88],[3819,3820,3821,3822],[3800,3824],{"trials":3844,"activeCount":97},[],{"intervention":3846,"totalTrials":93,"cells":3847},"Rituximab",{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3852,"PHASE3":3854,"PHASE4":3878,"NA":3880},{"trials":3849,"activeCount":97},[],{"trials":3851,"activeCount":97},[],{"trials":3853,"activeCount":97},[],{"trials":3855,"activeCount":97},[3856,3869],{"nctId":3857,"briefTitle":3858,"status":161,"phases":3859,"primaryCompletion":3860,"completion":3861,"start":3862,"enrollment":1392,"conditions":3863,"interventions":3867},"NCT03298698","Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome",[87],"2021-08-22","2022-01-22","2018-08-22",[3864,3865,3866],"Idiopathic Nephrotic Syndrome","Minimal Change Disease","Focal Segmental Glomerulosclerosis",[3846,3868],"Prednisone",{"nctId":3870,"briefTitle":3871,"status":103,"phases":3872,"primaryCompletion":2064,"completion":3873,"start":3874,"enrollment":596,"conditions":3875,"interventions":3877},"NCT00565331","Rituximab for Prevention of Rejection After Renal Transplantation",[86,87],"2015-06","2007-12",[3876],"Kidney Transplantation",[3846],{"trials":3879,"activeCount":97},[],{"trials":3881,"activeCount":97},[],{"intervention":3883,"totalTrials":93,"cells":3884},"Sirolimus",{"EARLY_PHASE1":3885,"PHASE1":3887,"PHASE2":3899,"PHASE3":3901,"PHASE4":3912,"NA":3914},{"trials":3886,"activeCount":97},[],{"trials":3888,"activeCount":97},[3889],{"nctId":3890,"briefTitle":3891,"status":103,"phases":3892,"primaryCompletion":3893,"start":3894,"conditions":3895,"interventions":3897},"NCT00509613","Phase 1 Study With Sorafenib and Sirolimus",[85],"2009-05","2007-06",[1235,3896],"Refractory to Standard Therapies",[3898,3883],"Sorafenib",{"trials":3900,"activeCount":97},[],{"trials":3902,"activeCount":97},[3903],{"nctId":3904,"briefTitle":3905,"status":161,"phases":3906,"primaryCompletion":3907,"completion":3377,"start":3908,"enrollment":491,"conditions":3909,"interventions":3911},"NCT03987152","Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life",[87],"2021-09-18","2017-09-18",[3910],"Vascular Malformations",[3883],{"trials":3913,"activeCount":97},[],{"trials":3915,"activeCount":97},[],{"intervention":3917,"totalTrials":93,"cells":3918},"Ursodeoxycholic acid",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3935,"PHASE4":3949,"NA":3951},{"trials":3920,"activeCount":97},[],{"trials":3922,"activeCount":97},[],{"trials":3924,"activeCount":97},[3925],{"nctId":3926,"briefTitle":3927,"status":103,"phases":3928,"primaryCompletion":636,"completion":636,"start":2064,"enrollment":3929,"conditions":3930,"interventions":3933},"NCT02021110","Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease",[86],34,[3931,3932],"Polycystic Liver Disease","Polycystic Kidney, Autosomal Dominant",[3934],"Ursodeoxycholic Acid",{"trials":3936,"activeCount":97},[3937],{"nctId":3938,"briefTitle":3939,"status":103,"phases":3940,"primaryCompletion":3941,"completion":1752,"start":3893,"enrollment":3942,"conditions":3943,"interventions":3947},"NCT00808743","Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis",[86,87],"2011-07",37,[3944,3945,3946],"Familial Adenomatous Polyposis","Duodenal Neoplasms","Duodenal Polyps",[3948,3917],"Celecoxib",{"trials":3950,"activeCount":97},[],{"trials":3952,"activeCount":97},[],{"intervention":3954,"totalTrials":93,"cells":3955},"Interferon-gamma, Recombinant",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3962,"PHASE4":3978,"NA":3980},{"trials":3957,"activeCount":97},[],{"trials":3959,"activeCount":97},[],{"trials":3961,"activeCount":97},[],{"trials":3963,"activeCount":97},[3964,3970],{"nctId":3965,"briefTitle":3966,"status":161,"phases":3967,"primaryCompletion":1752,"start":554,"enrollment":165,"conditions":3968,"interventions":3969},"NCT01270490","Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia",[87],[1130],[3954],{"nctId":3971,"briefTitle":3972,"status":103,"phases":3973,"primaryCompletion":1473,"completion":1473,"start":3974,"enrollment":561,"conditions":3975,"interventions":3977},"NCT01649921","The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis",[87],"2012-11",[33,3976],"Septic Shock",[3954],{"trials":3979,"activeCount":97},[],{"trials":3981,"activeCount":97},[],{"intervention":3983,"totalTrials":132,"cells":3984},"Zirconium-89 girentuximab PET\u002FCT",{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3991,"PHASE4":4000,"NA":4002},{"trials":3986,"activeCount":97},[],{"trials":3988,"activeCount":97},[],{"trials":3990,"activeCount":97},[],{"trials":3992,"activeCount":97},[3993],{"nctId":3994,"briefTitle":3995,"status":103,"phases":3996,"primaryCompletion":3997,"completion":3997,"start":534,"enrollment":637,"conditions":3998,"interventions":3999},"NCT02883153","Zirconium-89-girentuximab PET\u002FCT Imaging in Renal Cell Carcinoma",[86,87],"2017-06-06",[2317],[3983],{"trials":4001,"activeCount":97},[],{"trials":4003,"activeCount":97},[],{"intervention":4005,"totalTrials":132,"cells":4006},"Alt-711",{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4013,"PHASE4":4025,"NA":4027},{"trials":4008,"activeCount":97},[],{"trials":4010,"activeCount":97},[],{"trials":4012,"activeCount":97},[],{"trials":4014,"activeCount":97},[4015],{"nctId":4016,"briefTitle":4017,"status":103,"phases":4018,"primaryCompletion":4019,"completion":4019,"start":4020,"enrollment":3040,"conditions":4021,"interventions":4024},"NCT01417663","Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function",[86,87],"2011-06","2008-11",[1745,4022,1365,4023],"Aging","Physical Activity",[4005],{"trials":4026,"activeCount":97},[],{"trials":4028,"activeCount":97},[],{"intervention":4030,"totalTrials":132,"cells":4031},"mycophenolate mofetil orally 1000 mg twice a day",{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4050,"NA":4052},{"trials":4033,"activeCount":97},[],{"trials":4035,"activeCount":97},[],{"trials":4037,"activeCount":97},[],{"trials":4039,"activeCount":97},[4040],{"nctId":4041,"briefTitle":4042,"status":103,"phases":4043,"start":4044,"enrollment":637,"conditions":4045,"interventions":4047},"NCT00135967","Mycophenolate Mofetil in Membranous Nephropathy",[86,87],"2002-05",[4046],"Glomerulonephritis, Membranous",[4030,4048,4049],"prednisone 0,5 mg\u002Fkg orally on alternate days","intravenous (i.v.) methylprednisolone 1000 mg, total 9",{"trials":4051,"activeCount":97},[],{"trials":4053,"activeCount":97},[],{"intervention":4048,"totalTrials":132,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4062,"PHASE4":4068,"NA":4070},{"trials":4057,"activeCount":97},[],{"trials":4059,"activeCount":97},[],{"trials":4061,"activeCount":97},[],{"trials":4063,"activeCount":97},[4064],{"nctId":4041,"briefTitle":4042,"status":103,"phases":4065,"start":4044,"enrollment":637,"conditions":4066,"interventions":4067},[86,87],[4046],[4030,4048,4049],{"trials":4069,"activeCount":97},[],{"trials":4071,"activeCount":97},[],{"intervention":4049,"totalTrials":132,"cells":4073},{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4086,"NA":4088},{"trials":4075,"activeCount":97},[],{"trials":4077,"activeCount":97},[],{"trials":4079,"activeCount":97},[],{"trials":4081,"activeCount":97},[4082],{"nctId":4041,"briefTitle":4042,"status":103,"phases":4083,"start":4044,"enrollment":637,"conditions":4084,"interventions":4085},[86,87],[4046],[4030,4048,4049],{"trials":4087,"activeCount":97},[],{"trials":4089,"activeCount":97},[],{"intervention":4091,"totalTrials":132,"cells":4092},"hyperbaric oxygen",{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4099,"PHASE4":4110,"NA":4112},{"trials":4094,"activeCount":97},[],{"trials":4096,"activeCount":97},[],{"trials":4098,"activeCount":97},[],{"trials":4100,"activeCount":97},[4101],{"nctId":4102,"briefTitle":4103,"status":607,"phases":4104,"primaryCompletion":4105,"completion":4106,"start":1774,"enrollment":165,"conditions":4107,"interventions":4109},"NCT00989820","Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Osteoradionecrosis",[86,87],"2017-05-01","2020-03-01",[4108],"Osteoradionecrosis",[4091],{"trials":4111,"activeCount":97},[],{"trials":4113,"activeCount":97},[],{"intervention":4115,"totalTrials":132,"cells":4116},"Exenatide",{"EARLY_PHASE1":4117,"PHASE1":4119,"PHASE2":4121,"PHASE3":4123,"PHASE4":4135,"NA":4137},{"trials":4118,"activeCount":97},[],{"trials":4120,"activeCount":97},[],{"trials":4122,"activeCount":97},[],{"trials":4124,"activeCount":97},[4125],{"nctId":4126,"briefTitle":4127,"status":103,"phases":4128,"primaryCompletion":4129,"completion":4130,"start":4131,"enrollment":1102,"conditions":4132,"interventions":4134},"NCT02735031","Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes",[86,87],"2018-03-28","2018-04-09","2017-02-21",[1496,4133],"Hypoglycemia",[4115],{"trials":4136,"activeCount":97},[],{"trials":4138,"activeCount":97},[],{"intervention":1831,"totalTrials":132,"cells":4140},{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4153,"NA":4155},{"trials":4142,"activeCount":97},[],{"trials":4144,"activeCount":97},[],{"trials":4146,"activeCount":97},[],{"trials":4148,"activeCount":97},[4149],{"nctId":1824,"briefTitle":1825,"status":103,"phases":4150,"primaryCompletion":594,"completion":1827,"start":1828,"enrollment":165,"conditions":4151,"interventions":4152},[86,87],[33],[1813,1831],{"trials":4154,"activeCount":97},[],{"trials":4156,"activeCount":97},[],{"intervention":3868,"totalTrials":132,"cells":4158},{"EARLY_PHASE1":4159,"PHASE1":4161,"PHASE2":4163,"PHASE3":4165,"PHASE4":4171,"NA":4173},{"trials":4160,"activeCount":97},[],{"trials":4162,"activeCount":97},[],{"trials":4164,"activeCount":97},[],{"trials":4166,"activeCount":97},[4167],{"nctId":3857,"briefTitle":3858,"status":161,"phases":4168,"primaryCompletion":3860,"completion":3861,"start":3862,"enrollment":1392,"conditions":4169,"interventions":4170},[87],[3864,3865,3866],[3846,3868],{"trials":4172,"activeCount":97},[],{"trials":4174,"activeCount":97},[],{"intervention":4176,"totalTrials":132,"cells":4177},"ATG Fresenius",{"EARLY_PHASE1":4178,"PHASE1":4180,"PHASE2":4182,"PHASE3":4184,"PHASE4":4196,"NA":4198},{"trials":4179,"activeCount":97},[],{"trials":4181,"activeCount":97},[],{"trials":4183,"activeCount":97},[],{"trials":4185,"activeCount":97},[4186],{"nctId":4187,"briefTitle":4188,"status":161,"phases":4189,"primaryCompletion":2038,"completion":1361,"start":4190,"enrollment":4191,"conditions":4192,"interventions":4195},"NCT00733733","Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor",[87],"2008-01",180,[4193,4194],"Renal Transplant Patients","Recipients of a Kidney From a Non-Heart-Beating Donor",[4176],{"trials":4197,"activeCount":97},[],{"trials":4199,"activeCount":97},[],{"intervention":4201,"totalTrials":132,"cells":4202},"steroid eye drops",{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4207,"PHASE3":4209,"PHASE4":4221,"NA":4223},{"trials":4204,"activeCount":97},[],{"trials":4206,"activeCount":97},[],{"trials":4208,"activeCount":97},[],{"trials":4210,"activeCount":97},[4211],{"nctId":4212,"briefTitle":4213,"status":161,"phases":4214,"primaryCompletion":4215,"completion":4216,"start":4217,"enrollment":1392,"conditions":4218,"interventions":4220},"NCT05633576","Steroid Eye Drops in Chronic Central Serous Chorioretinopathy",[87],"2025-06-19","2025-07-19","2023-02-19",[4219],"Chronic Central Serous Chorioretinopathy",[4201],{"trials":4222,"activeCount":97},[],{"trials":4224,"activeCount":97},[],{"intervention":4226,"totalTrials":132,"cells":4227},"ferumoxtran-10",{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4232,"PHASE3":4234,"PHASE4":4245,"NA":4247},{"trials":4229,"activeCount":97},[],{"trials":4231,"activeCount":97},[],{"trials":4233,"activeCount":97},[],{"trials":4235,"activeCount":97},[4236],{"nctId":4237,"briefTitle":4238,"status":161,"phases":4239,"primaryCompletion":4240,"completion":4241,"start":3873,"enrollment":637,"conditions":4242,"interventions":4244},"NCT02751606","Nano MRI on 7 Tesla in Rectal and Breast Cancer",[87],"2019-06","2019-11",[4243,3750],"Rectal Neoplasms",[4226],{"trials":4246,"activeCount":97},[],{"trials":4248,"activeCount":97},[],{"intervention":3948,"totalTrials":132,"cells":4250},{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4263,"NA":4265},{"trials":4252,"activeCount":97},[],{"trials":4254,"activeCount":97},[],{"trials":4256,"activeCount":97},[],{"trials":4258,"activeCount":97},[4259],{"nctId":3938,"briefTitle":3939,"status":103,"phases":4260,"primaryCompletion":3941,"completion":1752,"start":3893,"enrollment":3942,"conditions":4261,"interventions":4262},[86,87],[3944,3945,3946],[3948,3917],{"trials":4264,"activeCount":97},[],{"trials":4266,"activeCount":97},[],{"intervention":4268,"totalTrials":132,"cells":4269},"nDC vaccination",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4288,"NA":4290},{"trials":4271,"activeCount":97},[],{"trials":4273,"activeCount":97},[],{"trials":4275,"activeCount":97},[],{"trials":4277,"activeCount":97},[4278],{"nctId":4279,"briefTitle":4280,"status":103,"phases":4281,"primaryCompletion":4282,"completion":4283,"start":2849,"enrollment":4284,"conditions":4285,"interventions":4287},"NCT02993315","Melanoma Patients Immunized with Natural DenDritic Cells",[87],"2024-01","2024-05",148,[4286],"Melanoma (Skin)",[4268],{"trials":4289,"activeCount":97},[],{"trials":4291,"activeCount":97},[],{"intervention":4293,"totalTrials":132,"cells":4294},"Cyclophosphamide and steroids",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4301,"PHASE4":4312,"NA":4314},{"trials":4296,"activeCount":97},[],{"trials":4298,"activeCount":97},[],{"trials":4300,"activeCount":97},[],{"trials":4302,"activeCount":97},[4303],{"nctId":4304,"briefTitle":4305,"status":103,"phases":4306,"primaryCompletion":4307,"completion":4307,"start":4308,"enrollment":4309,"conditions":4310,"interventions":4311},"NCT00135954","Treatment of Patients With Idiopathic Membranous Nephropathy",[87],"2008-07","1997-07",29,[4046],[4293],{"trials":4313,"activeCount":97},[],{"trials":4315,"activeCount":97},[],{"intervention":4317,"totalTrials":132,"cells":4318},"amoxicillin\u002Fclavulanic acid suspension",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4325,"PHASE4":4336,"NA":4338},{"trials":4320,"activeCount":97},[],{"trials":4322,"activeCount":97},[],{"trials":4324,"activeCount":97},[],{"trials":4326,"activeCount":97},[4327],{"nctId":4328,"briefTitle":4329,"status":161,"phases":4330,"primaryCompletion":2064,"completion":4331,"start":1677,"enrollment":4332,"conditions":4333,"interventions":4335},"NCT01598402","Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia",[86,87],"2014-12",106,[4334],"Head and Neck Cancer",[4317],{"trials":4337,"activeCount":97},[],{"trials":4339,"activeCount":97},[],{"intervention":4341,"totalTrials":132,"cells":4342},"Pembrolizumab",{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4360,"NA":4362},{"trials":4344,"activeCount":97},[],{"trials":4346,"activeCount":97},[],{"trials":4348,"activeCount":97},[],{"trials":4350,"activeCount":97},[4351],{"nctId":4352,"briefTitle":4353,"status":161,"phases":4354,"primaryCompletion":4355,"completion":4355,"start":4356,"enrollment":4357,"conditions":4358,"interventions":4359},"NCT04909684","Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC",[87],"2024-11","2020-11-18",750,[872],[4341],{"trials":4361,"activeCount":97},[],{"trials":4363,"activeCount":97},[],{"intervention":4365,"totalTrials":132,"cells":4366},"amitriptyline",{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4373,"PHASE4":4383,"NA":4385},{"trials":4368,"activeCount":97},[],{"trials":4370,"activeCount":97},[],{"trials":4372,"activeCount":97},[],{"trials":4374,"activeCount":97},[4375],{"nctId":4376,"briefTitle":4377,"status":161,"phases":4378,"primaryCompletion":1361,"completion":201,"start":1644,"enrollment":8,"conditions":4379,"interventions":4381},"NCT00740571","Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer",[87],[20,4380],"Neuralgia",[4365,4382],"pregabalin",{"trials":4384,"activeCount":97},[],{"trials":4386,"activeCount":97},[],{"intervention":4382,"totalTrials":132,"cells":4388},{"EARLY_PHASE1":4389,"PHASE1":4391,"PHASE2":4393,"PHASE3":4395,"PHASE4":4401,"NA":4403},{"trials":4390,"activeCount":97},[],{"trials":4392,"activeCount":97},[],{"trials":4394,"activeCount":97},[],{"trials":4396,"activeCount":97},[4397],{"nctId":4376,"briefTitle":4377,"status":161,"phases":4398,"primaryCompletion":1361,"completion":201,"start":1644,"enrollment":8,"conditions":4399,"interventions":4400},[87],[20,4380],[4365,4382],{"trials":4402,"activeCount":97},[],{"trials":4404,"activeCount":97},[],{"intervention":4406,"totalTrials":132,"cells":4407},"Pasireotide LAR 60 mg",{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4414,"PHASE4":4423,"NA":4425},{"trials":4409,"activeCount":97},[],{"trials":4411,"activeCount":97},[],{"trials":4413,"activeCount":97},[],{"trials":4415,"activeCount":97},[4416],{"nctId":4417,"briefTitle":4418,"status":103,"phases":4419,"primaryCompletion":106,"completion":1032,"start":2064,"enrollment":3929,"conditions":4420,"interventions":4422},"NCT02048319","Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts",[87],[4421],"Symptomatic Dominant Liver Cyst",[4406],{"trials":4424,"activeCount":97},[],{"trials":4426,"activeCount":97},[],{"intervention":4428,"totalTrials":132,"cells":4429},"Octreotide",{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4434,"PHASE3":4436,"PHASE4":4450,"NA":4452},{"trials":4431,"activeCount":97},[],{"trials":4433,"activeCount":97},[],{"trials":4435,"activeCount":97},[],{"trials":4437,"activeCount":97},[4438],{"nctId":4439,"briefTitle":4440,"status":103,"phases":4441,"primaryCompletion":4442,"completion":4443,"start":577,"enrollment":4444,"conditions":4445,"interventions":4449},"NCT02384122","Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias",[87],"2022-07","2023-05",62,[4446,3910,4447,4448],"Angiodysplasia","Gastrointestinal Hemorrhage","Anemia",[4428],{"trials":4451,"activeCount":97},[],{"trials":4453,"activeCount":97},[],{"intervention":4455,"totalTrials":132,"cells":4456},"vildagliptin + acarbose",{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4463,"PHASE4":4473,"NA":4475},{"trials":4458,"activeCount":97},[],{"trials":4460,"activeCount":97},[],{"trials":4462,"activeCount":97},[],{"trials":4464,"activeCount":97},[4465],{"nctId":4466,"briefTitle":4467,"status":103,"phases":4468,"primaryCompletion":1787,"completion":1033,"start":2038,"enrollment":107,"conditions":4469,"interventions":4471},"NCT01000688","Vildagliptin and Endothelium-dependent Vasodilatation",[87],[4470,1365],"Type 2 Diabetes",[4455,4472],"acarbose + vildagliptin",{"trials":4474,"activeCount":97},[],{"trials":4476,"activeCount":97},[],{"intervention":4472,"totalTrials":132,"cells":4478},{"EARLY_PHASE1":4479,"PHASE1":4481,"PHASE2":4483,"PHASE3":4485,"PHASE4":4491,"NA":4493},{"trials":4480,"activeCount":97},[],{"trials":4482,"activeCount":97},[],{"trials":4484,"activeCount":97},[],{"trials":4486,"activeCount":97},[4487],{"nctId":4466,"briefTitle":4467,"status":103,"phases":4488,"primaryCompletion":1787,"completion":1033,"start":2038,"enrollment":107,"conditions":4489,"interventions":4490},[87],[4470,1365],[4455,4472],{"trials":4492,"activeCount":97},[],{"trials":4494,"activeCount":97},[],{"intervention":4496,"totalTrials":132,"cells":4497},"Doxorubicin",{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4504,"PHASE4":4516,"NA":4518},{"trials":4499,"activeCount":97},[],{"trials":4501,"activeCount":97},[],{"trials":4503,"activeCount":97},[],{"trials":4505,"activeCount":97},[4506],{"nctId":4507,"briefTitle":4508,"status":103,"phases":4509,"primaryCompletion":4510,"start":4511,"enrollment":1128,"conditions":4512,"interventions":4513},"NCT00314977","Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.",[87],"2009-04","2006-02",[30],[4496,4514,4515],"Cyclophosphamide","Docetaxel",{"trials":4517,"activeCount":97},[],{"trials":4519,"activeCount":97},[],{"intervention":4514,"totalTrials":132,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4528,"PHASE4":4534,"NA":4536},{"trials":4523,"activeCount":97},[],{"trials":4525,"activeCount":97},[],{"trials":4527,"activeCount":97},[],{"trials":4529,"activeCount":97},[4530],{"nctId":4507,"briefTitle":4508,"status":103,"phases":4531,"primaryCompletion":4510,"start":4511,"enrollment":1128,"conditions":4532,"interventions":4533},[87],[30],[4496,4514,4515],{"trials":4535,"activeCount":97},[],{"trials":4537,"activeCount":97},[],{"intervention":4515,"totalTrials":132,"cells":4539},{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4544,"PHASE3":4546,"PHASE4":4552,"NA":4554},{"trials":4541,"activeCount":97},[],{"trials":4543,"activeCount":97},[],{"trials":4545,"activeCount":97},[],{"trials":4547,"activeCount":97},[4548],{"nctId":4507,"briefTitle":4508,"status":103,"phases":4549,"primaryCompletion":4510,"start":4511,"enrollment":1128,"conditions":4550,"interventions":4551},[87],[30],[4496,4514,4515],{"trials":4553,"activeCount":97},[],{"trials":4555,"activeCount":97},[],{"intervention":4557,"totalTrials":132,"cells":4558},"taurolidine",{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4565,"PHASE4":4575,"NA":4577},{"trials":4560,"activeCount":97},[],{"trials":4562,"activeCount":97},[],{"trials":4564,"activeCount":97},[],{"trials":4566,"activeCount":97},[4567],{"nctId":4568,"briefTitle":4569,"status":103,"phases":4570,"primaryCompletion":2039,"completion":2039,"start":4571,"enrollment":230,"conditions":4572,"interventions":4574},"NCT00321165","The AOT (Acridine Orange and Taurolidine) Trial",[87],"2006-06",[4573,640,33],"Parenteral Nutrition",[4557],{"trials":4576,"activeCount":97},[],{"trials":4578,"activeCount":97},[],{"intervention":4580,"totalTrials":93,"cells":4581},"Durvalumab",{"EARLY_PHASE1":4582,"PHASE1":4584,"PHASE2":4586,"PHASE3":4607,"PHASE4":4609,"NA":4611},{"trials":4583,"activeCount":97},[],{"trials":4585,"activeCount":97},[],{"trials":4587,"activeCount":97},[4588,4598],{"nctId":4589,"briefTitle":4590,"status":103,"phases":4591,"primaryCompletion":4592,"completion":4593,"start":4594,"enrollment":4595,"conditions":4596,"interventions":4597},"NCT03829007","PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC",[85,86],"2020-12-17","2021-12-09","2019-04-15",33,[4334],[4580],{"nctId":4599,"briefTitle":4600,"status":103,"phases":4601,"primaryCompletion":4602,"completion":4602,"start":4603,"enrollment":165,"conditions":4604,"interventions":4606},"NCT03853187","Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer",[86],"2022-12-06","2019-09-19",[4605],"Non-small Cell Lung Cancer",[4580],{"trials":4608,"activeCount":97},[],{"trials":4610,"activeCount":97},[],{"trials":4612,"activeCount":97},[],{"intervention":4614,"totalTrials":93,"cells":4615},"Rifampicin",{"EARLY_PHASE1":4616,"PHASE1":4618,"PHASE2":4631,"PHASE3":4643,"PHASE4":4645,"NA":4647},{"trials":4617,"activeCount":97},[],{"trials":4619,"activeCount":97},[4620],{"nctId":4621,"briefTitle":4622,"status":103,"phases":4623,"primaryCompletion":4624,"completion":4624,"start":4625,"enrollment":1034,"conditions":4626,"interventions":4628},"NCT04525235","Phenotyping of High Dose Rifampicin",[85],"2021-08-12","2021-01-07",[4627],"Tuberculosis",[4629,4630],"phenotyping cocktail","rifampicin",{"trials":4632,"activeCount":97},[4633],{"nctId":4634,"briefTitle":4635,"status":103,"phases":4636,"primaryCompletion":4637,"completion":4638,"start":4019,"enrollment":4639,"conditions":4640,"interventions":4642},"NCT01392911","Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB",[86],"2018-07","2018-11",128,[4641],"Pulmonary Tuberculosis (TB)",[4614],{"trials":4644,"activeCount":97},[],{"trials":4646,"activeCount":97},[],{"trials":4648,"activeCount":97},[],{"intervention":4650,"totalTrials":93,"cells":4651},"Tetrahydrocannabinol",{"EARLY_PHASE1":4652,"PHASE1":4654,"PHASE2":4656,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4653,"activeCount":97},[],{"trials":4655,"activeCount":97},[],{"trials":4657,"activeCount":97},[4658,4668],{"nctId":4659,"briefTitle":4660,"status":103,"phases":4661,"primaryCompletion":536,"completion":536,"start":4662,"enrollment":4309,"conditions":4663,"interventions":4667},"NCT01551511","Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain",[86],"2012-10",[4664,4665,4666],"Pancreatitis, Chronic","Abdominal Pain","Chronic Pain",[4650],{"nctId":4669,"briefTitle":4670,"status":103,"phases":4671,"primaryCompletion":536,"completion":536,"start":4662,"enrollment":3792,"conditions":4672,"interventions":4674},"NCT01562483","The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain",[86],[4673,4665,4666],"Postsurgical Pain",[4650],{"trials":4676,"activeCount":97},[],{"trials":4678,"activeCount":97},[],{"trials":4680,"activeCount":97},[],{"intervention":4682,"totalTrials":93,"cells":4683},"Namisol",{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4685,"activeCount":97},[],{"trials":4687,"activeCount":97},[],{"trials":4689,"activeCount":97},[4690,4699],{"nctId":4691,"briefTitle":4692,"status":103,"phases":4693,"primaryCompletion":1349,"completion":1349,"start":1359,"enrollment":1362,"conditions":4694,"interventions":4697},"NCT01318369","Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain",[86],[4695,4650,4696,4665],"Cannabinoid","Chronic Pancreatitis",[4682,4698],"Diazepam",{"nctId":4700,"briefTitle":4701,"status":161,"phases":4702,"primaryCompletion":593,"completion":1655,"start":1666,"enrollment":1392,"conditions":4703,"interventions":4705},"NCT01790555","Perioperative Δ9-THC for Postsurgical Pain",[86],[4704],"Pain",[4682,4706],"Diazepam\u002Fplacebo",{"trials":4708,"activeCount":97},[],{"trials":4710,"activeCount":97},[],{"trials":4712,"activeCount":97},[],{"intervention":4714,"totalTrials":93,"cells":4715},"autologous dendritic cell vaccine",{"EARLY_PHASE1":4716,"PHASE1":4718,"PHASE2":4720,"PHASE3":4738,"PHASE4":4740,"NA":4742},{"trials":4717,"activeCount":97},[],{"trials":4719,"activeCount":97},[],{"trials":4721,"activeCount":97},[4722,4729],{"nctId":4723,"briefTitle":4724,"status":103,"phases":4725,"primaryCompletion":1827,"completion":1827,"start":2073,"enrollment":4726,"conditions":4727,"interventions":4728},"NCT01530698","Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients",[85,86],28,[1044],[4714,4714],{"nctId":4730,"briefTitle":4731,"status":103,"phases":4732,"primaryCompletion":1788,"start":4733,"enrollment":4734,"conditions":4735,"interventions":4737},"NCT00243529","Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients",[85,86],"2004-04",64,[4736],"Melanoma Stage III or IV",[4714],{"trials":4739,"activeCount":97},[],{"trials":4741,"activeCount":97},[],{"trials":4743,"activeCount":97},[],{"intervention":4745,"totalTrials":93,"cells":4746},"delta-9-tetrahydrocannabinol",{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4759,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4748,"activeCount":97},[],{"trials":4750,"activeCount":97},[4751],{"nctId":4752,"briefTitle":4753,"status":103,"phases":4754,"primaryCompletion":553,"completion":553,"start":4755,"enrollment":512,"conditions":4756,"interventions":4758},"NCT01740960","Safety and Tolerability of Namisol in the Elderly",[85],"2012-08",[4757],"Drug Safety",[4745],{"trials":4760,"activeCount":97},[4761],{"nctId":4762,"briefTitle":4763,"status":103,"phases":4764,"primaryCompletion":536,"completion":536,"start":4765,"enrollment":390,"conditions":4766,"interventions":4771},"NCT01608217","Delta-THC in Dementia",[86],"2012-06",[4767,4704,4768,4769,4770],"Behavioural Disturbances","Dementia","Alzheimer's Dementia","Vascular Dementia",[4745,4772,4772],"Acetaminophen",{"trials":4774,"activeCount":97},[],{"trials":4776,"activeCount":97},[],{"trials":4778,"activeCount":97},[],{"intervention":1998,"totalTrials":93,"cells":4780},{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4785,"PHASE3":4800,"PHASE4":4802,"NA":4804},{"trials":4782,"activeCount":97},[],{"trials":4784,"activeCount":97},[],{"trials":4786,"activeCount":97},[4787,4791],{"nctId":1991,"briefTitle":1992,"status":607,"phases":4788,"primaryCompletion":1473,"completion":1473,"start":1994,"enrollment":501,"conditions":4789,"interventions":4790},[86],[1996],[113,1982,1998],{"nctId":4792,"briefTitle":4793,"status":103,"phases":4794,"primaryCompletion":201,"completion":554,"start":1773,"enrollment":165,"conditions":4795,"interventions":4796},"NCT00943540","Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients",[86],[1689,25],[4797,4798,4799],"raltegravir QD","atazanavir","lamivudine",{"trials":4801,"activeCount":97},[],{"trials":4803,"activeCount":97},[],{"trials":4805,"activeCount":97},[],{"intervention":4807,"totalTrials":93,"cells":4808},"UCB-NK cells",{"EARLY_PHASE1":4809,"PHASE1":4811,"PHASE2":4827,"PHASE3":4840,"PHASE4":4842,"NA":4844},{"trials":4810,"activeCount":97},[],{"trials":4812,"activeCount":97},[4813],{"nctId":4814,"briefTitle":4815,"status":103,"phases":4816,"primaryCompletion":4817,"completion":4818,"start":4819,"enrollment":4820,"conditions":4821,"interventions":4825},"NCT03539406","Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients",[85],"2023-05-01","2023-09-01","2019-06-04",11,[4822,4823,4824],"Recurrent Ovarian Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Primary Peritoneal Carcinoma",[4807,4826],"Chemotherapy",{"trials":4828,"activeCount":97},[4829],{"nctId":4830,"briefTitle":4831,"status":607,"phases":4832,"primaryCompletion":4833,"completion":4833,"start":4834,"enrollment":501,"conditions":4835,"interventions":4838},"NCT04347616","Natural Killer-cell Therapy for Acute Myeloid Leukemia",[85,86],"2026-01-30","2020-12-03",[4836,4837],"Acute Myeloid Leukemia Refractory","Acute Myeloid Leukemia, Relapsed, Adult",[4807,4839],"IL-2",{"trials":4841,"activeCount":97},[],{"trials":4843,"activeCount":97},[],{"trials":4845,"activeCount":97},[],{"intervention":4847,"totalTrials":93,"cells":4848},"EA-230",{"EARLY_PHASE1":4849,"PHASE1":4851,"PHASE2":4863,"PHASE3":4875,"PHASE4":4877,"NA":4879},{"trials":4850,"activeCount":97},[],{"trials":4852,"activeCount":97},[4853],{"nctId":4854,"briefTitle":4855,"status":103,"phases":4856,"primaryCompletion":4857,"completion":534,"start":4858,"enrollment":230,"conditions":4859,"interventions":4861},"NCT02629874","PK\u002FPD of EA-230 During Endotoxemia",[85],"2015-07","2015-02",[17,4860],"Systemic Inflammatory Response",[4847,4862],"Endotoxin",{"trials":4864,"activeCount":97},[4865],{"nctId":4866,"briefTitle":4867,"status":161,"phases":4868,"primaryCompletion":4869,"completion":4869,"start":4870,"enrollment":4191,"conditions":4871,"interventions":4874},"NCT03145220","Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)",[86],"2018-10","2016-06",[4872,4873],"Systemic Inflammatory Response Syndrome","Coronary Artery Bypass Grafting",[4847],{"trials":4876,"activeCount":97},[],{"trials":4878,"activeCount":97},[],{"trials":4880,"activeCount":97},[],{"intervention":4882,"totalTrials":93,"cells":4883},"Octreotide LAR",{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4885,"activeCount":97},[],{"trials":4887,"activeCount":97},[],{"trials":4889,"activeCount":97},[4890,4898],{"nctId":4891,"briefTitle":4892,"status":103,"phases":4893,"primaryCompletion":1406,"completion":1406,"start":1361,"enrollment":4894,"conditions":4895,"interventions":4896},"NCT01157858","Everolimus and LongActing Octreotide Trial in Polycystic Livers",[86],44,[3931],[4897,4882],"Everolimus",{"nctId":4899,"briefTitle":4900,"status":161,"phases":4901,"primaryCompletion":4637,"completion":4869,"start":2849,"enrollment":21,"conditions":4902,"interventions":4904},"NCT02874326","Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber",[86],[4903,4447,4448],"Hereditary Hemorrhagic Telangiectasia",[4882],{"trials":4906,"activeCount":97},[],{"trials":4908,"activeCount":97},[],{"trials":4910,"activeCount":97},[],{"intervention":4912,"totalTrials":93,"cells":4913},"TB31F",{"EARLY_PHASE1":4914,"PHASE1":4916,"PHASE2":4927,"PHASE3":4938,"PHASE4":4940,"NA":4942},{"trials":4915,"activeCount":97},[],{"trials":4917,"activeCount":97},[4918],{"nctId":4919,"briefTitle":4920,"status":103,"phases":4921,"primaryCompletion":4922,"completion":4922,"start":4923,"enrollment":1034,"conditions":4924,"interventions":4926},"NCT04238689","Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F",[85],"2021-03-04","2020-02-14",[4925],"Malaria,Falciparum",[4912],{"trials":4928,"activeCount":97},[4929],{"nctId":4930,"briefTitle":4931,"status":103,"phases":4932,"primaryCompletion":4933,"completion":4933,"start":4934,"enrollment":4935,"conditions":4936,"interventions":4937},"NCT06413108","Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali",[85,86],"2026-01-16","2024-07-12",167,[4925],[4912],{"trials":4939,"activeCount":97},[],{"trials":4941,"activeCount":97},[],{"trials":4943,"activeCount":97},[],{"intervention":4945,"totalTrials":132,"cells":4946},"Herpes zoster vaccination",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4964,"PHASE4":4966,"NA":4968},{"trials":4948,"activeCount":97},[],{"trials":4950,"activeCount":97},[],{"trials":4952,"activeCount":97},[4953],{"nctId":4954,"briefTitle":4955,"status":103,"phases":4956,"primaryCompletion":4957,"completion":4957,"start":4958,"enrollment":4284,"conditions":4959,"interventions":4962},"NCT05082688","Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)",[86],"2023-05-17","2021-09-20",[4960,4961],"Influenza","Herpes Zoster",[4945,4963],"Influenza Vaccine",{"trials":4965,"activeCount":97},[],{"trials":4967,"activeCount":97},[],{"trials":4969,"activeCount":97},[],{"intervention":4971,"totalTrials":132,"cells":4972},"RGD PET\u002FCT",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4988,"PHASE4":4990,"NA":4992},{"trials":4974,"activeCount":97},[],{"trials":4976,"activeCount":97},[],{"trials":4978,"activeCount":97},[4979],{"nctId":4980,"briefTitle":4981,"status":161,"phases":4982,"primaryCompletion":4983,"completion":4818,"start":4984,"enrollment":165,"conditions":4985,"interventions":4987},"NCT04222543","Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET\u002FCT Imaging",[86],"2022-09-01","2019-11-22",[4986],"Oropharyngeal Squamous Cell Carcinoma",[4971],{"trials":4989,"activeCount":97},[],{"trials":4991,"activeCount":97},[],{"trials":4993,"activeCount":97},[],{"intervention":4995,"totalTrials":132,"cells":4996},"A: myDC vaccination",{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5012,"PHASE4":5014,"NA":5016},{"trials":4998,"activeCount":97},[],{"trials":5000,"activeCount":97},[],{"trials":5002,"activeCount":97},[5003],{"nctId":5004,"briefTitle":5005,"status":103,"phases":5006,"primaryCompletion":5007,"completion":5007,"start":577,"enrollment":637,"conditions":5008,"interventions":5009},"NCT02574377","myDC\u002FpDC in Stage III Melanoma Patients",[85,86],"2021-09",[1044],[4995,5010,5011],"B: pDC vaccination","C: combined myDC\u002FpDC vaccination",{"trials":5013,"activeCount":97},[],{"trials":5015,"activeCount":97},[],{"trials":5017,"activeCount":97},[],{"intervention":5010,"totalTrials":132,"cells":5019},{"EARLY_PHASE1":5020,"PHASE1":5022,"PHASE2":5024,"PHASE3":5030,"PHASE4":5032,"NA":5034},{"trials":5021,"activeCount":97},[],{"trials":5023,"activeCount":97},[],{"trials":5025,"activeCount":97},[5026],{"nctId":5004,"briefTitle":5005,"status":103,"phases":5027,"primaryCompletion":5007,"completion":5007,"start":577,"enrollment":637,"conditions":5028,"interventions":5029},[85,86],[1044],[4995,5010,5011],{"trials":5031,"activeCount":97},[],{"trials":5033,"activeCount":97},[],{"trials":5035,"activeCount":97},[],{"intervention":5011,"totalTrials":132,"cells":5037},{"EARLY_PHASE1":5038,"PHASE1":5040,"PHASE2":5042,"PHASE3":5048,"PHASE4":5050,"NA":5052},{"trials":5039,"activeCount":97},[],{"trials":5041,"activeCount":97},[],{"trials":5043,"activeCount":97},[5044],{"nctId":5004,"briefTitle":5005,"status":103,"phases":5045,"primaryCompletion":5007,"completion":5007,"start":577,"enrollment":637,"conditions":5046,"interventions":5047},[85,86],[1044],[4995,5010,5011],{"trials":5049,"activeCount":97},[],{"trials":5051,"activeCount":97},[],{"trials":5053,"activeCount":97},[],{"intervention":5055,"totalTrials":132,"cells":5056},"Rifampicin in higher doses",{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5061,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5058,"activeCount":97},[],{"trials":5060,"activeCount":97},[],{"trials":5062,"activeCount":97},[5063],{"nctId":5064,"briefTitle":5065,"status":103,"phases":5066,"primaryCompletion":5067,"completion":5067,"start":510,"enrollment":748,"conditions":5068,"interventions":5069},"NCT00760149","Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis",[86],"2013-09",[4627],[5055],{"trials":5071,"activeCount":97},[],{"trials":5073,"activeCount":97},[],{"trials":5075,"activeCount":97},[],{"intervention":5077,"totalTrials":132,"cells":5078},"phenytoin",{"EARLY_PHASE1":5079,"PHASE1":5081,"PHASE2":5083,"PHASE3":5096,"PHASE4":5098,"NA":5100},{"trials":5080,"activeCount":97},[],{"trials":5082,"activeCount":97},[],{"trials":5084,"activeCount":97},[5085],{"nctId":5086,"briefTitle":5087,"status":103,"phases":5088,"primaryCompletion":4765,"completion":2273,"start":5089,"enrollment":5090,"conditions":5091,"interventions":5095},"NCT01187719","The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance",[86],"2010-05",66,[5092,5093,5094],"HIV-infection","Pregnancy","Mother to Child Transmission",[5077],{"trials":5097,"activeCount":97},[],{"trials":5099,"activeCount":97},[],{"trials":5101,"activeCount":97},[],{"intervention":5103,"totalTrials":132,"cells":5104},"Lu-177 PSMA-617",{"EARLY_PHASE1":5105,"PHASE1":5107,"PHASE2":5109,"PHASE3":5120,"PHASE4":5122,"NA":5124},{"trials":5106,"activeCount":97},[],{"trials":5108,"activeCount":97},[],{"trials":5110,"activeCount":97},[5111],{"nctId":5112,"briefTitle":5113,"status":103,"phases":5114,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":1102,"conditions":5117,"interventions":5119},"NCT03828838","Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer",[85,86],"2019-11-01","2018-07-01",[5118],"Prostate Neoplasm",[5103],{"trials":5121,"activeCount":97},[],{"trials":5123,"activeCount":97},[],{"trials":5125,"activeCount":97},[],{"intervention":5127,"totalTrials":132,"cells":5128},"immediate cediranib",{"EARLY_PHASE1":5129,"PHASE1":5131,"PHASE2":5133,"PHASE3":5144,"PHASE4":5146,"NA":5148},{"trials":5130,"activeCount":97},[],{"trials":5132,"activeCount":97},[],{"trials":5134,"activeCount":97},[5135],{"nctId":5136,"briefTitle":5137,"status":607,"phases":5138,"primaryCompletion":1677,"start":2073,"enrollment":512,"conditions":5139,"interventions":5142},"NCT01262612","Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion",[86],[5140,5141],"Malignant Ascites","Malignant Pleural Effusion",[5127,5143],"Start cediranib after 28 days Best Supportive Care",{"trials":5145,"activeCount":97},[],{"trials":5147,"activeCount":97},[],{"trials":5149,"activeCount":97},[],{"intervention":5143,"totalTrials":132,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5162,"PHASE4":5164,"NA":5166},{"trials":5153,"activeCount":97},[],{"trials":5155,"activeCount":97},[],{"trials":5157,"activeCount":97},[5158],{"nctId":5136,"briefTitle":5137,"status":607,"phases":5159,"primaryCompletion":1677,"start":2073,"enrollment":512,"conditions":5160,"interventions":5161},[86],[5140,5141],[5127,5143],{"trials":5163,"activeCount":97},[],{"trials":5165,"activeCount":97},[],{"trials":5167,"activeCount":97},[],{"intervention":5169,"totalTrials":132,"cells":5170},"Vemurafenib and Cobimetinib",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5175,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5172,"activeCount":97},[],{"trials":5174,"activeCount":97},[],{"trials":5176,"activeCount":97},[5177],{"nctId":5178,"briefTitle":5179,"status":161,"phases":5180,"primaryCompletion":5181,"completion":5182,"start":5183,"enrollment":1128,"conditions":5184,"interventions":5186},"NCT02968303","Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy",[86],"2022-10","2023-10","2017-01-27",[5185],"Melanoma, Malignant, of Soft Parts",[5169],{"trials":5188,"activeCount":97},[],{"trials":5190,"activeCount":97},[],{"trials":5192,"activeCount":97},[],{"intervention":4698,"totalTrials":132,"cells":5194},{"EARLY_PHASE1":5195,"PHASE1":5197,"PHASE2":5199,"PHASE3":5205,"PHASE4":5207,"NA":5209},{"trials":5196,"activeCount":97},[],{"trials":5198,"activeCount":97},[],{"trials":5200,"activeCount":97},[5201],{"nctId":4691,"briefTitle":4692,"status":103,"phases":5202,"primaryCompletion":1349,"completion":1349,"start":1359,"enrollment":1362,"conditions":5203,"interventions":5204},[86],[4695,4650,4696,4665],[4682,4698],{"trials":5206,"activeCount":97},[],{"trials":5208,"activeCount":97},[],{"trials":5210,"activeCount":97},[],{"intervention":5212,"totalTrials":132,"cells":5213},"Deferoxamine",{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5231,"PHASE4":5233,"NA":5235},{"trials":5215,"activeCount":97},[],{"trials":5217,"activeCount":97},[],{"trials":5219,"activeCount":97},[5220],{"nctId":5221,"briefTitle":5222,"status":161,"phases":5223,"primaryCompletion":5224,"completion":5225,"start":5226,"enrollment":1392,"conditions":5227,"interventions":5230},"NCT02875262","Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial",[85,86],"2024-01-01","2024-06-01","2022-12-02",[5228,5229],"Intracranial Aneurysm","Subarachnoid Hemorrhage",[5212],{"trials":5232,"activeCount":97},[],{"trials":5234,"activeCount":97},[],{"trials":5236,"activeCount":97},[],{"intervention":5238,"totalTrials":132,"cells":5239},"fosinopril",{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5244,"PHASE3":5255,"PHASE4":5257,"NA":5259},{"trials":5241,"activeCount":97},[],{"trials":5243,"activeCount":97},[],{"trials":5245,"activeCount":97},[5246],{"nctId":5247,"briefTitle":5248,"status":103,"phases":5249,"primaryCompletion":3941,"completion":3941,"start":5250,"enrollment":637,"conditions":5251,"interventions":5253},"NCT00315016","Eplerenone, ACE Inhibition and Albuminuria",[86],"2007-01",[5252],"Diabetic Nephropathy",[5254,5238],"eplerenone",{"trials":5256,"activeCount":97},[],{"trials":5258,"activeCount":97},[],{"trials":5260,"activeCount":97},[],{"intervention":5262,"totalTrials":132,"cells":5263},"Sulindac",{"EARLY_PHASE1":5264,"PHASE1":5266,"PHASE2":5268,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5265,"activeCount":97},[],{"trials":5267,"activeCount":97},[],{"trials":5269,"activeCount":97},[5270],{"nctId":5271,"briefTitle":5272,"status":161,"phases":5273,"completion":2248,"start":5274,"enrollment":637,"conditions":5275,"interventions":5277},"NCT00319007","Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis",[86],"2006-04",[5276],"Adenomatous Polyposis Coli",[5262,5278,5279],"VSL#3","Inulin",{"trials":5281,"activeCount":97},[],{"trials":5283,"activeCount":97},[],{"trials":5285,"activeCount":97},[],{"intervention":5278,"totalTrials":132,"cells":5287},{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5292,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5289,"activeCount":97},[],{"trials":5291,"activeCount":97},[],{"trials":5293,"activeCount":97},[5294],{"nctId":5271,"briefTitle":5272,"status":161,"phases":5295,"completion":2248,"start":5274,"enrollment":637,"conditions":5296,"interventions":5297},[86],[5276],[5262,5278,5279],{"trials":5299,"activeCount":97},[],{"trials":5301,"activeCount":97},[],{"trials":5303,"activeCount":97},[],{"intervention":5279,"totalTrials":132,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5307,"activeCount":97},[],{"trials":5309,"activeCount":97},[],{"trials":5311,"activeCount":97},[5312],{"nctId":5271,"briefTitle":5272,"status":161,"phases":5313,"completion":2248,"start":5274,"enrollment":637,"conditions":5314,"interventions":5315},[86],[5276],[5262,5278,5279],{"trials":5317,"activeCount":97},[],{"trials":5319,"activeCount":97},[],{"trials":5321,"activeCount":97},[],{"intervention":5323,"totalTrials":132,"cells":5324},"moxifloxacin",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5339,"PHASE4":5341,"NA":5343},{"trials":5326,"activeCount":97},[],{"trials":5328,"activeCount":97},[],{"trials":5330,"activeCount":97},[5331],{"nctId":5332,"briefTitle":5333,"status":103,"phases":5334,"primaryCompletion":5335,"completion":5335,"start":5336,"enrollment":2180,"conditions":5337,"interventions":5338},"NCT00306319","Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia",[86],"2006-05","2006-01",[4627],[5323],{"trials":5340,"activeCount":97},[],{"trials":5342,"activeCount":97},[],{"trials":5344,"activeCount":97},[],{"intervention":5346,"totalTrials":132,"cells":5347},"mDC vaccination",{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5367,"PHASE4":5369,"NA":5371},{"trials":5349,"activeCount":97},[],{"trials":5351,"activeCount":97},[],{"trials":5353,"activeCount":97},[5354],{"nctId":5355,"briefTitle":5356,"status":103,"phases":5357,"primaryCompletion":1474,"completion":5358,"start":577,"enrollment":1803,"conditions":5359,"interventions":5364},"NCT02692976","Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients",[86],"2019-03-06",[5360,5361,5362,5363],"Prostatic Neoplasms","Immunotherapy","Dendritic Cells","Vaccines",[5346,5365,5366],"pDC vaccination","mDC and pDC vaccination",{"trials":5368,"activeCount":97},[],{"trials":5370,"activeCount":97},[],{"trials":5372,"activeCount":97},[],{"intervention":5365,"totalTrials":132,"cells":5374},{"EARLY_PHASE1":5375,"PHASE1":5377,"PHASE2":5379,"PHASE3":5385,"PHASE4":5387,"NA":5389},{"trials":5376,"activeCount":97},[],{"trials":5378,"activeCount":97},[],{"trials":5380,"activeCount":97},[5381],{"nctId":5355,"briefTitle":5356,"status":103,"phases":5382,"primaryCompletion":1474,"completion":5358,"start":577,"enrollment":1803,"conditions":5383,"interventions":5384},[86],[5360,5361,5362,5363],[5346,5365,5366],{"trials":5386,"activeCount":97},[],{"trials":5388,"activeCount":97},[],{"trials":5390,"activeCount":97},[],{"intervention":5366,"totalTrials":132,"cells":5392},{"EARLY_PHASE1":5393,"PHASE1":5395,"PHASE2":5397,"PHASE3":5403,"PHASE4":5405,"NA":5407},{"trials":5394,"activeCount":97},[],{"trials":5396,"activeCount":97},[],{"trials":5398,"activeCount":97},[5399],{"nctId":5355,"briefTitle":5356,"status":103,"phases":5400,"primaryCompletion":1474,"completion":5358,"start":577,"enrollment":1803,"conditions":5401,"interventions":5402},[86],[5360,5361,5362,5363],[5346,5365,5366],{"trials":5404,"activeCount":97},[],{"trials":5406,"activeCount":97},[],{"trials":5408,"activeCount":97},[],{"intervention":5410,"totalTrials":132,"cells":5411},"Hydrochloroquine",{"EARLY_PHASE1":5412,"PHASE1":5414,"PHASE2":5416,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5413,"activeCount":97},[],{"trials":5415,"activeCount":97},[],{"trials":5417,"activeCount":97},[5418],{"nctId":5419,"briefTitle":5420,"status":161,"phases":5421,"primaryCompletion":2315,"start":554,"enrollment":165,"conditions":5422,"interventions":5423},"NCT01292408","Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients",[86],[30],[5410],{"trials":5425,"activeCount":97},[],{"trials":5427,"activeCount":97},[],{"trials":5429,"activeCount":97},[],{"intervention":5431,"totalTrials":132,"cells":5432},"anidulafungin 200 mg q48h",{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5437,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5434,"activeCount":97},[],{"trials":5436,"activeCount":97},[],{"trials":5438,"activeCount":97},[5439],{"nctId":5440,"briefTitle":5441,"status":103,"phases":5442,"primaryCompletion":1752,"completion":1752,"start":5443,"enrollment":1150,"conditions":5444,"interventions":5448},"NCT01249820","Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease",[86],"2010-11",[5445,5446,5447],"Leukemia","Myelodysplastic Syndrome","Leukemia, Myeloid, Acute",[5431,5449],"anidulafungin 300 mg q72h",{"trials":5451,"activeCount":97},[],{"trials":5453,"activeCount":97},[],{"trials":5455,"activeCount":97},[],{"intervention":5449,"totalTrials":132,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5459,"activeCount":97},[],{"trials":5461,"activeCount":97},[],{"trials":5463,"activeCount":97},[5464],{"nctId":5440,"briefTitle":5441,"status":103,"phases":5465,"primaryCompletion":1752,"completion":1752,"start":5443,"enrollment":1150,"conditions":5466,"interventions":5467},[86],[5445,5446,5447],[5431,5449],{"trials":5469,"activeCount":97},[],{"trials":5471,"activeCount":97},[],{"trials":5473,"activeCount":97},[],{"intervention":5475,"totalTrials":132,"cells":5476},"Mexiletine",{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5481,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5478,"activeCount":97},[],{"trials":5480,"activeCount":97},[],{"trials":5482,"activeCount":97},[5483],{"nctId":5484,"briefTitle":5485,"status":103,"phases":5486,"primaryCompletion":3873,"completion":3873,"start":1656,"enrollment":637,"conditions":5487,"interventions":5489},"NCT02045667","Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)",[86],[5488],"Non Dystrophic Myotonia",[5475],{"trials":5491,"activeCount":97},[],{"trials":5493,"activeCount":97},[],{"trials":5495,"activeCount":97},[],{"intervention":5497,"totalTrials":132,"cells":5498},"autologous dendritic cell vaccination",{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5503,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5500,"activeCount":97},[],{"trials":5502,"activeCount":97},[],{"trials":5504,"activeCount":97},[5505],{"nctId":5506,"briefTitle":5507,"status":103,"phases":5508,"primaryCompletion":1827,"completion":1827,"start":511,"enrollment":165,"conditions":5509,"interventions":5510},"NCT00940004","Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients",[85,86],[1044],[5497],{"trials":5512,"activeCount":97},[],{"trials":5514,"activeCount":97},[],{"trials":5516,"activeCount":97},[],{"intervention":5518,"totalTrials":132,"cells":5519},"tetracosactide hexacetaat",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5533,"PHASE4":5535,"NA":5537},{"trials":5521,"activeCount":97},[],{"trials":5523,"activeCount":97},[],{"trials":5525,"activeCount":97},[5526],{"nctId":5527,"briefTitle":5528,"status":103,"phases":5529,"primaryCompletion":201,"completion":553,"start":4307,"enrollment":165,"conditions":5530,"interventions":5532},"NCT00694863","Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy",[86],[5531],"Idiopathic Membranous Nephropathy",[5518],{"trials":5534,"activeCount":97},[],{"trials":5536,"activeCount":97},[],{"trials":5538,"activeCount":97},[],{"intervention":5540,"totalTrials":132,"cells":5541},"Canakinumab",{"EARLY_PHASE1":5542,"PHASE1":5544,"PHASE2":5546,"PHASE3":5555,"PHASE4":5557,"NA":5559},{"trials":5543,"activeCount":97},[],{"trials":5545,"activeCount":97},[],{"trials":5547,"activeCount":97},[5548],{"nctId":5549,"briefTitle":5550,"status":103,"phases":5551,"primaryCompletion":2065,"completion":1677,"start":554,"enrollment":2649,"conditions":5552,"interventions":5554},"NCT01276522","Efficacy and Safety of Canakinumab in Schnitzler Syndrome",[86],[5553],"Schnitzler Syndrome",[5540],{"trials":5556,"activeCount":97},[],{"trials":5558,"activeCount":97},[],{"trials":5560,"activeCount":97},[],{"intervention":5562,"totalTrials":132,"cells":5563},"68Ga-NODAGA-Exendin-4",{"EARLY_PHASE1":5564,"PHASE1":5566,"PHASE2":5568,"PHASE3":5580,"PHASE4":5582,"NA":5584},{"trials":5565,"activeCount":97},[],{"trials":5567,"activeCount":97},[],{"trials":5569,"activeCount":97},[5570],{"nctId":5571,"briefTitle":5572,"status":161,"phases":5573,"primaryCompletion":5574,"completion":5575,"start":5576,"enrollment":165,"conditions":5577,"interventions":5579},"NCT05622123","BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation",[86],"2024-02-28","2024-03-30","2023-02-23",[5578],"Type 1 Diabetes",[5562],{"trials":5581,"activeCount":97},[],{"trials":5583,"activeCount":97},[],{"trials":5585,"activeCount":97},[],{"intervention":5587,"totalTrials":132,"cells":5588},"MiHA-loaded PD-L-silenced DC Vaccination",{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5603,"PHASE4":5605,"NA":5607},{"trials":5590,"activeCount":97},[],{"trials":5592,"activeCount":97},[],{"trials":5594,"activeCount":97},[5595],{"nctId":5596,"briefTitle":5597,"status":103,"phases":5598,"primaryCompletion":5599,"completion":5599,"start":105,"enrollment":1102,"conditions":5600,"interventions":5602},"NCT02528682","MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT",[85,86],"2021-03-31",[5601],"Hematological Malignancies",[5587],{"trials":5604,"activeCount":97},[],{"trials":5606,"activeCount":97},[],{"trials":5608,"activeCount":97},[],{"intervention":5610,"totalTrials":132,"cells":5611},"CRT + Panitumumab",{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5616,"PHASE3":5626,"PHASE4":5628,"NA":5630},{"trials":5613,"activeCount":97},[],{"trials":5615,"activeCount":97},[],{"trials":5617,"activeCount":97},[5618],{"nctId":5619,"briefTitle":5620,"status":607,"phases":5621,"primaryCompletion":1734,"completion":4662,"start":554,"enrollment":561,"conditions":5622,"interventions":5624},"NCT01262183","Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus",[86],[5623],"Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus",[5610,5625],"Concurrent chemoradiation therapy without panitumumab",{"trials":5627,"activeCount":97},[],{"trials":5629,"activeCount":97},[],{"trials":5631,"activeCount":97},[],{"intervention":5625,"totalTrials":132,"cells":5633},{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5644,"PHASE4":5646,"NA":5648},{"trials":5635,"activeCount":97},[],{"trials":5637,"activeCount":97},[],{"trials":5639,"activeCount":97},[5640],{"nctId":5619,"briefTitle":5620,"status":607,"phases":5641,"primaryCompletion":1734,"completion":4662,"start":554,"enrollment":561,"conditions":5642,"interventions":5643},[86],[5623],[5610,5625],{"trials":5645,"activeCount":97},[],{"trials":5647,"activeCount":97},[],{"trials":5649,"activeCount":97},[],{"intervention":5651,"totalTrials":132,"cells":5652},"carbamazepine and nevirapine",{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5667,"PHASE4":5669,"NA":5671},{"trials":5654,"activeCount":97},[],{"trials":5656,"activeCount":97},[],{"trials":5658,"activeCount":97},[5659],{"nctId":5660,"briefTitle":5661,"status":103,"phases":5662,"primaryCompletion":2738,"completion":1361,"start":4511,"enrollment":5663,"conditions":5664,"interventions":5665},"NCT00294892","Pharmacokinetics Study on Nevirapine Resistance in Tanzania",[86],144,[25],[5651,5666],"Nevirapine",{"trials":5668,"activeCount":97},[],{"trials":5670,"activeCount":97},[],{"trials":5672,"activeCount":97},[],{"intervention":5674,"totalTrials":132,"cells":5675},"BCG vaccination",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5690,"PHASE4":5692,"NA":5694},{"trials":5677,"activeCount":97},[],{"trials":5679,"activeCount":97},[],{"trials":5681,"activeCount":97},[5682],{"nctId":5683,"briefTitle":5684,"status":103,"phases":5685,"primaryCompletion":2849,"completion":5686,"start":1032,"enrollment":165,"conditions":5687,"interventions":5689},"NCT02692963","Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection",[86],"2017-02",[3313,5688],"Plasmodium Falciparum",[5674],{"trials":5691,"activeCount":97},[],{"trials":5693,"activeCount":97},[],{"trials":5695,"activeCount":97},[],{"intervention":4839,"totalTrials":132,"cells":5697},{"EARLY_PHASE1":5698,"PHASE1":5700,"PHASE2":5702,"PHASE3":5708,"PHASE4":5710,"NA":5712},{"trials":5699,"activeCount":97},[],{"trials":5701,"activeCount":97},[],{"trials":5703,"activeCount":97},[5704],{"nctId":4830,"briefTitle":4831,"status":607,"phases":5705,"primaryCompletion":4833,"completion":4833,"start":4834,"enrollment":501,"conditions":5706,"interventions":5707},[85,86],[4836,4837],[4807,4839],{"trials":5709,"activeCount":97},[],{"trials":5711,"activeCount":97},[],{"trials":5713,"activeCount":97},[],{"intervention":5715,"totalTrials":132,"cells":5716},"Daclizumab",{"EARLY_PHASE1":5717,"PHASE1":5719,"PHASE2":5721,"PHASE3":5732,"PHASE4":5734,"NA":5736},{"trials":5718,"activeCount":97},[],{"trials":5720,"activeCount":97},[],{"trials":5722,"activeCount":97},[5723],{"nctId":5724,"briefTitle":5725,"status":103,"phases":5726,"primaryCompletion":5727,"completion":5727,"start":5728,"enrollment":21,"conditions":5729,"interventions":5730},"NCT00847106","Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients",[85,86],"2005-10","2004-03",[1044],[5715,5731],"Dendritic cells",{"trials":5733,"activeCount":97},[],{"trials":5735,"activeCount":97},[],{"trials":5737,"activeCount":97},[],{"intervention":5731,"totalTrials":132,"cells":5739},{"EARLY_PHASE1":5740,"PHASE1":5742,"PHASE2":5744,"PHASE3":5750,"PHASE4":5752,"NA":5754},{"trials":5741,"activeCount":97},[],{"trials":5743,"activeCount":97},[],{"trials":5745,"activeCount":97},[5746],{"nctId":5724,"briefTitle":5725,"status":103,"phases":5747,"primaryCompletion":5727,"completion":5727,"start":5728,"enrollment":21,"conditions":5748,"interventions":5749},[85,86],[1044],[5715,5731],{"trials":5751,"activeCount":97},[],{"trials":5753,"activeCount":97},[],{"trials":5755,"activeCount":97},[],{"intervention":5757,"totalTrials":132,"cells":5758},"Sulfadoxine-pyrimethamine",{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5763,"PHASE3":5775,"PHASE4":5777,"NA":5779},{"trials":5760,"activeCount":97},[],{"trials":5762,"activeCount":97},[],{"trials":5764,"activeCount":97},[5765],{"nctId":5766,"briefTitle":5767,"status":103,"phases":5768,"primaryCompletion":5769,"completion":5769,"start":4870,"enrollment":4309,"conditions":5770,"interventions":5771},"NCT02836002","Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1",[85,86],"2017-06-29",[3313],[5757,5772,5757,5772,5773,5774],"Piperaquine","malaria challenge infection, P. falciparum 3D7","Atovaquone-proguanil",{"trials":5776,"activeCount":97},[],{"trials":5778,"activeCount":97},[],{"trials":5780,"activeCount":97},[],{"intervention":5773,"totalTrials":132,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5784,"activeCount":97},[],{"trials":5786,"activeCount":97},[],{"trials":5788,"activeCount":97},[5789],{"nctId":5766,"briefTitle":5767,"status":103,"phases":5790,"primaryCompletion":5769,"completion":5769,"start":4870,"enrollment":4309,"conditions":5791,"interventions":5792},[85,86],[3313],[5757,5772,5757,5772,5773,5774],{"trials":5794,"activeCount":97},[],{"trials":5796,"activeCount":97},[],{"trials":5798,"activeCount":97},[],{"intervention":5774,"totalTrials":132,"cells":5800},{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5811,"PHASE4":5813,"NA":5815},{"trials":5802,"activeCount":97},[],{"trials":5804,"activeCount":97},[],{"trials":5806,"activeCount":97},[5807],{"nctId":5766,"briefTitle":5767,"status":103,"phases":5808,"primaryCompletion":5769,"completion":5769,"start":4870,"enrollment":4309,"conditions":5809,"interventions":5810},[85,86],[3313],[5757,5772,5757,5772,5773,5774],{"trials":5812,"activeCount":97},[],{"trials":5814,"activeCount":97},[],{"trials":5816,"activeCount":97},[],{"intervention":5818,"totalTrials":132,"cells":5819},"autologous dendritic cells electroporated with mRNA",{"EARLY_PHASE1":5820,"PHASE1":5822,"PHASE2":5824,"PHASE3":5833,"PHASE4":5835,"NA":5837},{"trials":5821,"activeCount":97},[],{"trials":5823,"activeCount":97},[],{"trials":5825,"activeCount":97},[5826],{"nctId":5827,"briefTitle":5828,"status":607,"phases":5829,"primaryCompletion":1032,"completion":1032,"start":511,"enrollment":2180,"conditions":5830,"interventions":5832},"NCT00929019","Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients",[85,86],[5831],"Uveal Melanoma",[5818],{"trials":5834,"activeCount":97},[],{"trials":5836,"activeCount":97},[],{"trials":5838,"activeCount":97},[],{"intervention":5840,"totalTrials":132,"cells":5841},"long-circulating liposomal prednisolone",{"EARLY_PHASE1":5842,"PHASE1":5844,"PHASE2":5846,"PHASE3":5855,"PHASE4":5857,"NA":5859},{"trials":5843,"activeCount":97},[],{"trials":5845,"activeCount":97},[],{"trials":5847,"activeCount":97},[5848],{"nctId":5849,"briefTitle":5850,"status":103,"phases":5851,"primaryCompletion":2039,"completion":1646,"start":5727,"enrollment":15,"conditions":5852,"interventions":5854},"NCT00241982","Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis",[86],[5853],"Rheumatoid Arthritis",[5840],{"trials":5856,"activeCount":97},[],{"trials":5858,"activeCount":97},[],{"trials":5860,"activeCount":97},[],{"intervention":5862,"totalTrials":132,"cells":5863},"atazanavir + placebo",{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5868,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5865,"activeCount":97},[],{"trials":5867,"activeCount":97},[],{"trials":5869,"activeCount":97},[5870],{"nctId":5871,"briefTitle":5872,"status":103,"phases":5873,"primaryCompletion":1939,"completion":1939,"start":5874,"enrollment":107,"conditions":5875,"interventions":5877},"NCT00696722","Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction",[86],"2008-06",[5876],"Type 2 Diabetes Mellitus Related Endothelial Dysfunction",[5862],{"trials":5879,"activeCount":97},[],{"trials":5881,"activeCount":97},[],{"trials":5883,"activeCount":97},[],{"intervention":5885,"totalTrials":132,"cells":5886},"Comirnaty",{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5901,"PHASE4":5903,"NA":5905},{"trials":5888,"activeCount":97},[],{"trials":5890,"activeCount":97},[],{"trials":5892,"activeCount":97},[5893],{"nctId":5894,"briefTitle":5895,"status":607,"phases":5896,"primaryCompletion":3704,"completion":3704,"start":5897,"enrollment":3040,"conditions":5898,"interventions":5900},"NCT05977127","Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly",[86],"2023-09-26",[5899,1419],"Vaccination; Infection",[5885],{"trials":5902,"activeCount":97},[],{"trials":5904,"activeCount":97},[],{"trials":5906,"activeCount":97},[],{"intervention":5908,"totalTrials":132,"cells":5909},"Cemiplimab",{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5914,"PHASE3":5928,"PHASE4":5930,"NA":5932},{"trials":5911,"activeCount":97},[],{"trials":5913,"activeCount":97},[],{"trials":5915,"activeCount":97},[5916],{"nctId":5917,"briefTitle":5918,"status":103,"phases":5919,"primaryCompletion":5920,"completion":5921,"start":5922,"enrollment":18,"conditions":5923,"interventions":5927},"NCT04873375","Cemiplimab for Secondary Angiosarcomas",[86],"2024-10-09","2024-10-18","2022-01-01",[5924,5925,5926],"Secondary Angiosarcoma","Locally Advanced Sarcoma","Metastasis",[5908],{"trials":5929,"activeCount":97},[],{"trials":5931,"activeCount":97},[],{"trials":5933,"activeCount":97},[],{"intervention":5935,"totalTrials":132,"cells":5936},"Atosiban",{"EARLY_PHASE1":5937,"PHASE1":5939,"PHASE2":5941,"PHASE3":5952,"PHASE4":5954,"NA":5956},{"trials":5938,"activeCount":97},[],{"trials":5940,"activeCount":97},[],{"trials":5942,"activeCount":97},[5943],{"nctId":5944,"briefTitle":5945,"status":161,"phases":5946,"primaryCompletion":5947,"completion":1974,"start":5948,"enrollment":1102,"conditions":5949,"interventions":5951},"NCT05382143","The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain",[86],"2022-06-01","2022-02-01",[5950],"Endometriosis",[5935],{"trials":5953,"activeCount":97},[],{"trials":5955,"activeCount":97},[],{"trials":5957,"activeCount":97},[],{"intervention":4706,"totalTrials":132,"cells":5959},{"EARLY_PHASE1":5960,"PHASE1":5962,"PHASE2":5964,"PHASE3":5970,"PHASE4":5972,"NA":5974},{"trials":5961,"activeCount":97},[],{"trials":5963,"activeCount":97},[],{"trials":5965,"activeCount":97},[5966],{"nctId":4700,"briefTitle":4701,"status":161,"phases":5967,"primaryCompletion":593,"completion":1655,"start":1666,"enrollment":1392,"conditions":5968,"interventions":5969},[86],[4704],[4682,4706],{"trials":5971,"activeCount":97},[],{"trials":5973,"activeCount":97},[],{"trials":5975,"activeCount":97},[],{"intervention":5977,"totalTrials":132,"cells":5978},"bolus injection, followed by a continuous",{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5996,"PHASE4":5998,"NA":6000},{"trials":5980,"activeCount":97},[],{"trials":5982,"activeCount":97},[],{"trials":5984,"activeCount":97},[5985],{"nctId":5986,"briefTitle":5987,"status":103,"phases":5988,"completion":5989,"start":5990,"enrollment":21,"conditions":5991,"interventions":5995},"NCT00457613","Effects of Alkaline Phosphatase on Renal Function in Septic Patients",[86],"2006-03","2004-11",[5992,5993,5994],"Severe","Septic","Shock",[5977],{"trials":5997,"activeCount":97},[],{"trials":5999,"activeCount":97},[],{"trials":6001,"activeCount":97},[],{"intervention":6003,"totalTrials":132,"cells":6004},"rosiglitazone",{"EARLY_PHASE1":6005,"PHASE1":6007,"PHASE2":6009,"PHASE3":6020,"PHASE4":6022,"NA":6024},{"trials":6006,"activeCount":97},[],{"trials":6008,"activeCount":97},[],{"trials":6010,"activeCount":97},[6011],{"nctId":6012,"briefTitle":6013,"status":103,"phases":6014,"primaryCompletion":4307,"completion":1645,"start":6015,"enrollment":31,"conditions":6016,"interventions":6019},"NCT00405015","The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.",[86],"2007-04",[6017,6018],"Ischemia-Reperfusion Injury","The Metabolic Syndrome",[6003],{"trials":6021,"activeCount":97},[],{"trials":6023,"activeCount":97},[],{"trials":6025,"activeCount":97},[],{"intervention":6027,"totalTrials":132,"cells":6028},"Lu-177-DOTA-girentuximab",{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6033,"PHASE3":6042,"PHASE4":6044,"NA":6046},{"trials":6030,"activeCount":97},[],{"trials":6032,"activeCount":97},[],{"trials":6034,"activeCount":97},[6035],{"nctId":6036,"briefTitle":6037,"status":103,"phases":6038,"primaryCompletion":3873,"completion":3873,"start":1678,"enrollment":26,"conditions":6039,"interventions":6041},"NCT02002312","Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer",[86],[6040],"Metastatic Clear Cell Renal Cell Carcinoma",[6027],{"trials":6043,"activeCount":97},[],{"trials":6045,"activeCount":97},[],{"trials":6047,"activeCount":97},[],{"intervention":4797,"totalTrials":132,"cells":6049},{"EARLY_PHASE1":6050,"PHASE1":6052,"PHASE2":6054,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":6051,"activeCount":97},[],{"trials":6053,"activeCount":97},[],{"trials":6055,"activeCount":97},[6056],{"nctId":4792,"briefTitle":4793,"status":103,"phases":6057,"primaryCompletion":201,"completion":554,"start":1773,"enrollment":165,"conditions":6058,"interventions":6059},[86],[1689,25],[4797,4798,4799],{"trials":6061,"activeCount":97},[],{"trials":6063,"activeCount":97},[],{"trials":6065,"activeCount":97},[],{"intervention":1046,"totalTrials":132,"cells":6067},{"EARLY_PHASE1":6068,"PHASE1":6070,"PHASE2":6072,"PHASE3":6078,"PHASE4":6080,"NA":6082},{"trials":6069,"activeCount":97},[],{"trials":6071,"activeCount":97},[],{"trials":6073,"activeCount":97},[6074],{"nctId":1038,"briefTitle":1039,"status":103,"phases":6075,"primaryCompletion":636,"completion":1032,"start":1041,"enrollment":1042,"conditions":6076,"interventions":6077},[86],[1044],[1020,1046],{"trials":6079,"activeCount":97},[],{"trials":6081,"activeCount":97},[],{"trials":6083,"activeCount":97},[],{"intervention":6085,"totalTrials":132,"cells":6086},"Capecitabine",{"EARLY_PHASE1":6087,"PHASE1":6089,"PHASE2":6091,"PHASE3":6101,"PHASE4":6103,"NA":6105},{"trials":6088,"activeCount":97},[],{"trials":6090,"activeCount":97},[],{"trials":6092,"activeCount":97},[6093],{"nctId":6094,"briefTitle":6095,"status":103,"phases":6096,"primaryCompletion":4755,"completion":1994,"start":5443,"enrollment":6097,"conditions":6098,"interventions":6100},"NCT01273051","Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer",[86],55,[6099],"Rectal Tumour",[6085],{"trials":6102,"activeCount":97},[],{"trials":6104,"activeCount":97},[],{"trials":6106,"activeCount":97},[],{"intervention":6108,"totalTrials":132,"cells":6109},"Cetuximab",{"EARLY_PHASE1":6110,"PHASE1":6112,"PHASE2":6114,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6111,"activeCount":97},[],{"trials":6113,"activeCount":97},[],{"trials":6115,"activeCount":97},[6116],{"nctId":6117,"briefTitle":6118,"status":161,"phases":6119,"primaryCompletion":6120,"completion":6121,"start":6122,"enrollment":150,"conditions":6123,"interventions":6125},"NCT02054442","A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck",[85,86],"2021-12","2022-12","2016-08",[6124],"Squamous Cell Carcinoma of the Head and Neck",[6108,6126],"Methotrexate",{"trials":6128,"activeCount":97},[],{"trials":6130,"activeCount":97},[],{"trials":6132,"activeCount":97},[],{"intervention":6134,"totalTrials":132,"cells":6135},"Minocycline",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6152,"PHASE4":6154,"NA":6156},{"trials":6137,"activeCount":97},[],{"trials":6139,"activeCount":97},[],{"trials":6141,"activeCount":97},[6142],{"nctId":6143,"briefTitle":6144,"status":607,"phases":6145,"primaryCompletion":6146,"completion":6147,"start":6148,"enrollment":512,"conditions":6149,"interventions":6151},"NCT05861258","Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease",[86],"2025-05-14","2025-06-11","2023-05-08",[6150],"Mycobacterium Avium Complex Pulmonary Disease",[6134],{"trials":6153,"activeCount":97},[],{"trials":6155,"activeCount":97},[],{"trials":6157,"activeCount":97},[],{"intervention":6159,"totalTrials":132,"cells":6160},"Sugammadex 100 MG\u002FML [Bridion]",{"EARLY_PHASE1":6161,"PHASE1":6163,"PHASE2":6165,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6162,"activeCount":97},[],{"trials":6164,"activeCount":97},[],{"trials":6166,"activeCount":97},[6167],{"nctId":6168,"briefTitle":6169,"status":103,"phases":6170,"primaryCompletion":6171,"completion":6171,"start":6172,"enrollment":165,"conditions":6173,"interventions":6175},"NCT05723406","The Immunomodulatory Effect of Sugammadex After Total Hip Replacement Surgery Under Neuraxial Anaesthesia: a Pilot Study",[86],"2023-11-23","2023-03-21",[1899,6174],"Osteoarthritis, Hip",[6159],{"trials":6177,"activeCount":97},[],{"trials":6179,"activeCount":97},[],{"trials":6181,"activeCount":97},[],{"intervention":6183,"totalTrials":132,"cells":6184},"kineret",{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6189,"PHASE3":6198,"PHASE4":6200,"NA":6202},{"trials":6186,"activeCount":97},[],{"trials":6188,"activeCount":97},[],{"trials":6190,"activeCount":97},[6191],{"nctId":6192,"briefTitle":6193,"status":161,"phases":6194,"primaryCompletion":6195,"completion":1677,"start":578,"enrollment":107,"conditions":6196,"interventions":6197},"NCT01285245","Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus",[86],"2011-09",[1722],[6183],{"trials":6199,"activeCount":97},[],{"trials":6201,"activeCount":97},[],{"trials":6203,"activeCount":97},[],{"intervention":6205,"totalTrials":132,"cells":6206},"arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant",{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6220,"PHASE4":6222,"NA":6224},{"trials":6208,"activeCount":97},[],{"trials":6210,"activeCount":97},[],{"trials":6212,"activeCount":97},[6213],{"nctId":6214,"briefTitle":6215,"status":103,"phases":6216,"primaryCompletion":1645,"completion":1645,"start":2155,"enrollment":3792,"conditions":6217,"interventions":6218},"NCT00509158","Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine",[85,86],[2699],[6205,6219],"arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant",{"trials":6221,"activeCount":97},[],{"trials":6223,"activeCount":97},[],{"trials":6225,"activeCount":97},[],{"intervention":6219,"totalTrials":132,"cells":6227},{"EARLY_PHASE1":6228,"PHASE1":6230,"PHASE2":6232,"PHASE3":6238,"PHASE4":6240,"NA":6242},{"trials":6229,"activeCount":97},[],{"trials":6231,"activeCount":97},[],{"trials":6233,"activeCount":97},[6234],{"nctId":6214,"briefTitle":6215,"status":103,"phases":6235,"primaryCompletion":1645,"completion":1645,"start":2155,"enrollment":3792,"conditions":6236,"interventions":6237},[85,86],[2699],[6205,6219],{"trials":6239,"activeCount":97},[],{"trials":6241,"activeCount":97},[],{"trials":6243,"activeCount":97},[],{"intervention":6245,"totalTrials":132,"cells":6246},"neo-adjuvant treatment with bevacizumab",{"EARLY_PHASE1":6247,"PHASE1":6249,"PHASE2":6251,"PHASE3":6263,"PHASE4":6265,"NA":6267},{"trials":6248,"activeCount":97},[],{"trials":6250,"activeCount":97},[],{"trials":6252,"activeCount":97},[6253],{"nctId":6254,"briefTitle":6255,"status":161,"phases":6256,"primaryCompletion":1828,"completion":1655,"start":4307,"enrollment":230,"conditions":6257,"interventions":6260},"NCT00659022","Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth",[86],[6258,6259],"Colorectal Neoplasms","Liver Neoplasms",[6245,6261,6262],"neoadjuvant treatment with capecitabine and oxaliplatin","neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin",{"trials":6264,"activeCount":97},[],{"trials":6266,"activeCount":97},[],{"trials":6268,"activeCount":97},[],{"intervention":6261,"totalTrials":132,"cells":6270},{"EARLY_PHASE1":6271,"PHASE1":6273,"PHASE2":6275,"PHASE3":6281,"PHASE4":6283,"NA":6285},{"trials":6272,"activeCount":97},[],{"trials":6274,"activeCount":97},[],{"trials":6276,"activeCount":97},[6277],{"nctId":6254,"briefTitle":6255,"status":161,"phases":6278,"primaryCompletion":1828,"completion":1655,"start":4307,"enrollment":230,"conditions":6279,"interventions":6280},[86],[6258,6259],[6245,6261,6262],{"trials":6282,"activeCount":97},[],{"trials":6284,"activeCount":97},[],{"trials":6286,"activeCount":97},[],{"intervention":6262,"totalTrials":132,"cells":6288},{"EARLY_PHASE1":6289,"PHASE1":6291,"PHASE2":6293,"PHASE3":6299,"PHASE4":6301,"NA":6303},{"trials":6290,"activeCount":97},[],{"trials":6292,"activeCount":97},[],{"trials":6294,"activeCount":97},[6295],{"nctId":6254,"briefTitle":6255,"status":161,"phases":6296,"primaryCompletion":1828,"completion":1655,"start":4307,"enrollment":230,"conditions":6297,"interventions":6298},[86],[6258,6259],[6245,6261,6262],{"trials":6300,"activeCount":97},[],{"trials":6302,"activeCount":97},[],{"trials":6304,"activeCount":97},[],{"intervention":6306,"totalTrials":132,"cells":6307},"CEA-loaded dendritic cell vaccine",{"EARLY_PHASE1":6308,"PHASE1":6310,"PHASE2":6312,"PHASE3":6322,"PHASE4":6324,"NA":6326},{"trials":6309,"activeCount":97},[],{"trials":6311,"activeCount":97},[],{"trials":6313,"activeCount":97},[6314],{"nctId":6315,"briefTitle":6316,"status":103,"phases":6317,"primaryCompletion":5443,"completion":5443,"start":6318,"enrollment":637,"conditions":6319,"interventions":6321},"NCT00228189","Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients",[85,86],"2003-12",[23,6320],"Liver Metastases",[6306],{"trials":6323,"activeCount":97},[],{"trials":6325,"activeCount":97},[],{"trials":6327,"activeCount":97},[],{"intervention":6329,"totalTrials":132,"cells":6330},"ITF2357",{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6335,"PHASE3":6348,"PHASE4":6350,"NA":6352},{"trials":6332,"activeCount":97},[],{"trials":6334,"activeCount":97},[],{"trials":6336,"activeCount":97},[6337],{"nctId":6338,"briefTitle":6339,"status":161,"phases":6340,"start":6341,"enrollment":165,"conditions":6342,"interventions":6347},"NCT00442182","The Efficacy and Safety of ITF2357 in AIS",[86],"2006-09",[6343,6344,6345,6346],"Autoinflammatory Syndromes","HIDS","TRAPS","Schnitzler's Syndrome",[6329],{"trials":6349,"activeCount":97},[],{"trials":6351,"activeCount":97},[],{"trials":6353,"activeCount":97},[],{"intervention":6355,"totalTrials":132,"cells":6356},"Peptide-pulsed dendritic cells",{"EARLY_PHASE1":6357,"PHASE1":6359,"PHASE2":6361,"PHASE3":6370,"PHASE4":6372,"NA":6374},{"trials":6358,"activeCount":97},[],{"trials":6360,"activeCount":97},[],{"trials":6362,"activeCount":97},[6363],{"nctId":6364,"briefTitle":6365,"status":103,"phases":6366,"primaryCompletion":1775,"start":6367,"enrollment":1392,"conditions":6368,"interventions":6369},"NCT00243594","Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection",[85,86],"1999-09",[4736],[6355],{"trials":6371,"activeCount":97},[],{"trials":6373,"activeCount":97},[],{"trials":6375,"activeCount":97},[],{"intervention":6377,"totalTrials":132,"cells":6378},"Dendritic Cells for endometrial cancer",{"EARLY_PHASE1":6379,"PHASE1":6381,"PHASE2":6383,"PHASE3":6394,"PHASE4":6396,"NA":6398},{"trials":6380,"activeCount":97},[],{"trials":6382,"activeCount":97},[],{"trials":6384,"activeCount":97},[6385],{"nctId":6386,"briefTitle":6387,"status":103,"phases":6388,"primaryCompletion":6389,"completion":6389,"start":6390,"enrollment":2649,"conditions":6391,"interventions":6393},"NCT04212377","Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients",[86],"2021-03-09","2019-04-08",[6392],"Endometrial Cancer",[6377],{"trials":6395,"activeCount":97},[],{"trials":6397,"activeCount":97},[],{"trials":6399,"activeCount":97},[],{"intervention":6401,"totalTrials":132,"cells":6402},"Lutetium-177-PSMA-I&T",{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6407,"PHASE3":6419,"PHASE4":6421,"NA":6423},{"trials":6404,"activeCount":97},[],{"trials":6406,"activeCount":97},[],{"trials":6408,"activeCount":97},[6409],{"nctId":6410,"briefTitle":6411,"status":103,"phases":6412,"primaryCompletion":6413,"completion":6413,"start":6414,"enrollment":512,"conditions":6415,"interventions":6418},"NCT04291300","Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients",[86],"2023-02-13","2020-05-26",[6416,1152,6417],"Salivary Gland Cancer","Adenoid Cystic Carcinoma",[6401],{"trials":6420,"activeCount":97},[],{"trials":6422,"activeCount":97},[],{"trials":6424,"activeCount":97},[],{"intervention":6426,"totalTrials":132,"cells":6427},"colecalciferol",{"EARLY_PHASE1":6428,"PHASE1":6430,"PHASE2":6432,"PHASE3":6442,"PHASE4":6444,"NA":6446},{"trials":6429,"activeCount":97},[],{"trials":6431,"activeCount":97},[],{"trials":6433,"activeCount":97},[6434],{"nctId":6435,"briefTitle":6436,"status":161,"phases":6437,"completion":6438,"start":5336,"enrollment":915,"conditions":6439,"interventions":6441},"NCT00306410","The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients",[86],"2007-07",[6440,25],"Vitamin D Deficiency",[6426],{"trials":6443,"activeCount":97},[],{"trials":6445,"activeCount":97},[],{"trials":6447,"activeCount":97},[],{"intervention":6449,"totalTrials":132,"cells":6450},"[111In]In-DOTA-ANTI-CEA antibody",{"EARLY_PHASE1":6451,"PHASE1":6453,"PHASE2":6455,"PHASE3":6468,"PHASE4":6470,"NA":6472},{"trials":6452,"activeCount":97},[],{"trials":6454,"activeCount":97},[],{"trials":6456,"activeCount":97},[6457],{"nctId":6458,"briefTitle":6459,"status":161,"phases":6460,"primaryCompletion":6461,"completion":6462,"start":6463,"enrollment":165,"conditions":6464,"interventions":6467},"NCT06395337","Multimodal Imaging in Rectal Cancer & Pancreatic Cancer",[85,86],"2025-05-02","2025-06-02","2024-05-02",[6465,6466],"Rectal Cancer","Pancreatic Cancer",[6449],{"trials":6469,"activeCount":97},[],{"trials":6471,"activeCount":97},[],{"trials":6473,"activeCount":97},[],{"intervention":6475,"totalTrials":132,"cells":6476},"177Lu-PSMA-617",{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6481,"PHASE3":6492,"PHASE4":6494,"NA":6496},{"trials":6478,"activeCount":97},[],{"trials":6480,"activeCount":97},[],{"trials":6482,"activeCount":97},[6483],{"nctId":6484,"briefTitle":6485,"status":103,"phases":6486,"primaryCompletion":6487,"completion":941,"start":6488,"enrollment":6489,"conditions":6490,"interventions":6491},"NCT04443062","Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer",[86],"2025-04-01","2020-07-20",58,[28],[6475],{"trials":6493,"activeCount":97},[],{"trials":6495,"activeCount":97},[],{"trials":6497,"activeCount":97},[],{"intervention":6499,"totalTrials":132,"cells":6500},"lanadelumab",{"EARLY_PHASE1":6501,"PHASE1":6503,"PHASE2":6505,"PHASE3":6517,"PHASE4":6519,"NA":6521},{"trials":6502,"activeCount":97},[],{"trials":6504,"activeCount":97},[],{"trials":6506,"activeCount":97},[6507],{"nctId":6508,"briefTitle":6509,"status":103,"phases":6510,"primaryCompletion":6511,"completion":6512,"start":6513,"enrollment":6514,"conditions":6515,"interventions":6516},"NCT04422509","Lanadelumab for Treatment of COVID-19 Disease",[85,86],"2021-02-25","2021-04-30","2020-10-30",43,[1419],[6499],{"trials":6518,"activeCount":97},[],{"trials":6520,"activeCount":97},[],{"trials":6522,"activeCount":97},[],{"intervention":6524,"totalTrials":132,"cells":6525},"Pb(PfCS@UIS4)-infected mosquitoes",{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6542,"PHASE4":6544,"NA":6546},{"trials":6527,"activeCount":97},[],{"trials":6529,"activeCount":97},[],{"trials":6531,"activeCount":97},[6532],{"nctId":6533,"briefTitle":6534,"status":103,"phases":6535,"primaryCompletion":4129,"completion":6536,"start":6537,"enrollment":1362,"conditions":6538,"interventions":6541},"NCT03138096","Safety and Protective Efficacy of Pb(PfCS@UIS4)",[85,86],"2018-10-03","2017-05-29",[4925,5688,6539,6540],"Plasmodium Berghei","Controlled Human Malaria Infection (CHMI)",[6524],{"trials":6543,"activeCount":97},[],{"trials":6545,"activeCount":97},[],{"trials":6547,"activeCount":97},[],{"intervention":6549,"totalTrials":132,"cells":6550},"Indium-111-DOTA-Labetuzumab-IRDye800CW",{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6555,"PHASE3":6569,"PHASE4":6571,"NA":6573},{"trials":6552,"activeCount":97},[],{"trials":6554,"activeCount":97},[],{"trials":6556,"activeCount":97},[6557],{"nctId":6558,"briefTitle":6559,"status":161,"phases":6560,"primaryCompletion":6561,"completion":5007,"start":6562,"enrollment":4309,"conditions":6563,"interventions":6568},"NCT03699332","Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin",[85,86],"2021-03","2018-12-01",[6564,23,6565,6566,6567],"Peritoneal Carcinomatosis","Carcinoma","Neoplasms","Gastrointestinal Cancer",[6549],{"trials":6570,"activeCount":97},[],{"trials":6572,"activeCount":97},[],{"trials":6574,"activeCount":97},[],{"intervention":6576,"totalTrials":132,"cells":6577},"Hypoxic Gas Mixture",{"EARLY_PHASE1":6578,"PHASE1":6580,"PHASE2":6582,"PHASE3":6593,"PHASE4":6595,"NA":6597},{"trials":6579,"activeCount":97},[],{"trials":6581,"activeCount":97},[],{"trials":6583,"activeCount":97},[6584],{"nctId":6585,"briefTitle":6586,"status":103,"phases":6587,"primaryCompletion":6588,"completion":6588,"start":6589,"enrollment":4309,"conditions":6590,"interventions":6592},"NCT05214287","Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease",[85,86],"2023-07-12","2022-02-22",[14,6591],"Effect of Drug",[6576],{"trials":6594,"activeCount":97},[],{"trials":6596,"activeCount":97},[],{"trials":6598,"activeCount":97},[],{"intervention":4772,"totalTrials":132,"cells":6600},{"EARLY_PHASE1":6601,"PHASE1":6603,"PHASE2":6605,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6602,"activeCount":97},[],{"trials":6604,"activeCount":97},[],{"trials":6606,"activeCount":97},[6607],{"nctId":4762,"briefTitle":4763,"status":103,"phases":6608,"primaryCompletion":536,"completion":536,"start":4765,"enrollment":390,"conditions":6609,"interventions":6610},[86],[4767,4704,4768,4769,4770],[4745,4772,4772],{"trials":6612,"activeCount":97},[],{"trials":6614,"activeCount":97},[],{"trials":6616,"activeCount":97},[],{"intervention":6618,"totalTrials":132,"cells":6619},"Ipilimumab",{"EARLY_PHASE1":6620,"PHASE1":6622,"PHASE2":6624,"PHASE3":6637,"PHASE4":6639,"NA":6641},{"trials":6621,"activeCount":97},[],{"trials":6623,"activeCount":97},[],{"trials":6625,"activeCount":97},[6626],{"nctId":6627,"briefTitle":6628,"status":103,"phases":6629,"primaryCompletion":6630,"completion":6631,"start":6632,"enrollment":6633,"conditions":6634,"interventions":6635},"NCT04717154","Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer",[86],"2024-08-15","2025-12-18","2021-01-19",69,[3289],[6618,6636],"Nivolumab",{"trials":6638,"activeCount":97},[],{"trials":6640,"activeCount":97},[],{"trials":6642,"activeCount":97},[],{"intervention":6636,"totalTrials":132,"cells":6644},{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6649,"PHASE3":6655,"PHASE4":6657,"NA":6659},{"trials":6646,"activeCount":97},[],{"trials":6648,"activeCount":97},[],{"trials":6650,"activeCount":97},[6651],{"nctId":6627,"briefTitle":6628,"status":103,"phases":6652,"primaryCompletion":6630,"completion":6631,"start":6632,"enrollment":6633,"conditions":6653,"interventions":6654},[86],[3289],[6618,6636],{"trials":6656,"activeCount":97},[],{"trials":6658,"activeCount":97},[],{"trials":6660,"activeCount":97},[],{"intervention":6662,"totalTrials":132,"cells":6663},"Gelofusine",{"EARLY_PHASE1":6664,"PHASE1":6666,"PHASE2":6668,"PHASE3":6678,"PHASE4":6680,"NA":6682},{"trials":6665,"activeCount":97},[],{"trials":6667,"activeCount":97},[],{"trials":6669,"activeCount":97},[6670],{"nctId":6671,"briefTitle":6672,"status":103,"phases":6673,"primaryCompletion":6674,"completion":6674,"start":1994,"enrollment":512,"conditions":6675,"interventions":6677},"NCT02541734","Effect of Gelofusine on GLP1-receptor Imaging",[85,86],"2017-05",[6676,1722],"Diabetes Mellitus, Non-Insulin-Dependent",[6662],{"trials":6679,"activeCount":97},[],{"trials":6681,"activeCount":97},[],{"trials":6683,"activeCount":97},[],{"intervention":6685,"totalTrials":132,"cells":6686},"Dapagliflozin",{"EARLY_PHASE1":6687,"PHASE1":6689,"PHASE2":6691,"PHASE3":6702,"PHASE4":6704,"NA":6706},{"trials":6688,"activeCount":97},[],{"trials":6690,"activeCount":97},[],{"trials":6692,"activeCount":97},[6693],{"nctId":6694,"briefTitle":6695,"status":103,"phases":6696,"primaryCompletion":6697,"completion":6697,"start":6698,"enrollment":21,"conditions":6699,"interventions":6701},"NCT03556033","Effect of Dapagliflozin on IAH in T1DM",[86],"2019-12-20","2018-11-23",[1496,4133,6700],"Hypoglycemia Unawareness",[6685],{"trials":6703,"activeCount":97},[],{"trials":6705,"activeCount":97},[],{"trials":6707,"activeCount":97},[],{"intervention":6709,"totalTrials":132,"cells":6710},"Clofazimine",{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6726,"PHASE4":6728,"NA":6730},{"trials":6712,"activeCount":97},[],{"trials":6714,"activeCount":97},[],{"trials":6716,"activeCount":97},[6717],{"nctId":6718,"briefTitle":6719,"status":103,"phases":6720,"primaryCompletion":4817,"completion":6721,"start":6722,"enrollment":512,"conditions":6723,"interventions":6725},"NCT05294146","Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease",[86],"2023-08-08","2022-02-14",[6724],"Nontuberculous Mycobacterial Diseases",[6709],{"trials":6727,"activeCount":97},[],{"trials":6729,"activeCount":97},[],{"trials":6731,"activeCount":97},[],{"intervention":6733,"totalTrials":132,"cells":6734},"decitabine",{"EARLY_PHASE1":6735,"PHASE1":6737,"PHASE2":6739,"PHASE3":6750,"PHASE4":6752,"NA":6754},{"trials":6736,"activeCount":97},[],{"trials":6738,"activeCount":97},[],{"trials":6740,"activeCount":97},[6741],{"nctId":6742,"briefTitle":6743,"status":103,"phases":6744,"primaryCompletion":6745,"completion":6745,"start":594,"enrollment":6746,"conditions":6747,"interventions":6749},"NCT02252107","10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1",[86],"2019-05",46,[6748],"Acute Myeloid Leukemia (AML)",[6733],{"trials":6751,"activeCount":97},[],{"trials":6753,"activeCount":97},[],{"trials":6755,"activeCount":97},[],{"intervention":6757,"totalTrials":132,"cells":6758},"Saquinavir and Ritonavir",{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6763,"PHASE3":6771,"PHASE4":6773,"NA":6775},{"trials":6760,"activeCount":97},[],{"trials":6762,"activeCount":97},[],{"trials":6764,"activeCount":97},[6765],{"nctId":6766,"briefTitle":6767,"status":103,"phases":6768,"primaryCompletion":4190,"completion":1687,"start":1503,"enrollment":1392,"conditions":6769,"interventions":6770},"NCT00145561","The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.",[85,86],[25],[6757],{"trials":6772,"activeCount":97},[],{"trials":6774,"activeCount":97},[],{"trials":6776,"activeCount":97},[],{"intervention":6778,"totalTrials":132,"cells":6779},"Temsirolimus",{"EARLY_PHASE1":6780,"PHASE1":6782,"PHASE2":6784,"PHASE3":6795,"PHASE4":6797,"NA":6799},{"trials":6781,"activeCount":97},[],{"trials":6783,"activeCount":97},[],{"trials":6785,"activeCount":97},[6786],{"nctId":6787,"briefTitle":6788,"status":161,"phases":6789,"primaryCompletion":4755,"start":6790,"enrollment":6791,"conditions":6792,"interventions":6794},"NCT01246817","Temsirolimus-RCC-imaging",[86],"2009-08",51,[6793],"Renal Cell Cancer",[6778],{"trials":6796,"activeCount":97},[],{"trials":6798,"activeCount":97},[],{"trials":6800,"activeCount":97},[],{"intervention":6802,"totalTrials":132,"cells":6803},"Cabozantinib",{"EARLY_PHASE1":6804,"PHASE1":6806,"PHASE2":6808,"PHASE3":6818,"PHASE4":6820,"NA":6822},{"trials":6805,"activeCount":97},[],{"trials":6807,"activeCount":97},[],{"trials":6809,"activeCount":97},[6810],{"nctId":6811,"briefTitle":6812,"status":607,"phases":6813,"primaryCompletion":6814,"completion":6814,"start":6815,"enrollment":1034,"conditions":6816,"interventions":6817},"NCT03729297","Cabozantinib in Advanced Salivary Gland Cancer Patients",[86],"2019-11-06","2018-09-05",[6416],[6802],{"trials":6819,"activeCount":97},[],{"trials":6821,"activeCount":97},[],{"trials":6823,"activeCount":97},[],{"intervention":6825,"totalTrials":132,"cells":6826},"Azithromycin",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6841,"PHASE4":6843,"NA":6845},{"trials":6828,"activeCount":97},[],{"trials":6830,"activeCount":97},[],{"trials":6832,"activeCount":97},[6833],{"nctId":6834,"briefTitle":6835,"status":2006,"phases":6836,"primaryCompletion":2064,"completion":1655,"start":2697,"enrollment":97,"conditions":6837,"interventions":6839},"NCT01783340","Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine\u002FAzithromycin Prophylaxis",[85,86],[6838],"Malaria, Falciparum",[6825,6840],"Immunization with falciparum",{"trials":6842,"activeCount":97},[],{"trials":6844,"activeCount":97},[],{"trials":6846,"activeCount":97},[],{"intervention":6840,"totalTrials":132,"cells":6848},{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6850,"activeCount":97},[],{"trials":6852,"activeCount":97},[],{"trials":6854,"activeCount":97},[6855],{"nctId":6834,"briefTitle":6835,"status":2006,"phases":6856,"primaryCompletion":2064,"completion":1655,"start":2697,"enrollment":97,"conditions":6857,"interventions":6858},[85,86],[6838],[6825,6840],{"trials":6860,"activeCount":97},[],{"trials":6862,"activeCount":97},[],{"trials":6864,"activeCount":97},[],{"intervention":6866,"totalTrials":132,"cells":6867},"Delta-THC",{"EARLY_PHASE1":6868,"PHASE1":6870,"PHASE2":6872,"PHASE3":6880,"PHASE4":6882,"NA":6884},{"trials":6869,"activeCount":97},[],{"trials":6871,"activeCount":97},[],{"trials":6873,"activeCount":97},[6874],{"nctId":6875,"briefTitle":6876,"status":103,"phases":6877,"primaryCompletion":2064,"completion":2064,"start":6195,"enrollment":15,"conditions":6878,"interventions":6879},"NCT01302340","Delta-THC in Behavioral Disturbances in Dementia",[86],[4768],[6866,6866],{"trials":6881,"activeCount":97},[],{"trials":6883,"activeCount":97},[],{"trials":6885,"activeCount":97},[],{"intervention":6887,"totalTrials":132,"cells":6888},"Paroxetine",{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6903,"PHASE4":6905,"NA":6907},{"trials":6890,"activeCount":97},[],{"trials":6892,"activeCount":97},[],{"trials":6894,"activeCount":97},[6895],{"nctId":6896,"briefTitle":6897,"status":607,"phases":6898,"primaryCompletion":1390,"completion":1390,"start":1349,"enrollment":627,"conditions":6899,"interventions":6901},"NCT01841502","Interaction Between Paroxetine and Telaprevir",[86],[6900,1658],"Hepatitis C Infection",[6887,6902],"telaprevir",{"trials":6904,"activeCount":97},[],{"trials":6906,"activeCount":97},[],{"trials":6908,"activeCount":97},[],{"intervention":6902,"totalTrials":132,"cells":6910},{"EARLY_PHASE1":6911,"PHASE1":6913,"PHASE2":6915,"PHASE3":6921,"PHASE4":6923,"NA":6925},{"trials":6912,"activeCount":97},[],{"trials":6914,"activeCount":97},[],{"trials":6916,"activeCount":97},[6917],{"nctId":6896,"briefTitle":6897,"status":607,"phases":6918,"primaryCompletion":1390,"completion":1390,"start":1349,"enrollment":627,"conditions":6919,"interventions":6920},[86],[6900,1658],[6887,6902],{"trials":6922,"activeCount":97},[],{"trials":6924,"activeCount":97},[],{"trials":6926,"activeCount":97},[],{"intervention":6928,"totalTrials":132,"cells":6929},"Paclitaxel, Carboplatin and Bevacizumab,Erlotinib",{"EARLY_PHASE1":6930,"PHASE1":6932,"PHASE2":6934,"PHASE3":6944,"PHASE4":6946,"NA":6948},{"trials":6931,"activeCount":97},[],{"trials":6933,"activeCount":97},[],{"trials":6935,"activeCount":97},[6936],{"nctId":6937,"briefTitle":6938,"status":103,"phases":6939,"primaryCompletion":6940,"completion":2806,"start":1644,"enrollment":1927,"conditions":6941,"interventions":6943},"NCT00702975","Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and\u002For Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy",[86],"2013-02",[6942,872],"Locally Advanced Non-Small Cell Lung Cancer",[6928],{"trials":6945,"activeCount":97},[],{"trials":6947,"activeCount":97},[],{"trials":6949,"activeCount":97},[],{"intervention":112,"totalTrials":93,"cells":6951},{"EARLY_PHASE1":6952,"PHASE1":6954,"PHASE2":6964,"PHASE3":6966,"PHASE4":6968,"NA":6970},{"trials":6953,"activeCount":97},[],{"trials":6955,"activeCount":97},[6956,6960],{"nctId":1718,"briefTitle":1719,"status":103,"phases":6957,"primaryCompletion":635,"completion":1032,"start":105,"enrollment":165,"conditions":6958,"interventions":6959},[85],[109,1722,515],[112,1711],{"nctId":101,"briefTitle":102,"status":103,"phases":6961,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":6962,"interventions":6963},[85],[109,110],[112,113,114,92],{"trials":6965,"activeCount":97},[],{"trials":6967,"activeCount":97},[],{"trials":6969,"activeCount":97},[],{"trials":6971,"activeCount":97},[],{"intervention":1682,"totalTrials":93,"cells":6973},{"EARLY_PHASE1":6974,"PHASE1":6976,"PHASE2":6990,"PHASE3":6992,"PHASE4":6994,"NA":6996},{"trials":6975,"activeCount":97},[],{"trials":6977,"activeCount":97},[6978,6986],{"nctId":6979,"briefTitle":6980,"status":103,"phases":6981,"primaryCompletion":1677,"completion":2315,"start":1359,"enrollment":1362,"conditions":6982,"interventions":6984},"NCT01470690","Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)",[85],[1680,6983],"Gastric Acid-related Disorders",[1682,6985],"Omeprazole",{"nctId":1674,"briefTitle":1675,"status":103,"phases":6987,"primaryCompletion":1360,"completion":1677,"start":1678,"enrollment":1362,"conditions":6988,"interventions":6989},[85],[25,1680],[1682,1660],{"trials":6991,"activeCount":97},[],{"trials":6993,"activeCount":97},[],{"trials":6995,"activeCount":97},[],{"trials":6997,"activeCount":97},[],{"intervention":114,"totalTrials":93,"cells":6999},{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7012,"PHASE3":7014,"PHASE4":7016,"NA":7018},{"trials":7001,"activeCount":97},[],{"trials":7003,"activeCount":97},[7004,7008],{"nctId":101,"briefTitle":102,"status":103,"phases":7005,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":7006,"interventions":7007},[85],[109,110],[112,113,114,92],{"nctId":1770,"briefTitle":1771,"status":103,"phases":7009,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1362,"conditions":7010,"interventions":7011},[85],[1689,1777],[1779,1780,114],{"trials":7013,"activeCount":97},[],{"trials":7015,"activeCount":97},[],{"trials":7017,"activeCount":97},[],{"trials":7019,"activeCount":97},[],{"intervention":7021,"totalTrials":132,"cells":7022},"raltegravir single dose",{"EARLY_PHASE1":7023,"PHASE1":7025,"PHASE2":7035,"PHASE3":7037,"PHASE4":7039,"NA":7041},{"trials":7024,"activeCount":97},[],{"trials":7026,"activeCount":97},[7027],{"nctId":7028,"briefTitle":7029,"status":103,"phases":7030,"primaryCompletion":202,"completion":2065,"start":5443,"enrollment":18,"conditions":7031,"interventions":7033},"NCT01246804","The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)",[85],[25,1658,7032],"Mild Cognitive Impairment",[7021,7034],"ginkgo biloba multiple dose",{"trials":7036,"activeCount":97},[],{"trials":7038,"activeCount":97},[],{"trials":7040,"activeCount":97},[],{"trials":7042,"activeCount":97},[],{"intervention":7034,"totalTrials":132,"cells":7044},{"EARLY_PHASE1":7045,"PHASE1":7047,"PHASE2":7053,"PHASE3":7055,"PHASE4":7057,"NA":7059},{"trials":7046,"activeCount":97},[],{"trials":7048,"activeCount":97},[7049],{"nctId":7028,"briefTitle":7029,"status":103,"phases":7050,"primaryCompletion":202,"completion":2065,"start":5443,"enrollment":18,"conditions":7051,"interventions":7052},[85],[25,1658,7032],[7021,7034],{"trials":7054,"activeCount":97},[],{"trials":7056,"activeCount":97},[],{"trials":7058,"activeCount":97},[],{"trials":7060,"activeCount":97},[],{"intervention":7062,"totalTrials":132,"cells":7063},"Indium labeled IMP-205xm734",{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7076,"PHASE3":7078,"PHASE4":7080,"NA":7082},{"trials":7065,"activeCount":97},[],{"trials":7067,"activeCount":97},[7068],{"nctId":7069,"briefTitle":7070,"status":103,"phases":7071,"primaryCompletion":3244,"completion":3244,"start":7072,"enrollment":2973,"conditions":7073,"interventions":7075},"NCT00185081","Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging",[85],"2005-07",[7074],"Colonic Neoplasms",[7062],{"trials":7077,"activeCount":97},[],{"trials":7079,"activeCount":97},[],{"trials":7081,"activeCount":97},[],{"trials":7083,"activeCount":97},[],{"intervention":7085,"totalTrials":132,"cells":7086},"Avelumab",{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7100,"PHASE3":7102,"PHASE4":7104,"NA":7106},{"trials":7088,"activeCount":97},[],{"trials":7090,"activeCount":97},[7091],{"nctId":7092,"briefTitle":7093,"status":103,"phases":7094,"primaryCompletion":7095,"completion":7096,"start":7097,"enrollment":1362,"conditions":7098,"interventions":7099},"NCT03514719","PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)",[85],"2021-09-15","2021-12-02","2018-10-01",[2099],[7085],{"trials":7101,"activeCount":97},[],{"trials":7103,"activeCount":97},[],{"trials":7105,"activeCount":97},[],{"trials":7107,"activeCount":97},[],{"intervention":7109,"totalTrials":132,"cells":7110},"PDC or myDC",{"EARLY_PHASE1":7111,"PHASE1":7113,"PHASE2":7121,"PHASE3":7123,"PHASE4":7125,"NA":7127},{"trials":7112,"activeCount":97},[],{"trials":7114,"activeCount":97},[7115],{"nctId":7116,"briefTitle":7117,"status":103,"phases":7118,"primaryCompletion":1827,"completion":1827,"start":1687,"enrollment":637,"conditions":7119,"interventions":7120},"NCT01690377","Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients",[85],[1044],[7109],{"trials":7122,"activeCount":97},[],{"trials":7124,"activeCount":97},[],{"trials":7126,"activeCount":97},[],{"trials":7128,"activeCount":97},[],{"intervention":7130,"totalTrials":132,"cells":7131},"Lopinavir\u002Fritonavir",{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7142,"PHASE3":7144,"PHASE4":7146,"NA":7148},{"trials":7133,"activeCount":97},[],{"trials":7135,"activeCount":97},[7136],{"nctId":7137,"briefTitle":7138,"status":103,"phases":7139,"primaryCompletion":1788,"completion":1788,"start":1644,"enrollment":512,"conditions":7140,"interventions":7141},"NCT00665951","Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir\u002FRitonavir for HIV Infected Children (SURF)",[85],[25],[7130,7130,7130],{"trials":7143,"activeCount":97},[],{"trials":7145,"activeCount":97},[],{"trials":7147,"activeCount":97},[],{"trials":7149,"activeCount":97},[],{"intervention":6985,"totalTrials":132,"cells":7151},{"EARLY_PHASE1":7152,"PHASE1":7154,"PHASE2":7160,"PHASE3":7162,"PHASE4":7164,"NA":7166},{"trials":7153,"activeCount":97},[],{"trials":7155,"activeCount":97},[7156],{"nctId":6979,"briefTitle":6980,"status":103,"phases":7157,"primaryCompletion":1677,"completion":2315,"start":1359,"enrollment":1362,"conditions":7158,"interventions":7159},[85],[1680,6983],[1682,6985],{"trials":7161,"activeCount":97},[],{"trials":7163,"activeCount":97},[],{"trials":7165,"activeCount":97},[],{"trials":7167,"activeCount":97},[],{"intervention":7169,"totalTrials":132,"cells":7170},"TF2",{"EARLY_PHASE1":7171,"PHASE1":7173,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7172,"activeCount":97},[],{"trials":7174,"activeCount":97},[7175],{"nctId":7176,"briefTitle":7177,"status":103,"phases":7178,"primaryCompletion":1359,"completion":1359,"start":1773,"enrollment":165,"conditions":7179,"interventions":7180},"NCT00860860","Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer",[85],[6258],[7169,7181],"IMP-288 labeled with In111 and Lu177",{"trials":7183,"activeCount":97},[],{"trials":7185,"activeCount":97},[],{"trials":7187,"activeCount":97},[],{"trials":7189,"activeCount":97},[],{"intervention":7181,"totalTrials":132,"cells":7191},{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7200,"PHASE3":7202,"PHASE4":7204,"NA":7206},{"trials":7193,"activeCount":97},[],{"trials":7195,"activeCount":97},[7196],{"nctId":7176,"briefTitle":7177,"status":103,"phases":7197,"primaryCompletion":1359,"completion":1359,"start":1773,"enrollment":165,"conditions":7198,"interventions":7199},[85],[6258],[7169,7181],{"trials":7201,"activeCount":97},[],{"trials":7203,"activeCount":97},[],{"trials":7205,"activeCount":97},[],{"trials":7207,"activeCount":97},[],{"intervention":7209,"totalTrials":132,"cells":7210},"abiraterone",{"EARLY_PHASE1":7211,"PHASE1":7213,"PHASE2":7222,"PHASE3":7224,"PHASE4":7226,"NA":7228},{"trials":7212,"activeCount":97},[],{"trials":7214,"activeCount":97},[7215],{"nctId":7216,"briefTitle":7217,"status":103,"phases":7218,"primaryCompletion":7219,"completion":7219,"start":6122,"enrollment":26,"conditions":7220,"interventions":7221},"NCT02883166","Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake",[85],"2019-03",[28],[7209],{"trials":7223,"activeCount":97},[],{"trials":7225,"activeCount":97},[],{"trials":7227,"activeCount":97},[],{"trials":7229,"activeCount":97},[],{"intervention":7231,"totalTrials":132,"cells":7232},"Adrecizumab",{"EARLY_PHASE1":7233,"PHASE1":7235,"PHASE2":7246,"PHASE3":7248,"PHASE4":7250,"NA":7252},{"trials":7234,"activeCount":97},[],{"trials":7236,"activeCount":97},[7237],{"nctId":7238,"briefTitle":7239,"status":103,"phases":7240,"primaryCompletion":7241,"completion":7241,"start":7242,"enrollment":1362,"conditions":7243,"interventions":7245},"NCT02991508","Adrecizumab Phase 1 Trial",[85],"2016-09-22","2016-05-23",[7244],"Healthy Volunteers",[7231],{"trials":7247,"activeCount":97},[],{"trials":7249,"activeCount":97},[],{"trials":7251,"activeCount":97},[],{"trials":7253,"activeCount":97},[],{"intervention":7255,"totalTrials":132,"cells":7256},"valacyclovir oral solution",{"EARLY_PHASE1":7257,"PHASE1":7259,"PHASE2":7270,"PHASE3":7272,"PHASE4":7274,"NA":7276},{"trials":7258,"activeCount":97},[],{"trials":7260,"activeCount":97},[7261],{"nctId":7262,"briefTitle":7263,"status":103,"phases":7264,"primaryCompletion":4857,"completion":4857,"start":2064,"enrollment":107,"conditions":7265,"interventions":7268},"NCT01689285","Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir",[85],[7266,7267],"Varicella Zoster Virus Infection","Herpes Simplex Virus Infection",[7269,7255],"valacyclovir",{"trials":7271,"activeCount":97},[],{"trials":7273,"activeCount":97},[],{"trials":7275,"activeCount":97},[],{"trials":7277,"activeCount":97},[],{"intervention":7279,"totalTrials":132,"cells":7280},"Tamoxifen 40mg QD",{"EARLY_PHASE1":7281,"PHASE1":7283,"PHASE2":7291,"PHASE3":7293,"PHASE4":7295,"NA":7297},{"trials":7282,"activeCount":97},[],{"trials":7284,"activeCount":97},[7285],{"nctId":7286,"briefTitle":7287,"status":103,"phases":7288,"primaryCompletion":2065,"completion":1753,"start":510,"enrollment":2973,"conditions":7289,"interventions":7290},"NCT01192308","PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)",[85],[30],[7279],{"trials":7292,"activeCount":97},[],{"trials":7294,"activeCount":97},[],{"trials":7296,"activeCount":97},[],{"trials":7298,"activeCount":97},[],{"intervention":7300,"totalTrials":132,"cells":7301},"AMPD1 polymorphism",{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7314,"PHASE3":7316,"PHASE4":7318,"NA":7320},{"trials":7303,"activeCount":97},[],{"trials":7305,"activeCount":97},[7306],{"nctId":7307,"briefTitle":7308,"status":103,"phases":7309,"primaryCompletion":7310,"completion":7310,"start":203,"enrollment":4595,"conditions":7311,"interventions":7312},"NCT00513110","A Possible Therapeutic Role for Adenosine During Inflammation",[85],"2008-08",[17],[7300,7313],"Caffeine",{"trials":7315,"activeCount":97},[],{"trials":7317,"activeCount":97},[],{"trials":7319,"activeCount":97},[],{"trials":7321,"activeCount":97},[],{"intervention":7323,"totalTrials":132,"cells":7324},"Aminoguanidine",{"EARLY_PHASE1":7325,"PHASE1":7327,"PHASE2":7337,"PHASE3":7339,"PHASE4":7341,"NA":7343},{"trials":7326,"activeCount":97},[],{"trials":7328,"activeCount":97},[7329],{"nctId":7330,"briefTitle":7331,"status":103,"phases":7332,"primaryCompletion":3245,"completion":3245,"start":7333,"enrollment":478,"conditions":7334,"interventions":7335},"NCT00184990","Effect of Selective iNOS Inhibition During Human Endotoxemia",[85],"2005-01",[17],[7323,7336],"endotoxin",{"trials":7338,"activeCount":97},[],{"trials":7340,"activeCount":97},[],{"trials":7342,"activeCount":97},[],{"trials":7344,"activeCount":97},[],{"intervention":7346,"totalTrials":132,"cells":7347},"Zepatier whole",{"EARLY_PHASE1":7348,"PHASE1":7350,"PHASE2":7362,"PHASE3":7364,"PHASE4":7366,"NA":7368},{"trials":7349,"activeCount":97},[],{"trials":7351,"activeCount":97},[7352],{"nctId":7353,"briefTitle":7354,"status":103,"phases":7355,"primaryCompletion":7356,"completion":7356,"start":7357,"enrollment":4820,"conditions":7358,"interventions":7360},"NCT03817619","Bioequivalence Study of Crushed Elbasvir\u002FGrazoprevir Compared to the Whole Tablet",[85],"2019-07-30","2019-03-28",[109,7359],"Deglutition Disorders",[7346,7361],"Zepatier crushed",{"trials":7363,"activeCount":97},[],{"trials":7365,"activeCount":97},[],{"trials":7367,"activeCount":97},[],{"trials":7369,"activeCount":97},[],{"intervention":7361,"totalTrials":132,"cells":7371},{"EARLY_PHASE1":7372,"PHASE1":7374,"PHASE2":7380,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7373,"activeCount":97},[],{"trials":7375,"activeCount":97},[7376],{"nctId":7353,"briefTitle":7354,"status":103,"phases":7377,"primaryCompletion":7356,"completion":7356,"start":7357,"enrollment":4820,"conditions":7378,"interventions":7379},[85],[109,7359],[7346,7361],{"trials":7381,"activeCount":97},[],{"trials":7383,"activeCount":97},[],{"trials":7385,"activeCount":97},[],{"trials":7387,"activeCount":97},[],{"intervention":1649,"totalTrials":132,"cells":7389},{"EARLY_PHASE1":7390,"PHASE1":7392,"PHASE2":7398,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7391,"activeCount":97},[],{"trials":7393,"activeCount":97},[7394],{"nctId":1641,"briefTitle":1642,"status":103,"phases":7395,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1362,"conditions":7396,"interventions":7397},[85],[25],[1649,1633,1650],{"trials":7399,"activeCount":97},[],{"trials":7401,"activeCount":97},[],{"trials":7403,"activeCount":97},[],{"trials":7405,"activeCount":97},[],{"intervention":1650,"totalTrials":132,"cells":7407},{"EARLY_PHASE1":7408,"PHASE1":7410,"PHASE2":7416,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7409,"activeCount":97},[],{"trials":7411,"activeCount":97},[7412],{"nctId":1641,"briefTitle":1642,"status":103,"phases":7413,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1362,"conditions":7414,"interventions":7415},[85],[25],[1649,1633,1650],{"trials":7417,"activeCount":97},[],{"trials":7419,"activeCount":97},[],{"trials":7421,"activeCount":97},[],{"trials":7423,"activeCount":97},[],{"intervention":7425,"totalTrials":132,"cells":7426},"repeated injections of endotoxin during 5 days",{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7437,"PHASE3":7439,"PHASE4":7441,"NA":7443},{"trials":7428,"activeCount":97},[],{"trials":7430,"activeCount":97},[7431],{"nctId":7432,"briefTitle":7433,"status":103,"phases":7434,"primaryCompletion":3874,"completion":3874,"start":5727,"enrollment":107,"conditions":7435,"interventions":7436},"NCT00246714","Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans",[85],[17],[7425],{"trials":7438,"activeCount":97},[],{"trials":7440,"activeCount":97},[],{"trials":7442,"activeCount":97},[],{"trials":7444,"activeCount":97},[],{"intervention":1661,"totalTrials":132,"cells":7446},{"EARLY_PHASE1":7447,"PHASE1":7449,"PHASE2":7455,"PHASE3":7457,"PHASE4":7459,"NA":7461},{"trials":7448,"activeCount":97},[],{"trials":7450,"activeCount":97},[7451],{"nctId":1652,"briefTitle":1653,"status":103,"phases":7452,"primaryCompletion":1655,"completion":1655,"start":1656,"enrollment":1362,"conditions":7453,"interventions":7454},[85],[110,1658],[1660,1661],{"trials":7456,"activeCount":97},[],{"trials":7458,"activeCount":97},[],{"trials":7460,"activeCount":97},[],{"trials":7462,"activeCount":97},[],{"intervention":7464,"totalTrials":132,"cells":7465},"Temsirolimus\u002FPLD",{"EARLY_PHASE1":7466,"PHASE1":7468,"PHASE2":7479,"PHASE3":7481,"PHASE4":7483,"NA":7485},{"trials":7467,"activeCount":97},[],{"trials":7469,"activeCount":97},[7470],{"nctId":7471,"briefTitle":7472,"status":161,"phases":7473,"primaryCompletion":7474,"completion":4755,"start":511,"enrollment":637,"conditions":7475,"interventions":7478},"NCT00982631","A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®\u002FCaelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer",[85],"2012-02",[7476,6392,7477],"Advanced\u002FRecurrent Breast Cancer","Ovarian Cancer",[7464],{"trials":7480,"activeCount":97},[],{"trials":7482,"activeCount":97},[],{"trials":7484,"activeCount":97},[],{"trials":7486,"activeCount":97},[],{"intervention":7488,"totalTrials":132,"cells":7489},"R0.6C transmission blocking vaccine",{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7503,"PHASE3":7505,"PHASE4":7507,"NA":7509},{"trials":7491,"activeCount":97},[],{"trials":7493,"activeCount":97},[7494],{"nctId":7495,"briefTitle":7496,"status":103,"phases":7497,"primaryCompletion":7498,"completion":7498,"start":7499,"enrollment":7500,"conditions":7501,"interventions":7502},"NCT04862416","Safety and Efficacy of R0.6C Vaccine",[85],"2022-06-29","2021-05-17",32,[3313,4925],[7488],{"trials":7504,"activeCount":97},[],{"trials":7506,"activeCount":97},[],{"trials":7508,"activeCount":97},[],{"trials":7510,"activeCount":97},[],{"intervention":7512,"totalTrials":132,"cells":7513},"5-formyltetrahydrofolate",{"EARLY_PHASE1":7514,"PHASE1":7516,"PHASE2":7526,"PHASE3":7528,"PHASE4":7530,"NA":7532},{"trials":7515,"activeCount":97},[],{"trials":7517,"activeCount":97},[7518],{"nctId":7519,"briefTitle":7520,"status":103,"phases":7521,"primaryCompletion":7522,"completion":7522,"start":3101,"enrollment":3942,"conditions":7523,"interventions":7525},"NCT00877227","Does B Vitamin Supplementation Decrease Homocysteine Concentrations in Newborns",[85],"2003-11",[7524],"Mild Hyperhomocysteinemia",[7512],{"trials":7527,"activeCount":97},[],{"trials":7529,"activeCount":97},[],{"trials":7531,"activeCount":97},[],{"trials":7533,"activeCount":97},[],{"intervention":7535,"totalTrials":132,"cells":7536},"Triumeq",{"EARLY_PHASE1":7537,"PHASE1":7539,"PHASE2":7549,"PHASE3":7551,"PHASE4":7553,"NA":7555},{"trials":7538,"activeCount":97},[],{"trials":7540,"activeCount":97},[7541],{"nctId":7542,"briefTitle":7543,"status":103,"phases":7544,"primaryCompletion":535,"completion":535,"start":635,"enrollment":15,"conditions":7545,"interventions":7546},"NCT02569346","Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet",[85],[110],[7535,7547,7548],"Triumeq crushed + breakfast","Triumeq crushed + drip feed",{"trials":7550,"activeCount":97},[],{"trials":7552,"activeCount":97},[],{"trials":7554,"activeCount":97},[],{"trials":7556,"activeCount":97},[],{"intervention":7547,"totalTrials":132,"cells":7558},{"EARLY_PHASE1":7559,"PHASE1":7561,"PHASE2":7567,"PHASE3":7569,"PHASE4":7571,"NA":7573},{"trials":7560,"activeCount":97},[],{"trials":7562,"activeCount":97},[7563],{"nctId":7542,"briefTitle":7543,"status":103,"phases":7564,"primaryCompletion":535,"completion":535,"start":635,"enrollment":15,"conditions":7565,"interventions":7566},[85],[110],[7535,7547,7548],{"trials":7568,"activeCount":97},[],{"trials":7570,"activeCount":97},[],{"trials":7572,"activeCount":97},[],{"trials":7574,"activeCount":97},[],{"intervention":7548,"totalTrials":132,"cells":7576},{"EARLY_PHASE1":7577,"PHASE1":7579,"PHASE2":7585,"PHASE3":7587,"PHASE4":7589,"NA":7591},{"trials":7578,"activeCount":97},[],{"trials":7580,"activeCount":97},[7581],{"nctId":7542,"briefTitle":7543,"status":103,"phases":7582,"primaryCompletion":535,"completion":535,"start":635,"enrollment":15,"conditions":7583,"interventions":7584},[85],[110],[7535,7547,7548],{"trials":7586,"activeCount":97},[],{"trials":7588,"activeCount":97},[],{"trials":7590,"activeCount":97},[],{"trials":7592,"activeCount":97},[],{"intervention":4629,"totalTrials":132,"cells":7594},{"EARLY_PHASE1":7595,"PHASE1":7597,"PHASE2":7603,"PHASE3":7605,"PHASE4":7607,"NA":7609},{"trials":7596,"activeCount":97},[],{"trials":7598,"activeCount":97},[7599],{"nctId":4621,"briefTitle":4622,"status":103,"phases":7600,"primaryCompletion":4624,"completion":4624,"start":4625,"enrollment":1034,"conditions":7601,"interventions":7602},[85],[4627],[4629,4630],{"trials":7604,"activeCount":97},[],{"trials":7606,"activeCount":97},[],{"trials":7608,"activeCount":97},[],{"trials":7610,"activeCount":97},[],{"intervention":7612,"totalTrials":132,"cells":7613},"fosamprenavir\u002Fritonavir",{"EARLY_PHASE1":7614,"PHASE1":7616,"PHASE2":7625,"PHASE3":7627,"PHASE4":7629,"NA":7631},{"trials":7615,"activeCount":97},[],{"trials":7617,"activeCount":97},[7618],{"nctId":7619,"briefTitle":7620,"status":103,"phases":7621,"primaryCompletion":1787,"completion":1787,"start":1373,"enrollment":1362,"conditions":7622,"interventions":7623},"NCT00977301","Interaction Between Fosamprenavir\u002FRitonavir and a Single-dose Olanzapine (FORZA)",[85],[25],[7612,7624,7624],"olanzapine",{"trials":7626,"activeCount":97},[],{"trials":7628,"activeCount":97},[],{"trials":7630,"activeCount":97},[],{"trials":7632,"activeCount":97},[],{"intervention":7624,"totalTrials":132,"cells":7634},{"EARLY_PHASE1":7635,"PHASE1":7637,"PHASE2":7643,"PHASE3":7645,"PHASE4":7647,"NA":7649},{"trials":7636,"activeCount":97},[],{"trials":7638,"activeCount":97},[7639],{"nctId":7619,"briefTitle":7620,"status":103,"phases":7640,"primaryCompletion":1787,"completion":1787,"start":1373,"enrollment":1362,"conditions":7641,"interventions":7642},[85],[25],[7612,7624,7624],{"trials":7644,"activeCount":97},[],{"trials":7646,"activeCount":97},[],{"trials":7648,"activeCount":97},[],{"trials":7650,"activeCount":97},[],{"intervention":7652,"totalTrials":132,"cells":7653},"Indium-111-DOTA-Girentuximab-IRDye800CW",{"EARLY_PHASE1":7654,"PHASE1":7656,"PHASE2":7666,"PHASE3":7668,"PHASE4":7670,"NA":7672},{"trials":7655,"activeCount":97},[],{"trials":7657,"activeCount":97},[7658],{"nctId":7659,"briefTitle":7660,"status":161,"phases":7661,"primaryCompletion":6120,"completion":7662,"start":3873,"enrollment":637,"conditions":7663,"interventions":7665},"NCT02497599","Intraoperative Dual-modality Imaging in Renal Cell Carcinoma",[85],"2022-04",[7664],"Carcinoma, Renal Cell",[7652],{"trials":7667,"activeCount":97},[],{"trials":7669,"activeCount":97},[],{"trials":7671,"activeCount":97},[],{"trials":7673,"activeCount":97},[],{"intervention":7675,"totalTrials":132,"cells":7676},"ABNCoV2 Vaccine",{"EARLY_PHASE1":7677,"PHASE1":7679,"PHASE2":7693,"PHASE3":7695,"PHASE4":7697,"NA":7699},{"trials":7678,"activeCount":97},[],{"trials":7680,"activeCount":97},[7681],{"nctId":7682,"briefTitle":7683,"status":103,"phases":7684,"primaryCompletion":7685,"completion":7686,"start":7687,"enrollment":7688,"conditions":7689,"interventions":7692},"NCT04839146","Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)",[85],"2021-12-30","2022-02-25","2021-03-11",45,[7690,2185,7691],"Covid19","SARS-CoV-2 Infection",[7675],{"trials":7694,"activeCount":97},[],{"trials":7696,"activeCount":97},[],{"trials":7698,"activeCount":97},[],{"trials":7700,"activeCount":97},[],{"intervention":7702,"totalTrials":132,"cells":7703},"DTG DT",{"EARLY_PHASE1":7704,"PHASE1":7706,"PHASE2":7718,"PHASE3":7720,"PHASE4":7722,"NA":7724},{"trials":7705,"activeCount":97},[],{"trials":7707,"activeCount":97},[7708],{"nctId":7709,"briefTitle":7710,"status":103,"phases":7711,"primaryCompletion":7712,"completion":7713,"start":7714,"enrollment":107,"conditions":7715,"interventions":7716},"NCT05489406","Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F\u002FTAF TOS.",[85],"2023-03-24","2023-11-30","2022-10-06",[3379],[7702,7717],"F\u002FTAF TOS",{"trials":7719,"activeCount":97},[],{"trials":7721,"activeCount":97},[],{"trials":7723,"activeCount":97},[],{"trials":7725,"activeCount":97},[],{"intervention":7717,"totalTrials":132,"cells":7727},{"EARLY_PHASE1":7728,"PHASE1":7730,"PHASE2":7736,"PHASE3":7738,"PHASE4":7740,"NA":7742},{"trials":7729,"activeCount":97},[],{"trials":7731,"activeCount":97},[7732],{"nctId":7709,"briefTitle":7710,"status":103,"phases":7733,"primaryCompletion":7712,"completion":7713,"start":7714,"enrollment":107,"conditions":7734,"interventions":7735},[85],[3379],[7702,7717],{"trials":7737,"activeCount":97},[],{"trials":7739,"activeCount":97},[],{"trials":7741,"activeCount":97},[],{"trials":7743,"activeCount":97},[],{"intervention":1691,"totalTrials":132,"cells":7745},{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7754,"PHASE3":7756,"PHASE4":7758,"NA":7760},{"trials":7747,"activeCount":97},[],{"trials":7749,"activeCount":97},[7750],{"nctId":1684,"briefTitle":1685,"status":103,"phases":7751,"primaryCompletion":1645,"completion":1645,"start":1687,"enrollment":1362,"conditions":7752,"interventions":7753},[85],[1689],[1691,1633],{"trials":7755,"activeCount":97},[],{"trials":7757,"activeCount":97},[],{"trials":7759,"activeCount":97},[],{"trials":7761,"activeCount":97},[],{"intervention":7763,"totalTrials":132,"cells":7764},"capiri-sutent",{"EARLY_PHASE1":7765,"PHASE1":7767,"PHASE2":7775,"PHASE3":7777,"PHASE4":7779,"NA":7781},{"trials":7766,"activeCount":97},[],{"trials":7768,"activeCount":97},[7769],{"nctId":7770,"briefTitle":7771,"status":161,"phases":7772,"primaryCompletion":1753,"completion":553,"start":3244,"enrollment":7500,"conditions":7773,"interventions":7774},"NCT00777478","Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer",[85],[23],[7763],{"trials":7776,"activeCount":97},[],{"trials":7778,"activeCount":97},[],{"trials":7780,"activeCount":97},[],{"trials":7782,"activeCount":97},[],{"intervention":7784,"totalTrials":132,"cells":7785},"Stribild",{"EARLY_PHASE1":7786,"PHASE1":7788,"PHASE2":7797,"PHASE3":7799,"PHASE4":7801,"NA":7803},{"trials":7787,"activeCount":97},[],{"trials":7789,"activeCount":97},[7790],{"nctId":7791,"briefTitle":7792,"status":103,"phases":7793,"primaryCompletion":4858,"completion":4858,"start":4858,"enrollment":1362,"conditions":7794,"interventions":7795},"NCT02325934","Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet",[85],[110],[7784,7796],"Stribild, crushed",{"trials":7798,"activeCount":97},[],{"trials":7800,"activeCount":97},[],{"trials":7802,"activeCount":97},[],{"trials":7804,"activeCount":97},[],{"intervention":7796,"totalTrials":132,"cells":7806},{"EARLY_PHASE1":7807,"PHASE1":7809,"PHASE2":7815,"PHASE3":7817,"PHASE4":7819,"NA":7821},{"trials":7808,"activeCount":97},[],{"trials":7810,"activeCount":97},[7811],{"nctId":7791,"briefTitle":7792,"status":103,"phases":7812,"primaryCompletion":4858,"completion":4858,"start":4858,"enrollment":1362,"conditions":7813,"interventions":7814},[85],[110],[7784,7796],{"trials":7816,"activeCount":97},[],{"trials":7818,"activeCount":97},[],{"trials":7820,"activeCount":97},[],{"trials":7822,"activeCount":97},[],{"intervention":4826,"totalTrials":132,"cells":7824},{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7833,"PHASE3":7835,"PHASE4":7837,"NA":7839},{"trials":7826,"activeCount":97},[],{"trials":7828,"activeCount":97},[7829],{"nctId":4814,"briefTitle":4815,"status":103,"phases":7830,"primaryCompletion":4817,"completion":4818,"start":4819,"enrollment":4820,"conditions":7831,"interventions":7832},[85],[4822,4823,4824],[4807,4826],{"trials":7834,"activeCount":97},[],{"trials":7836,"activeCount":97},[],{"trials":7838,"activeCount":97},[],{"trials":7840,"activeCount":97},[],{"intervention":1780,"totalTrials":132,"cells":7842},{"EARLY_PHASE1":7843,"PHASE1":7845,"PHASE2":7851,"PHASE3":7853,"PHASE4":7855,"NA":7857},{"trials":7844,"activeCount":97},[],{"trials":7846,"activeCount":97},[7847],{"nctId":1770,"briefTitle":1771,"status":103,"phases":7848,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1362,"conditions":7849,"interventions":7850},[85],[1689,1777],[1779,1780,114],{"trials":7852,"activeCount":97},[],{"trials":7854,"activeCount":97},[],{"trials":7856,"activeCount":97},[],{"trials":7858,"activeCount":97},[],{"intervention":7860,"totalTrials":132,"cells":7861},"velpatasvir",{"EARLY_PHASE1":7862,"PHASE1":7864,"PHASE2":7874,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7863,"activeCount":97},[],{"trials":7865,"activeCount":97},[7866],{"nctId":7867,"briefTitle":7868,"status":103,"phases":7869,"primaryCompletion":6562,"completion":6562,"start":7870,"enrollment":4820,"conditions":7871,"interventions":7873},"NCT03513393","Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.",[85],"2018-08-01",[109,7872],"Swallowing Disorder",[7860,7860,7860],{"trials":7875,"activeCount":97},[],{"trials":7877,"activeCount":97},[],{"trials":7879,"activeCount":97},[],{"trials":7881,"activeCount":97},[],{"intervention":7883,"totalTrials":132,"cells":7884},"Potassium channel blockers: TEA, Quinin, Tolbutamide",{"EARLY_PHASE1":7885,"PHASE1":7887,"PHASE2":7897,"PHASE3":7899,"PHASE4":7901,"NA":7903},{"trials":7886,"activeCount":97},[],{"trials":7888,"activeCount":97},[7889],{"nctId":7890,"briefTitle":7891,"status":103,"phases":7892,"primaryCompletion":7893,"completion":7893,"start":3101,"enrollment":3792,"conditions":7894,"interventions":7895},"NCT00185003","Blockade of Vascular Potassium Channels During Human Endotoxemia",[85],"2005-06",[17],[7336,7883,7896],"L-NMMA",{"trials":7898,"activeCount":97},[],{"trials":7900,"activeCount":97},[],{"trials":7902,"activeCount":97},[],{"trials":7904,"activeCount":97},[],{"intervention":7896,"totalTrials":132,"cells":7906},{"EARLY_PHASE1":7907,"PHASE1":7909,"PHASE2":7915,"PHASE3":7917,"PHASE4":7919,"NA":7921},{"trials":7908,"activeCount":97},[],{"trials":7910,"activeCount":97},[7911],{"nctId":7890,"briefTitle":7891,"status":103,"phases":7912,"primaryCompletion":7893,"completion":7893,"start":3101,"enrollment":3792,"conditions":7913,"interventions":7914},[85],[17],[7336,7883,7896],{"trials":7916,"activeCount":97},[],{"trials":7918,"activeCount":97},[],{"trials":7920,"activeCount":97},[],{"trials":7922,"activeCount":97},[],{"intervention":7924,"totalTrials":132,"cells":7925},"Methylprednisolone",{"EARLY_PHASE1":7926,"PHASE1":7937,"PHASE2":7939,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7927,"activeCount":97},[7928],{"nctId":7929,"briefTitle":7930,"status":161,"phases":7931,"primaryCompletion":7932,"completion":7932,"start":164,"enrollment":637,"conditions":7933,"interventions":7936},"NCT03059979","The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )",[84],"2021-07-01",[7934,7935],"Systemic Sclerosis","Raynaud Phenomena",[7924],{"trials":7938,"activeCount":97},[],{"trials":7940,"activeCount":97},[],{"trials":7942,"activeCount":97},[],{"trials":7944,"activeCount":97},[],{"trials":7946,"activeCount":97},[],{"intervention":4960,"totalTrials":132,"cells":7948},{"EARLY_PHASE1":7949,"PHASE1":7961,"PHASE2":7963,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7950,"activeCount":97},[7951],{"nctId":7952,"briefTitle":7953,"status":103,"phases":7954,"primaryCompletion":1963,"completion":7955,"start":7956,"enrollment":7957,"conditions":7958,"interventions":7959},"NCT05401448","Non-specific Effects of FLU-MMR Vaccines in Adults",[84],"2022-08-31","2021-06-01",638,[1419],[4960,7960],"MMR vaccines",{"trials":7962,"activeCount":97},[],{"trials":7964,"activeCount":97},[],{"trials":7966,"activeCount":97},[],{"trials":7968,"activeCount":97},[],{"trials":7970,"activeCount":97},[],{"intervention":7960,"totalTrials":132,"cells":7972},{"EARLY_PHASE1":7973,"PHASE1":7979,"PHASE2":7981,"PHASE3":7983,"PHASE4":7985,"NA":7987},{"trials":7974,"activeCount":97},[7975],{"nctId":7952,"briefTitle":7953,"status":103,"phases":7976,"primaryCompletion":1963,"completion":7955,"start":7956,"enrollment":7957,"conditions":7977,"interventions":7978},[84],[1419],[4960,7960],{"trials":7980,"activeCount":97},[],{"trials":7982,"activeCount":97},[],{"trials":7984,"activeCount":97},[],{"trials":7986,"activeCount":97},[],{"trials":7988,"activeCount":97},[],{"intervention":3043,"totalTrials":1634,"cells":7990},{"EARLY_PHASE1":7991,"PHASE1":7993,"PHASE2":7995,"PHASE3":8012,"PHASE4":8014,"NA":8036},{"trials":7992,"activeCount":97},[],{"trials":7994,"activeCount":97},[],{"trials":7996,"activeCount":97},[7997,8005],{"nctId":7998,"briefTitle":7999,"status":103,"phases":8000,"primaryCompletion":7072,"completion":7072,"start":4733,"enrollment":637,"conditions":8001,"interventions":8003},"NCT00184951","Pharmacokinetic Study of Rosuvastatin and Lopinavir\u002FRitonavir in HIV Patients",[86],[25,8002],"Hyperlipidemia",[8004],"Rosuvastatin",{"nctId":8006,"briefTitle":8007,"status":103,"phases":8008,"completion":203,"start":5274,"enrollment":165,"conditions":8009,"interventions":8011},"NCT00315510","Rosuvastatin and Ischemia Reperfusion",[86],[8010],"Ischemia",[8004],{"trials":8013,"activeCount":97},[],{"trials":8015,"activeCount":97},[8016,8024,8028],{"nctId":8017,"briefTitle":8018,"status":103,"phases":8019,"primaryCompletion":8020,"completion":8021,"start":3894,"enrollment":1362,"conditions":8022,"interventions":8023},"NCT00457652","Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?",[88],"2007-09","2007-11",[1755],[8004],{"nctId":3036,"briefTitle":3037,"status":103,"phases":8025,"primaryCompletion":3039,"completion":509,"start":2738,"enrollment":3040,"conditions":8026,"interventions":8027},[88],[1755,1365],[3043,3023,3044,3045],{"nctId":8029,"briefTitle":8030,"status":103,"phases":8031,"primaryCompletion":6790,"completion":2738,"start":1939,"enrollment":2649,"conditions":8032,"interventions":8034},"NCT00851175","Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?",[88],[8033,1745],"Atherosclerosis",[3043,8035],"caffeine",{"trials":8037,"activeCount":97},[8038],{"nctId":8039,"briefTitle":8040,"status":103,"phases":8041,"primaryCompletion":2039,"completion":8042,"start":8021,"enrollment":1362,"conditions":8043,"interventions":8045},"NCT00554138","The Effect of Rosuvastatin on Adenosine Metabolism",[89],"2008-04",[8044],"Adenosine Metabolism",[3043],{"intervention":8047,"totalTrials":1634,"cells":8048},"dipyridamole",{"EARLY_PHASE1":8049,"PHASE1":8051,"PHASE2":8053,"PHASE3":8055,"PHASE4":8057,"NA":8093},{"trials":8050,"activeCount":97},[],{"trials":8052,"activeCount":97},[],{"trials":8054,"activeCount":97},[],{"trials":8056,"activeCount":97},[],{"trials":8058,"activeCount":97},[8059,8065,8073,8081,8087],{"nctId":8060,"briefTitle":8061,"status":103,"phases":8062,"primaryCompletion":2155,"completion":2039,"start":3894,"enrollment":1102,"conditions":8063,"interventions":8064},"NCT00457405","Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?",[88],[6017,8033],[8047],{"nctId":8066,"briefTitle":8067,"status":103,"phases":8068,"primaryCompletion":7474,"completion":2273,"start":2972,"enrollment":8069,"conditions":8070,"interventions":8071},"NCT01295567","Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?",[88],95,[1745,1746],[8072],"Dipyridamole",{"nctId":8074,"briefTitle":8075,"status":103,"phases":8076,"primaryCompletion":2038,"completion":3039,"start":1645,"enrollment":637,"conditions":8077,"interventions":8080},"NCT00767663","Persantin Preceding Elective PCI",[88],[8078,8079,8033],"Coronary Heart Disease","Percutaneous Transluminal Coronary Angioplasty",[8047],{"nctId":8082,"briefTitle":8083,"status":103,"phases":8084,"primaryCompletion":1033,"completion":1033,"start":509,"enrollment":637,"conditions":8085,"interventions":8086},"NCT01091571","The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia",[88],[17],[8072],{"nctId":8088,"briefTitle":8089,"status":103,"phases":8090,"primaryCompletion":3310,"completion":6015,"start":5250,"enrollment":165,"conditions":8091,"interventions":8092},"NCT00430170","Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?",[88],[1745,6017],[8072,8035],{"trials":8094,"activeCount":97},[8095],{"nctId":8096,"briefTitle":8097,"status":103,"phases":8098,"completion":8099,"start":8100,"enrollment":512,"conditions":8101,"interventions":8104},"NCT00268554","Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole",[89],"2006-07","2005-12",[8102,8103],"Hyperemia","Hypoxia",[8047,8035],{"intervention":8035,"totalTrials":1634,"cells":8106},{"EARLY_PHASE1":8107,"PHASE1":8109,"PHASE2":8115,"PHASE3":8117,"PHASE4":8119,"NA":8129},{"trials":8108,"activeCount":97},[],{"trials":8110,"activeCount":97},[8111],{"nctId":7307,"briefTitle":7308,"status":103,"phases":8112,"primaryCompletion":7310,"completion":7310,"start":203,"enrollment":4595,"conditions":8113,"interventions":8114},[85],[17],[7300,7313],{"trials":8116,"activeCount":97},[],{"trials":8118,"activeCount":97},[],{"trials":8120,"activeCount":97},[8121,8125],{"nctId":8029,"briefTitle":8030,"status":103,"phases":8122,"primaryCompletion":6790,"completion":2738,"start":1939,"enrollment":2649,"conditions":8123,"interventions":8124},[88],[8033,1745],[3043,8035],{"nctId":8088,"briefTitle":8089,"status":103,"phases":8126,"primaryCompletion":3310,"completion":6015,"start":5250,"enrollment":165,"conditions":8127,"interventions":8128},[88],[1745,6017],[8072,8035],{"trials":8130,"activeCount":97},[8131,8141,8150],{"nctId":8132,"briefTitle":8133,"status":8134,"phases":8135,"start":8136,"enrollment":2649,"conditions":8137,"interventions":8138},"NCT00184847","Adenosine Receptors Influence Ischemia-Reperfusion Injury","SUSPENDED",[89],"2005-03",[6017],[8139,8140,8035],"acetylcholine","adenosine",{"nctId":8142,"briefTitle":8143,"status":103,"phases":8144,"completion":5336,"start":8145,"enrollment":1362,"conditions":8146,"interventions":8148},"NCT00184912","The Effect of Caffeine on Ischemic Preconditioning",[89],"2003-09",[7313,8147,6017],"Ischemic Preconditioning",[8035,8149],"Technetium-TC99m-labeled Annexin A5",{"nctId":8096,"briefTitle":8097,"status":103,"phases":8151,"completion":8099,"start":8100,"enrollment":512,"conditions":8152,"interventions":8153},[89],[8102,8103],[8047,8035],{"intervention":7336,"totalTrials":8155,"cells":8156},5,{"EARLY_PHASE1":8157,"PHASE1":8159,"PHASE2":8173,"PHASE3":8175,"PHASE4":8185,"NA":8187},{"trials":8158,"activeCount":97},[],{"trials":8160,"activeCount":97},[8161,8165,8169],{"nctId":7330,"briefTitle":7331,"status":103,"phases":8162,"primaryCompletion":3245,"completion":3245,"start":7333,"enrollment":478,"conditions":8163,"interventions":8164},[85],[17],[7323,7336],{"nctId":4854,"briefTitle":4855,"status":103,"phases":8166,"primaryCompletion":4857,"completion":534,"start":4858,"enrollment":230,"conditions":8167,"interventions":8168},[85],[17,4860],[4847,4862],{"nctId":7890,"briefTitle":7891,"status":103,"phases":8170,"primaryCompletion":7893,"completion":7893,"start":3101,"enrollment":3792,"conditions":8171,"interventions":8172},[85],[17],[7336,7883,7896],{"trials":8174,"activeCount":97},[],{"trials":8176,"activeCount":97},[8177],{"nctId":8178,"briefTitle":8179,"status":103,"phases":8180,"primaryCompletion":593,"completion":1656,"start":5067,"enrollment":165,"conditions":8181,"interventions":8183},"NCT01766414","In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II",[87],[8182,17,753,33],"Innate Immune Response",[8184,4862],"C1-esterase inhibitor",{"trials":8186,"activeCount":97},[],{"trials":8188,"activeCount":97},[8189],{"nctId":8190,"briefTitle":8191,"status":103,"phases":8192,"primaryCompletion":5089,"completion":595,"start":3039,"enrollment":637,"conditions":8193,"interventions":8195},"NCT01349699","Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia",[89],[8194,4448],"Systemic Inflammatory Process",[8196,8197,7336],"iron sucrose","Deferasirox",{"intervention":113,"totalTrials":561,"cells":8199},{"EARLY_PHASE1":8200,"PHASE1":8202,"PHASE2":8208,"PHASE3":8218,"PHASE4":8220,"NA":8222},{"trials":8201,"activeCount":97},[],{"trials":8203,"activeCount":97},[8204],{"nctId":101,"briefTitle":102,"status":103,"phases":8205,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":8206,"interventions":8207},[85],[109,110],[112,113,114,92],{"trials":8209,"activeCount":97},[8210,8214],{"nctId":1991,"briefTitle":1992,"status":607,"phases":8211,"primaryCompletion":1473,"completion":1473,"start":1994,"enrollment":501,"conditions":8212,"interventions":8213},[86],[1996],[113,1982,1998],{"nctId":4792,"briefTitle":4793,"status":103,"phases":8215,"primaryCompletion":201,"completion":554,"start":1773,"enrollment":165,"conditions":8216,"interventions":8217},[86],[1689,25],[4797,4798,4799],{"trials":8219,"activeCount":97},[],{"trials":8221,"activeCount":97},[],{"trials":8223,"activeCount":97},[8224],{"nctId":8225,"briefTitle":8226,"status":103,"phases":8227,"primaryCompletion":509,"completion":4857,"start":3893,"enrollment":637,"conditions":8228,"interventions":8230},"NCT00916448","The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia",[89],[17,753,8229,33],"Multi Organ Dysfunction Syndrome",[113,8231],"E. coli endotoxin",{"intervention":8233,"totalTrials":627,"cells":8234},"CPS-immunization",{"EARLY_PHASE1":8235,"PHASE1":8237,"PHASE2":8239,"PHASE3":8241,"PHASE4":8243,"NA":8245},{"trials":8236,"activeCount":97},[],{"trials":8238,"activeCount":97},[],{"trials":8240,"activeCount":97},[],{"trials":8242,"activeCount":97},[],{"trials":8244,"activeCount":97},[],{"trials":8246,"activeCount":97},[8247,8256,8268],{"nctId":8248,"briefTitle":8249,"status":103,"phases":8250,"primaryCompletion":4857,"completion":4857,"start":536,"enrollment":21,"conditions":8251,"interventions":8252},"NCT02080026","Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis",[89],[3313],[8233,8253,8254,8255],"Controlled Human Malaria Infection","chloroquine","atovaquone\u002Fproguanil",{"nctId":8257,"briefTitle":8258,"status":607,"phases":8259,"primaryCompletion":8260,"completion":8260,"start":8261,"enrollment":6514,"conditions":8262,"interventions":8264},"NCT03813108","Safety and Efficacy of NF135 CPS Immunization",[89],"2021-02-01","2019-04-01",[4925,8253,8263],"Immunization; Infection",[8233,8265,8266,8233,8267],"malaria challenge infection, P. falciparum NF135.C10","malaria challenge infection, P. falciparum NF54","Atovaquone \u002F Proguanil Oral Tablet [Malarone]",{"nctId":8269,"briefTitle":8270,"status":103,"phases":8271,"primaryCompletion":106,"completion":106,"start":594,"enrollment":1392,"conditions":8272,"interventions":8273},"NCT02098590","Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection",[89],[3313],[8233,8265,8274,8266,8255],"malaria challenge infection, P. falciparum NF166.C8",{"intervention":8276,"totalTrials":627,"cells":8277},"Lipopolysaccharide",{"EARLY_PHASE1":8278,"PHASE1":8280,"PHASE2":8282,"PHASE3":8292,"PHASE4":8294,"NA":8296},{"trials":8279,"activeCount":97},[],{"trials":8281,"activeCount":97},[],{"trials":8283,"activeCount":97},[8284],{"nctId":8285,"briefTitle":8286,"status":103,"phases":8287,"primaryCompletion":2064,"completion":2064,"start":593,"enrollment":637,"conditions":8288,"interventions":8291},"NCT01978158","Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α",[85,86],[8103,8289,8290],"Normoxia","Hyperoxia",[8276],{"trials":8293,"activeCount":97},[],{"trials":8295,"activeCount":97},[],{"trials":8297,"activeCount":97},[8298,8304],{"nctId":8299,"briefTitle":8300,"status":103,"phases":8301,"primaryCompletion":2806,"completion":1666,"start":6940,"enrollment":637,"conditions":8302,"interventions":8303},"NCT01835457","Concentration\u002FMeditation Limits Inflammation",[89],[639],[8276],{"nctId":8305,"briefTitle":8306,"status":103,"phases":8307,"primaryCompletion":578,"completion":2065,"start":202,"enrollment":132,"conditions":8308,"interventions":8309},"NCT01352871","The Effects of Concentration\u002FMeditation on the Innate Immune Response During Human Endotoxemia",[],[8182],[8310],"lipopolysaccharide",{"intervention":8312,"totalTrials":627,"cells":8313},"Malarone treatment",{"EARLY_PHASE1":8314,"PHASE1":8316,"PHASE2":8318,"PHASE3":8320,"PHASE4":8322,"NA":8324},{"trials":8315,"activeCount":97},[],{"trials":8317,"activeCount":97},[],{"trials":8319,"activeCount":97},[],{"trials":8321,"activeCount":97},[],{"trials":8323,"activeCount":97},[],{"trials":8325,"activeCount":97},[8326,8333,8343],{"nctId":8327,"briefTitle":8328,"status":103,"phases":8329,"primaryCompletion":1752,"completion":1752,"start":1406,"enrollment":1803,"conditions":8330,"interventions":8331},"NCT01660854","Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites",[89],[6838],[8332,8312],"Heterologous challenge",{"nctId":8334,"briefTitle":8335,"status":103,"phases":8336,"primaryCompletion":2315,"completion":552,"start":578,"enrollment":637,"conditions":8337,"interventions":8339},"NCT01218893","Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis",[89],[8338],"Plasmodium Falciparum Malaria",[8340,8341,8342,8312],"Chloroquine prophylaxis","Immunization","Plasmodium falciparum challenge",{"nctId":8344,"briefTitle":8345,"status":103,"phases":8346,"primaryCompletion":4765,"completion":4765,"start":578,"enrollment":1034,"conditions":8347,"interventions":8348},"NCT01236612","Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis",[89],[8338],[8340,8341,8349,8350,8312],"Plasmodium falciparum Bloodstage challenge","Plasmodium falciparum mosquito challenge",{"intervention":527,"totalTrials":627,"cells":8352},{"EARLY_PHASE1":8353,"PHASE1":8355,"PHASE2":8357,"PHASE3":8363,"PHASE4":8365,"NA":8371},{"trials":8354,"activeCount":97},[],{"trials":8356,"activeCount":97},[],{"trials":8358,"activeCount":97},[8359],{"nctId":518,"briefTitle":519,"status":103,"phases":8360,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":8361,"interventions":8362},[86],[503],[154,527],{"trials":8364,"activeCount":97},[],{"trials":8366,"activeCount":97},[8367],{"nctId":2669,"briefTitle":2670,"status":103,"phases":8368,"primaryCompletion":2672,"completion":2672,"start":2673,"enrollment":230,"conditions":8369,"interventions":8370},[88],[2675],[2656,527],{"trials":8372,"activeCount":97},[8373],{"nctId":8374,"briefTitle":8375,"status":161,"phases":8376,"primaryCompletion":8377,"completion":8377,"start":8378,"enrollment":3566,"conditions":8379,"interventions":8382},"NCT03939273","The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery",[89],"2023-03","2022-03",[4872,8380,1977,8381],"Postoperative Shock","Extracorporeal Circulation; Complications",[8383,8384,8385,8386,527],"Vancomycin","Metronidazole","Ciprofloxacin Pill","Fluconazole Oral Product",{"intervention":8388,"totalTrials":627,"cells":8389},"Eplerenone",{"EARLY_PHASE1":8390,"PHASE1":8392,"PHASE2":8394,"PHASE3":8400,"PHASE4":8402,"NA":8411},{"trials":8391,"activeCount":97},[],{"trials":8393,"activeCount":97},[],{"trials":8395,"activeCount":97},[8396],{"nctId":5247,"briefTitle":5248,"status":103,"phases":8397,"primaryCompletion":3941,"completion":3941,"start":5250,"enrollment":637,"conditions":8398,"interventions":8399},[86],[5252],[5254,5238],{"trials":8401,"activeCount":97},[],{"trials":8403,"activeCount":97},[8404],{"nctId":8405,"briefTitle":8406,"status":103,"phases":8407,"primaryCompletion":2064,"completion":1656,"start":2697,"enrollment":26,"conditions":8408,"interventions":8410},"NCT01837108","Eplerenone and Extracellular Adenosine Formation",[88],[8409],"Pharmacodynamics",[8388],{"trials":8412,"activeCount":97},[8413],{"nctId":8414,"briefTitle":8415,"status":103,"phases":8416,"primaryCompletion":534,"completion":105,"start":1828,"enrollment":1362,"conditions":8417,"interventions":8419},"NCT02118753","The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium",[89],[8418],"Ischemia-reperfusion Injury",[8388],{"intervention":8421,"totalTrials":627,"cells":8422},"Valacyclovir",{"EARLY_PHASE1":8423,"PHASE1":8425,"PHASE2":8431,"PHASE3":8433,"PHASE4":8435,"NA":8444},{"trials":8424,"activeCount":97},[],{"trials":8426,"activeCount":97},[8427],{"nctId":7262,"briefTitle":7263,"status":103,"phases":8428,"primaryCompletion":4857,"completion":4857,"start":2064,"enrollment":107,"conditions":8429,"interventions":8430},[85],[7266,7267],[7269,7255],{"trials":8432,"activeCount":97},[],{"trials":8434,"activeCount":97},[],{"trials":8436,"activeCount":97},[8437],{"nctId":8438,"briefTitle":8439,"status":103,"phases":8440,"primaryCompletion":635,"completion":635,"start":2273,"enrollment":8441,"conditions":8442,"interventions":8443},"NCT01682109","Palatability Testing of a New Paediatric Formulation of Valacyclovir",[88],41,[7266,7267],[8421],{"trials":8445,"activeCount":97},[8446],{"nctId":8447,"briefTitle":8448,"status":607,"phases":8449,"primaryCompletion":8450,"completion":8450,"start":8451,"enrollment":478,"conditions":8452,"interventions":8453},"NCT04081480","Pharmacokinetics of Valacyclovir Oral Solution in Children",[89],"2021-05-12","2019-12-10",[7267,7266],[8421],{"intervention":8340,"totalTrials":627,"cells":8455},{"EARLY_PHASE1":8456,"PHASE1":8458,"PHASE2":8460,"PHASE3":8462,"PHASE4":8464,"NA":8466},{"trials":8457,"activeCount":97},[],{"trials":8459,"activeCount":97},[],{"trials":8461,"activeCount":97},[],{"trials":8463,"activeCount":97},[],{"trials":8465,"activeCount":97},[],{"trials":8467,"activeCount":97},[8468,8476,8480],{"nctId":8469,"briefTitle":8470,"status":103,"phases":8471,"primaryCompletion":553,"completion":2697,"start":2315,"enrollment":165,"conditions":8472,"interventions":8473},"NCT01422954","Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis",[89],[3313,5688],[8340,8474,8341,8253,8475],"Mefloquine prophylaxis","Malarone",{"nctId":8334,"briefTitle":8335,"status":103,"phases":8477,"primaryCompletion":2315,"completion":552,"start":578,"enrollment":637,"conditions":8478,"interventions":8479},[89],[8338],[8340,8341,8342,8312],{"nctId":8344,"briefTitle":8345,"status":103,"phases":8481,"primaryCompletion":4765,"completion":4765,"start":578,"enrollment":1034,"conditions":8482,"interventions":8483},[89],[8338],[8340,8341,8349,8350,8312],{"intervention":8341,"totalTrials":627,"cells":8485},{"EARLY_PHASE1":8486,"PHASE1":8488,"PHASE2":8490,"PHASE3":8492,"PHASE4":8494,"NA":8496},{"trials":8487,"activeCount":97},[],{"trials":8489,"activeCount":97},[],{"trials":8491,"activeCount":97},[],{"trials":8493,"activeCount":97},[],{"trials":8495,"activeCount":97},[],{"trials":8497,"activeCount":97},[8498,8502,8506],{"nctId":8469,"briefTitle":8470,"status":103,"phases":8499,"primaryCompletion":553,"completion":2697,"start":2315,"enrollment":165,"conditions":8500,"interventions":8501},[89],[3313,5688],[8340,8474,8341,8253,8475],{"nctId":8334,"briefTitle":8335,"status":103,"phases":8503,"primaryCompletion":2315,"completion":552,"start":578,"enrollment":637,"conditions":8504,"interventions":8505},[89],[8338],[8340,8341,8342,8312],{"nctId":8344,"briefTitle":8345,"status":103,"phases":8507,"primaryCompletion":4765,"completion":4765,"start":578,"enrollment":1034,"conditions":8508,"interventions":8509},[89],[8338],[8340,8341,8349,8350,8312],{"intervention":8511,"totalTrials":627,"cells":8512},"Lanreotide",{"EARLY_PHASE1":8513,"PHASE1":8515,"PHASE2":8517,"PHASE3":8519,"PHASE4":8538,"NA":8540},{"trials":8514,"activeCount":97},[],{"trials":8516,"activeCount":97},[],{"trials":8518,"activeCount":97},[],{"trials":8520,"activeCount":97},[8521,8532],{"nctId":8522,"briefTitle":8523,"status":161,"phases":8524,"primaryCompletion":1645,"completion":6790,"start":8042,"enrollment":1042,"conditions":8525,"interventions":8530},"NCT00771888","Open-Label Extension of LOCKCYST Trial",[86,87],[3931,8526,8527,8528,8529],"Hepatomegaly","Liver Diseases","Polycystic Kidney","Autosomal Dominant",[8531],"lanreotide",{"nctId":8533,"briefTitle":8534,"status":103,"phases":8535,"start":2155,"enrollment":2250,"conditions":8536,"interventions":8537},"NCT00565097","Lanreotide as Treatment of Polycystic Livers",[86,87],[3931,8526,8527,3932],[8511],{"trials":8539,"activeCount":97},[],{"trials":8541,"activeCount":97},[8542],{"nctId":8543,"briefTitle":8544,"status":103,"phases":8545,"primaryCompletion":536,"completion":536,"start":2065,"enrollment":6514,"conditions":8546,"interventions":8547},"NCT01354405","Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)",[],[3931],[8511],{"intervention":8549,"totalTrials":627,"cells":8550},"micafungin",{"EARLY_PHASE1":8551,"PHASE1":8553,"PHASE2":8555,"PHASE3":8564,"PHASE4":8566,"NA":8576},{"trials":8552,"activeCount":97},[],{"trials":8554,"activeCount":97},[],{"trials":8556,"activeCount":97},[8557],{"nctId":8558,"briefTitle":8559,"status":103,"phases":8560,"primaryCompletion":4870,"completion":1838,"start":594,"enrollment":637,"conditions":8561,"interventions":8563},"NCT02172768","Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease",[86],[8562,1805,1807,1808],"Acute Graft Versus Host Disease Grade II-IV",[8549],{"trials":8565,"activeCount":97},[],{"trials":8567,"activeCount":97},[8568],{"nctId":8569,"briefTitle":8570,"status":103,"phases":8571,"primaryCompletion":8572,"completion":8572,"start":164,"enrollment":1362,"conditions":8573,"interventions":8574},"NCT03102658","Micafungin Pharmacokinetics in Obese Patients",[88],"2017-07",[3542],[8575],"Micafungin",{"trials":8577,"activeCount":97},[8578],{"nctId":8579,"briefTitle":8580,"status":103,"phases":8581,"primaryCompletion":1828,"completion":1828,"start":1752,"enrollment":165,"conditions":8582,"interventions":8584},"NCT01783379","Pharmacokinetics of Micafungin in Patients Intensive Care Unit",[],[8583],"Invasive Fungal Infection",[8549],{"intervention":4963,"totalTrials":93,"cells":8586},{"EARLY_PHASE1":8587,"PHASE1":8589,"PHASE2":8591,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8588,"activeCount":97},[],{"trials":8590,"activeCount":97},[],{"trials":8592,"activeCount":97},[8593],{"nctId":4954,"briefTitle":4955,"status":103,"phases":8594,"primaryCompletion":4957,"completion":4957,"start":4958,"enrollment":4284,"conditions":8595,"interventions":8596},[86],[4960,4961],[4945,4963],{"trials":8598,"activeCount":97},[],{"trials":8600,"activeCount":97},[],{"trials":8602,"activeCount":97},[8603],{"nctId":8604,"briefTitle":8605,"status":103,"phases":8606,"primaryCompletion":4020,"completion":1373,"start":1645,"enrollment":491,"conditions":8607,"interventions":8609},"NCT00979381","Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor",[],[2317,8608],"GIST",[8610],"influenza vaccine",{"intervention":8149,"totalTrials":93,"cells":8612},{"EARLY_PHASE1":8613,"PHASE1":8615,"PHASE2":8617,"PHASE3":8619,"PHASE4":8621,"NA":8623},{"trials":8614,"activeCount":97},[],{"trials":8616,"activeCount":97},[],{"trials":8618,"activeCount":97},[],{"trials":8620,"activeCount":97},[],{"trials":8622,"activeCount":97},[],{"trials":8624,"activeCount":97},[8625,8633],{"nctId":8626,"briefTitle":8627,"status":8134,"phases":8628,"start":7333,"enrollment":1392,"conditions":8629,"interventions":8630},"NCT00184938","Opioid Receptors Influence Ischemia-Reperfusion Injury",[89],[6017],[8631,8632,8149],"morphine","naloxone",{"nctId":8142,"briefTitle":8143,"status":103,"phases":8634,"completion":5336,"start":8145,"enrollment":1362,"conditions":8635,"interventions":8636},[89],[7313,8147,6017],[8035,8149],{"intervention":8253,"totalTrials":93,"cells":8638},{"EARLY_PHASE1":8639,"PHASE1":8641,"PHASE2":8643,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8640,"activeCount":97},[],{"trials":8642,"activeCount":97},[],{"trials":8644,"activeCount":97},[],{"trials":8646,"activeCount":97},[],{"trials":8648,"activeCount":97},[],{"trials":8650,"activeCount":97},[8651,8655],{"nctId":8248,"briefTitle":8249,"status":103,"phases":8652,"primaryCompletion":4857,"completion":4857,"start":536,"enrollment":21,"conditions":8653,"interventions":8654},[89],[3313],[8233,8253,8254,8255],{"nctId":8469,"briefTitle":8470,"status":103,"phases":8656,"primaryCompletion":553,"completion":2697,"start":2315,"enrollment":165,"conditions":8657,"interventions":8658},[89],[3313,5688],[8340,8474,8341,8253,8475],{"intervention":8255,"totalTrials":93,"cells":8660},{"EARLY_PHASE1":8661,"PHASE1":8663,"PHASE2":8665,"PHASE3":8667,"PHASE4":8669,"NA":8671},{"trials":8662,"activeCount":97},[],{"trials":8664,"activeCount":97},[],{"trials":8666,"activeCount":97},[],{"trials":8668,"activeCount":97},[],{"trials":8670,"activeCount":97},[],{"trials":8672,"activeCount":97},[8673,8677],{"nctId":8248,"briefTitle":8249,"status":103,"phases":8674,"primaryCompletion":4857,"completion":4857,"start":536,"enrollment":21,"conditions":8675,"interventions":8676},[89],[3313],[8233,8253,8254,8255],{"nctId":8269,"briefTitle":8270,"status":103,"phases":8678,"primaryCompletion":106,"completion":106,"start":594,"enrollment":1392,"conditions":8679,"interventions":8680},[89],[3313],[8233,8265,8274,8266,8255],{"intervention":8265,"totalTrials":93,"cells":8682},{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8689,"PHASE4":8691,"NA":8693},{"trials":8684,"activeCount":97},[],{"trials":8686,"activeCount":97},[],{"trials":8688,"activeCount":97},[],{"trials":8690,"activeCount":97},[],{"trials":8692,"activeCount":97},[],{"trials":8694,"activeCount":97},[8695,8699],{"nctId":8257,"briefTitle":8258,"status":607,"phases":8696,"primaryCompletion":8260,"completion":8260,"start":8261,"enrollment":6514,"conditions":8697,"interventions":8698},[89],[4925,8253,8263],[8233,8265,8266,8233,8267],{"nctId":8269,"briefTitle":8270,"status":103,"phases":8700,"primaryCompletion":106,"completion":106,"start":594,"enrollment":1392,"conditions":8701,"interventions":8702},[89],[3313],[8233,8265,8274,8266,8255],{"intervention":8266,"totalTrials":93,"cells":8704},{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8709,"PHASE3":8711,"PHASE4":8713,"NA":8715},{"trials":8706,"activeCount":97},[],{"trials":8708,"activeCount":97},[],{"trials":8710,"activeCount":97},[],{"trials":8712,"activeCount":97},[],{"trials":8714,"activeCount":97},[],{"trials":8716,"activeCount":97},[8717,8721],{"nctId":8257,"briefTitle":8258,"status":607,"phases":8718,"primaryCompletion":8260,"completion":8260,"start":8261,"enrollment":6514,"conditions":8719,"interventions":8720},[89],[4925,8253,8263],[8233,8265,8266,8233,8267],{"nctId":8269,"briefTitle":8270,"status":103,"phases":8722,"primaryCompletion":106,"completion":106,"start":594,"enrollment":1392,"conditions":8723,"interventions":8724},[89],[3313],[8233,8265,8274,8266,8255],{"intervention":4897,"totalTrials":93,"cells":8726},{"EARLY_PHASE1":8727,"PHASE1":8729,"PHASE2":8731,"PHASE3":8737,"PHASE4":8739,"NA":8741},{"trials":8728,"activeCount":97},[],{"trials":8730,"activeCount":97},[],{"trials":8732,"activeCount":97},[8733],{"nctId":4891,"briefTitle":4892,"status":103,"phases":8734,"primaryCompletion":1406,"completion":1406,"start":1361,"enrollment":4894,"conditions":8735,"interventions":8736},[86],[3931],[4897,4882],{"trials":8738,"activeCount":97},[],{"trials":8740,"activeCount":97},[],{"trials":8742,"activeCount":97},[8743],{"nctId":8744,"briefTitle":8745,"status":103,"phases":8746,"primaryCompletion":105,"completion":164,"start":3873,"enrollment":491,"conditions":8747,"interventions":8748},"NCT02809404","Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)",[],[30,2317],[4897],{"intervention":8750,"totalTrials":93,"cells":8751},"methotrexate",{"EARLY_PHASE1":8752,"PHASE1":8754,"PHASE2":8756,"PHASE3":8762,"PHASE4":8764,"NA":8766},{"trials":8753,"activeCount":97},[],{"trials":8755,"activeCount":97},[],{"trials":8757,"activeCount":97},[8758],{"nctId":6117,"briefTitle":6118,"status":161,"phases":8759,"primaryCompletion":6120,"completion":6121,"start":6122,"enrollment":150,"conditions":8760,"interventions":8761},[85,86],[6124],[6108,6126],{"trials":8763,"activeCount":97},[],{"trials":8765,"activeCount":97},[],{"trials":8767,"activeCount":97},[8768],{"nctId":8769,"briefTitle":8770,"status":103,"phases":8771,"primaryCompletion":201,"completion":4019,"start":1925,"enrollment":1634,"conditions":8772,"interventions":8774},"NCT00441961","Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis",[89],[8773],"Fasciitis",[8750],{"intervention":8776,"totalTrials":93,"cells":8777},"Cefazolin",{"EARLY_PHASE1":8778,"PHASE1":8780,"PHASE2":8782,"PHASE3":8784,"PHASE4":8801,"NA":8803},{"trials":8779,"activeCount":97},[],{"trials":8781,"activeCount":97},[],{"trials":8783,"activeCount":97},[],{"trials":8785,"activeCount":97},[8786],{"nctId":8787,"briefTitle":8788,"status":161,"phases":8789,"primaryCompletion":2376,"completion":8790,"start":8791,"enrollment":8792,"conditions":8793,"interventions":8800},"NCT06402591","Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.",[87],"2024-12-01","2019-01-01",751,[8794,8795,8796,8797,8798,8799],"Infection Prosthesis Hip and Knee","Infection, Prosthesis Related","Joint Infection","Infection, Surgical Site","Surgical Site Infection","Infection Pro",[8776],{"trials":8802,"activeCount":97},[],{"trials":8804,"activeCount":97},[8805],{"nctId":8806,"briefTitle":8807,"status":103,"phases":8808,"primaryCompletion":534,"completion":105,"start":4331,"enrollment":2649,"conditions":8809,"interventions":8811},"NCT02368015","Penetration of Cefazolin Into Hepatic Cysts",[89],[8810],"Hepatic Cyst",[8812],"cefazolin",{"intervention":5666,"totalTrials":93,"cells":8814},{"EARLY_PHASE1":8815,"PHASE1":8817,"PHASE2":8819,"PHASE3":8825,"PHASE4":8827,"NA":8829},{"trials":8816,"activeCount":97},[],{"trials":8818,"activeCount":97},[],{"trials":8820,"activeCount":97},[8821],{"nctId":5660,"briefTitle":5661,"status":103,"phases":8822,"primaryCompletion":2738,"completion":1361,"start":4511,"enrollment":5663,"conditions":8823,"interventions":8824},[86],[25],[5651,5666],{"trials":8826,"activeCount":97},[],{"trials":8828,"activeCount":97},[],{"trials":8830,"activeCount":97},[8831],{"nctId":8832,"briefTitle":8833,"status":103,"phases":8834,"primaryCompletion":8835,"completion":8835,"start":8836,"enrollment":5663,"conditions":8837,"interventions":8843},"NCT03227653","Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV",[],"2017-12-31","2017-06-19",[8838,8839,8840,8841,8842],"Efavirenz","Child Behavior","Cognitive Symptom","Medication Adherence","Drug-Related Side Effects and Adverse Reactions",[8838,5666,8844],"Lopinavir-Ritonavir Drug Combination",{"intervention":5772,"totalTrials":93,"cells":8846},{"EARLY_PHASE1":8847,"PHASE1":8849,"PHASE2":8851,"PHASE3":8857,"PHASE4":8859,"NA":8861},{"trials":8848,"activeCount":97},[],{"trials":8850,"activeCount":97},[],{"trials":8852,"activeCount":97},[8853],{"nctId":5766,"briefTitle":5767,"status":103,"phases":8854,"primaryCompletion":5769,"completion":5769,"start":4870,"enrollment":4309,"conditions":8855,"interventions":8856},[85,86],[3313],[5757,5772,5757,5772,5773,5774],{"trials":8858,"activeCount":97},[],{"trials":8860,"activeCount":97},[],{"trials":8862,"activeCount":97},[8863],{"nctId":8864,"briefTitle":8865,"status":103,"phases":8866,"primaryCompletion":8867,"completion":8868,"start":8869,"enrollment":1362,"conditions":8870,"interventions":8873},"NCT03454048","Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2",[89],"2018-11-01","2018-11-20","2018-05-07",[4925,8871,8253,8872],"Gametocytes","Transmission",[5772,5772,8874,8875],"Sulfadoxine pyrimethamine","Atovaquone Proguanil",{"intervention":8139,"totalTrials":93,"cells":8877},{"EARLY_PHASE1":8878,"PHASE1":8880,"PHASE2":8882,"PHASE3":8884,"PHASE4":8886,"NA":8888},{"trials":8879,"activeCount":97},[],{"trials":8881,"activeCount":97},[],{"trials":8883,"activeCount":97},[],{"trials":8885,"activeCount":97},[],{"trials":8887,"activeCount":97},[],{"trials":8889,"activeCount":97},[8890,8894],{"nctId":8132,"briefTitle":8133,"status":8134,"phases":8891,"start":8136,"enrollment":2649,"conditions":8892,"interventions":8893},[89],[6017],[8139,8140,8035],{"nctId":1356,"briefTitle":1357,"status":103,"phases":8895,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":8896,"interventions":8897},[89],[1364,20,1365],[1367,1368,1332],{"intervention":8140,"totalTrials":93,"cells":8899},{"EARLY_PHASE1":8900,"PHASE1":8902,"PHASE2":8904,"PHASE3":8906,"PHASE4":8908,"NA":8910},{"trials":8901,"activeCount":97},[],{"trials":8903,"activeCount":97},[],{"trials":8905,"activeCount":97},[],{"trials":8907,"activeCount":97},[],{"trials":8909,"activeCount":97},[],{"trials":8911,"activeCount":97},[8912,8916],{"nctId":8132,"briefTitle":8133,"status":8134,"phases":8913,"start":8136,"enrollment":2649,"conditions":8914,"interventions":8915},[89],[6017],[8139,8140,8035],{"nctId":8917,"briefTitle":8918,"status":103,"phases":8919,"completion":1926,"start":8920,"enrollment":165,"conditions":8921,"interventions":8923},"NCT00184821","Ischemic Injury and Ischemic Preconditioning in Diabetes",[],"2004-06",[8922,6017],"Diabetes Mellitus, Insulin-Dependent",[8924,8925,8140],"Diazoxide","glibenclamide",{"intervention":620,"totalTrials":93,"cells":8927},{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8932,"PHASE3":8934,"PHASE4":8936,"NA":8942},{"trials":8929,"activeCount":97},[],{"trials":8931,"activeCount":97},[],{"trials":8933,"activeCount":97},[],{"trials":8935,"activeCount":97},[],{"trials":8937,"activeCount":97},[8938],{"nctId":2906,"briefTitle":2907,"status":103,"phases":8939,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":8940,"interventions":8941},[88],[2913,640,28],[620,2893,2915,2916],{"trials":8943,"activeCount":97},[8944],{"nctId":605,"briefTitle":606,"status":607,"phases":8945,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":8946,"interventions":8947},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":3898,"totalTrials":93,"cells":8949},{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8958,"PHASE3":8960,"PHASE4":8962,"NA":8964},{"trials":8951,"activeCount":97},[],{"trials":8953,"activeCount":97},[8954],{"nctId":3890,"briefTitle":3891,"status":103,"phases":8955,"primaryCompletion":3893,"start":3894,"conditions":8956,"interventions":8957},[85],[1235,3896],[3898,3883],{"trials":8959,"activeCount":97},[],{"trials":8961,"activeCount":97},[],{"trials":8963,"activeCount":97},[],{"trials":8965,"activeCount":97},[8966],{"nctId":8967,"briefTitle":8968,"status":103,"phases":8969,"primaryCompletion":1734,"completion":4765,"start":6438,"enrollment":1150,"conditions":8970,"interventions":8972},"NCT00602862","Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250",[89],[8971],"Clear Cell Renal Cell Carcinoma",[3898,8973,8974],"111Indium-bevacizumab","111Indium-cG250",{"intervention":8976,"totalTrials":93,"cells":8977},"Pazopanib",{"EARLY_PHASE1":8978,"PHASE1":8980,"PHASE2":8990,"PHASE3":8992,"PHASE4":8994,"NA":8996},{"trials":8979,"activeCount":97},[],{"trials":8981,"activeCount":97},[8982],{"nctId":8983,"briefTitle":8984,"status":103,"phases":8985,"primaryCompletion":4638,"completion":4638,"start":536,"enrollment":8986,"conditions":8987,"interventions":8988},"NCT02138526","Pazopanib Tolerability When Given With Food",[85],78,[20],[8989],"pazopanib",{"trials":8991,"activeCount":97},[],{"trials":8993,"activeCount":97},[],{"trials":8995,"activeCount":97},[],{"trials":8997,"activeCount":97},[8998],{"nctId":8999,"briefTitle":9000,"status":103,"phases":9001,"primaryCompletion":9002,"completion":9002,"start":2064,"enrollment":15,"conditions":9003,"interventions":9005},"NCT01995981","Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS",[],"2017-11-10",[9004],"Sarcoma, Soft Tissue",[8976],{"intervention":9007,"totalTrials":93,"cells":9008},"indomethacin",{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9013,"PHASE3":9015,"PHASE4":9025,"NA":9027},{"trials":9010,"activeCount":97},[],{"trials":9012,"activeCount":97},[],{"trials":9014,"activeCount":97},[],{"trials":9016,"activeCount":97},[9017],{"nctId":9018,"briefTitle":9019,"status":103,"phases":9020,"completion":1503,"start":9021,"enrollment":128,"conditions":9022,"interventions":9024},"NCT00432081","Effect of Indomethacin on the Progression of Alzheimer's Disease",[87],"2000-05",[9023],"Alzheimer Disease",[9007],{"trials":9026,"activeCount":97},[],{"trials":9028,"activeCount":97},[9029],{"nctId":9030,"briefTitle":9031,"status":103,"phases":9032,"primaryCompletion":9033,"completion":9033,"start":9034,"enrollment":9035,"conditions":9036,"interventions":9038},"NCT02884219","Early Treatment Versus Expectative Management of PDA in Preterm Infants",[89],"2022-03-15","2016-12-23",273,[9037],"Patent Ductus Arteriosus",[9039,9040],"Ibuprofen","Indomethacin",{"intervention":8184,"totalTrials":93,"cells":9042},{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9047,"PHASE3":9049,"PHASE4":9055,"NA":9057},{"trials":9044,"activeCount":97},[],{"trials":9046,"activeCount":97},[],{"trials":9048,"activeCount":97},[],{"trials":9050,"activeCount":97},[9051],{"nctId":8178,"briefTitle":8179,"status":103,"phases":9052,"primaryCompletion":593,"completion":1656,"start":5067,"enrollment":165,"conditions":9053,"interventions":9054},[87],[8182,17,753,33],[8184,4862],{"trials":9056,"activeCount":97},[],{"trials":9058,"activeCount":97},[9059],{"nctId":9060,"briefTitle":9061,"status":103,"phases":9062,"primaryCompletion":3244,"completion":6790,"start":4020,"enrollment":165,"conditions":9063,"interventions":9064},"NCT00785018","In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia",[89],[17,753,8229],[8184,9065],"Endotoxin administration",{"intervention":9067,"totalTrials":93,"cells":9068},"Sodium Lactate",{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9073,"PHASE3":9075,"PHASE4":9077,"NA":9079},{"trials":9070,"activeCount":97},[],{"trials":9072,"activeCount":97},[],{"trials":9074,"activeCount":97},[],{"trials":9076,"activeCount":97},[],{"trials":9078,"activeCount":97},[],{"trials":9080,"activeCount":97},[9081,9092],{"nctId":9082,"briefTitle":9083,"status":161,"phases":9084,"primaryCompletion":9085,"completion":9086,"start":9087,"enrollment":1102,"conditions":9088,"interventions":9090},"NCT03730909","The Effect Lactate Administration on Cerebral Blood Flow During Hypoglycemia",[89],"2019-04-11","2019-06-11","2018-06-11",[9089,6700],"Type1diabetes",[9067,9091],"Sodium chloride",{"nctId":9093,"briefTitle":9094,"status":103,"phases":9095,"primaryCompletion":6674,"completion":9096,"start":9097,"enrollment":1298,"conditions":9098,"interventions":9100},"NCT03286816","The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia",[89],"2017-08","2016-11",[9099],"Type 1 Diabetes Mellitus With Hypoglycemia",[9101,9067],"SodiumChloride",{"intervention":9103,"totalTrials":132,"cells":9104},"Tiotropium",{"EARLY_PHASE1":9105,"PHASE1":9107,"PHASE2":9109,"PHASE3":9111,"PHASE4":9113,"NA":9115},{"trials":9106,"activeCount":97},[],{"trials":9108,"activeCount":97},[],{"trials":9110,"activeCount":97},[],{"trials":9112,"activeCount":97},[],{"trials":9114,"activeCount":97},[],{"trials":9116,"activeCount":97},[9117],{"nctId":9118,"briefTitle":9119,"status":103,"phases":9120,"primaryCompletion":2065,"completion":2065,"start":2738,"enrollment":1392,"conditions":9121,"interventions":9125},"NCT00981851","Interaction in Chronic Obstructive Pulmonary Disease Experiment",[89],[9122,1745,9123,9124],"Chronic Obstructive Pulmonary Disease","Smoking","Bronchodilation",[9103],{"intervention":8631,"totalTrials":132,"cells":9127},{"EARLY_PHASE1":9128,"PHASE1":9130,"PHASE2":9132,"PHASE3":9134,"PHASE4":9136,"NA":9138},{"trials":9129,"activeCount":97},[],{"trials":9131,"activeCount":97},[],{"trials":9133,"activeCount":97},[],{"trials":9135,"activeCount":97},[],{"trials":9137,"activeCount":97},[],{"trials":9139,"activeCount":97},[9140],{"nctId":8626,"briefTitle":8627,"status":8134,"phases":9141,"start":7333,"enrollment":1392,"conditions":9142,"interventions":9143},[89],[6017],[8631,8632,8149],{"intervention":8632,"totalTrials":132,"cells":9145},{"EARLY_PHASE1":9146,"PHASE1":9148,"PHASE2":9150,"PHASE3":9152,"PHASE4":9154,"NA":9156},{"trials":9147,"activeCount":97},[],{"trials":9149,"activeCount":97},[],{"trials":9151,"activeCount":97},[],{"trials":9153,"activeCount":97},[],{"trials":9155,"activeCount":97},[],{"trials":9157,"activeCount":97},[9158],{"nctId":8626,"briefTitle":8627,"status":8134,"phases":9159,"start":7333,"enrollment":1392,"conditions":9160,"interventions":9161},[89],[6017],[8631,8632,8149],{"intervention":8254,"totalTrials":132,"cells":9163},{"EARLY_PHASE1":9164,"PHASE1":9166,"PHASE2":9168,"PHASE3":9170,"PHASE4":9172,"NA":9174},{"trials":9165,"activeCount":97},[],{"trials":9167,"activeCount":97},[],{"trials":9169,"activeCount":97},[],{"trials":9171,"activeCount":97},[],{"trials":9173,"activeCount":97},[],{"trials":9175,"activeCount":97},[9176],{"nctId":8248,"briefTitle":8249,"status":103,"phases":9177,"primaryCompletion":4857,"completion":4857,"start":536,"enrollment":21,"conditions":9178,"interventions":9179},[89],[3313],[8233,8253,8254,8255],{"intervention":9181,"totalTrials":132,"cells":9182},"Artemether-lumefantrine combination",{"EARLY_PHASE1":9183,"PHASE1":9185,"PHASE2":9187,"PHASE3":9189,"PHASE4":9191,"NA":9193},{"trials":9184,"activeCount":97},[],{"trials":9186,"activeCount":97},[],{"trials":9188,"activeCount":97},[],{"trials":9190,"activeCount":97},[],{"trials":9192,"activeCount":97},[],{"trials":9194,"activeCount":97},[9195],{"nctId":9196,"briefTitle":9197,"status":103,"phases":9198,"primaryCompletion":3974,"completion":3974,"start":1734,"enrollment":9199,"conditions":9200,"interventions":9201},"NCT01575613","Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission",[89],17506,[3313],[9181,9202,9203,9204],"Bacillus thuringiensis","Long lasting insecticide treated net","Indoor Residual Spraying",{"intervention":9202,"totalTrials":132,"cells":9206},{"EARLY_PHASE1":9207,"PHASE1":9209,"PHASE2":9211,"PHASE3":9213,"PHASE4":9215,"NA":9217},{"trials":9208,"activeCount":97},[],{"trials":9210,"activeCount":97},[],{"trials":9212,"activeCount":97},[],{"trials":9214,"activeCount":97},[],{"trials":9216,"activeCount":97},[],{"trials":9218,"activeCount":97},[9219],{"nctId":9196,"briefTitle":9197,"status":103,"phases":9220,"primaryCompletion":3974,"completion":3974,"start":1734,"enrollment":9199,"conditions":9221,"interventions":9222},[89],[3313],[9181,9202,9203,9204],{"intervention":9203,"totalTrials":132,"cells":9224},{"EARLY_PHASE1":9225,"PHASE1":9227,"PHASE2":9229,"PHASE3":9231,"PHASE4":9233,"NA":9235},{"trials":9226,"activeCount":97},[],{"trials":9228,"activeCount":97},[],{"trials":9230,"activeCount":97},[],{"trials":9232,"activeCount":97},[],{"trials":9234,"activeCount":97},[],{"trials":9236,"activeCount":97},[9237],{"nctId":9196,"briefTitle":9197,"status":103,"phases":9238,"primaryCompletion":3974,"completion":3974,"start":1734,"enrollment":9199,"conditions":9239,"interventions":9240},[89],[3313],[9181,9202,9203,9204],{"intervention":9204,"totalTrials":132,"cells":9242},{"EARLY_PHASE1":9243,"PHASE1":9245,"PHASE2":9247,"PHASE3":9249,"PHASE4":9251,"NA":9253},{"trials":9244,"activeCount":97},[],{"trials":9246,"activeCount":97},[],{"trials":9248,"activeCount":97},[],{"trials":9250,"activeCount":97},[],{"trials":9252,"activeCount":97},[],{"trials":9254,"activeCount":97},[9255],{"nctId":9196,"briefTitle":9197,"status":103,"phases":9256,"primaryCompletion":3974,"completion":3974,"start":1734,"enrollment":9199,"conditions":9257,"interventions":9258},[89],[3313],[9181,9202,9203,9204],{"intervention":8332,"totalTrials":132,"cells":9260},{"EARLY_PHASE1":9261,"PHASE1":9263,"PHASE2":9265,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9262,"activeCount":97},[],{"trials":9264,"activeCount":97},[],{"trials":9266,"activeCount":97},[],{"trials":9268,"activeCount":97},[],{"trials":9270,"activeCount":97},[],{"trials":9272,"activeCount":97},[9273],{"nctId":8327,"briefTitle":8328,"status":103,"phases":9274,"primaryCompletion":1752,"completion":1752,"start":1406,"enrollment":1803,"conditions":9275,"interventions":9276},[89],[6838],[8332,8312],{"intervention":8267,"totalTrials":132,"cells":9278},{"EARLY_PHASE1":9279,"PHASE1":9281,"PHASE2":9283,"PHASE3":9285,"PHASE4":9287,"NA":9289},{"trials":9280,"activeCount":97},[],{"trials":9282,"activeCount":97},[],{"trials":9284,"activeCount":97},[],{"trials":9286,"activeCount":97},[],{"trials":9288,"activeCount":97},[],{"trials":9290,"activeCount":97},[9291],{"nctId":8257,"briefTitle":8258,"status":607,"phases":9292,"primaryCompletion":8260,"completion":8260,"start":8261,"enrollment":6514,"conditions":9293,"interventions":9294},[89],[4925,8253,8263],[8233,8265,8266,8233,8267],{"intervention":9296,"totalTrials":132,"cells":9297},"Cefuroxime",{"EARLY_PHASE1":9298,"PHASE1":9300,"PHASE2":9302,"PHASE3":9304,"PHASE4":9306,"NA":9308},{"trials":9299,"activeCount":97},[],{"trials":9301,"activeCount":97},[],{"trials":9303,"activeCount":97},[],{"trials":9305,"activeCount":97},[],{"trials":9307,"activeCount":97},[],{"trials":9309,"activeCount":97},[9310],{"nctId":9311,"briefTitle":9312,"status":161,"phases":9313,"primaryCompletion":9314,"completion":9314,"start":9315,"enrollment":1392,"conditions":9316,"interventions":9319},"NCT04470973","Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.",[],"2023-12-15","2020-07-15",[33,3976,9317,9318],"Infection, Bacterial","Critically Ill",[9296,9320],"Amikacin",{"intervention":9320,"totalTrials":132,"cells":9322},{"EARLY_PHASE1":9323,"PHASE1":9325,"PHASE2":9327,"PHASE3":9329,"PHASE4":9331,"NA":9333},{"trials":9324,"activeCount":97},[],{"trials":9326,"activeCount":97},[],{"trials":9328,"activeCount":97},[],{"trials":9330,"activeCount":97},[],{"trials":9332,"activeCount":97},[],{"trials":9334,"activeCount":97},[9335],{"nctId":9311,"briefTitle":9312,"status":161,"phases":9336,"primaryCompletion":9314,"completion":9314,"start":9315,"enrollment":1392,"conditions":9337,"interventions":9338},[],[33,3976,9317,9318],[9296,9320],{"intervention":9340,"totalTrials":132,"cells":9341},"Pioglitazone",{"EARLY_PHASE1":9342,"PHASE1":9344,"PHASE2":9346,"PHASE3":9348,"PHASE4":9350,"NA":9352},{"trials":9343,"activeCount":97},[],{"trials":9345,"activeCount":97},[],{"trials":9347,"activeCount":97},[],{"trials":9349,"activeCount":97},[],{"trials":9351,"activeCount":97},[],{"trials":9353,"activeCount":97},[9354],{"nctId":9355,"briefTitle":9356,"status":103,"phases":9357,"conditions":9358,"interventions":9360},"NCT00151710","Effects of Pioglitazone in Congenital Adrenal Hyperplasia",[89],[9359],"Congenital Adrenal Hyperplasia",[9340],{"intervention":9362,"totalTrials":132,"cells":9363},"Digoxin",{"EARLY_PHASE1":9364,"PHASE1":9366,"PHASE2":9368,"PHASE3":9370,"PHASE4":9372,"NA":9374},{"trials":9365,"activeCount":97},[],{"trials":9367,"activeCount":97},[],{"trials":9369,"activeCount":97},[],{"trials":9371,"activeCount":97},[],{"trials":9373,"activeCount":97},[],{"trials":9375,"activeCount":97},[9376],{"nctId":9377,"briefTitle":9378,"status":103,"phases":9379,"primaryCompletion":9380,"completion":5224,"start":4602,"enrollment":2649,"conditions":9381,"interventions":9383},"NCT05507775","Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma",[89],"2023-06-21",[9382],"Non-Medullary Thyroid Carcinoma",[9362],{"intervention":8383,"totalTrials":132,"cells":9385},{"EARLY_PHASE1":9386,"PHASE1":9388,"PHASE2":9390,"PHASE3":9392,"PHASE4":9394,"NA":9396},{"trials":9387,"activeCount":97},[],{"trials":9389,"activeCount":97},[],{"trials":9391,"activeCount":97},[],{"trials":9393,"activeCount":97},[],{"trials":9395,"activeCount":97},[],{"trials":9397,"activeCount":97},[9398],{"nctId":8374,"briefTitle":8375,"status":161,"phases":9399,"primaryCompletion":8377,"completion":8377,"start":8378,"enrollment":3566,"conditions":9400,"interventions":9401},[89],[4872,8380,1977,8381],[8383,8384,8385,8386,527],{"intervention":8384,"totalTrials":132,"cells":9403},{"EARLY_PHASE1":9404,"PHASE1":9406,"PHASE2":9408,"PHASE3":9410,"PHASE4":9412,"NA":9414},{"trials":9405,"activeCount":97},[],{"trials":9407,"activeCount":97},[],{"trials":9409,"activeCount":97},[],{"trials":9411,"activeCount":97},[],{"trials":9413,"activeCount":97},[],{"trials":9415,"activeCount":97},[9416],{"nctId":8374,"briefTitle":8375,"status":161,"phases":9417,"primaryCompletion":8377,"completion":8377,"start":8378,"enrollment":3566,"conditions":9418,"interventions":9419},[89],[4872,8380,1977,8381],[8383,8384,8385,8386,527],{"intervention":8385,"totalTrials":132,"cells":9421},{"EARLY_PHASE1":9422,"PHASE1":9424,"PHASE2":9426,"PHASE3":9428,"PHASE4":9430,"NA":9432},{"trials":9423,"activeCount":97},[],{"trials":9425,"activeCount":97},[],{"trials":9427,"activeCount":97},[],{"trials":9429,"activeCount":97},[],{"trials":9431,"activeCount":97},[],{"trials":9433,"activeCount":97},[9434],{"nctId":8374,"briefTitle":8375,"status":161,"phases":9435,"primaryCompletion":8377,"completion":8377,"start":8378,"enrollment":3566,"conditions":9436,"interventions":9437},[89],[4872,8380,1977,8381],[8383,8384,8385,8386,527],{"intervention":8386,"totalTrials":132,"cells":9439},{"EARLY_PHASE1":9440,"PHASE1":9442,"PHASE2":9444,"PHASE3":9446,"PHASE4":9448,"NA":9450},{"trials":9441,"activeCount":97},[],{"trials":9443,"activeCount":97},[],{"trials":9445,"activeCount":97},[],{"trials":9447,"activeCount":97},[],{"trials":9449,"activeCount":97},[],{"trials":9451,"activeCount":97},[9452],{"nctId":8374,"briefTitle":8375,"status":161,"phases":9453,"primaryCompletion":8377,"completion":8377,"start":8378,"enrollment":3566,"conditions":9454,"interventions":9455},[89],[4872,8380,1977,8381],[8383,8384,8385,8386,527],{"intervention":9457,"totalTrials":132,"cells":9458},"Rocuronium",{"EARLY_PHASE1":9459,"PHASE1":9461,"PHASE2":9463,"PHASE3":9465,"PHASE4":9467,"NA":9469},{"trials":9460,"activeCount":97},[],{"trials":9462,"activeCount":97},[],{"trials":9464,"activeCount":97},[],{"trials":9466,"activeCount":97},[],{"trials":9468,"activeCount":97},[],{"trials":9470,"activeCount":97},[9471],{"nctId":9472,"briefTitle":9473,"status":161,"phases":9474,"primaryCompletion":4241,"completion":9475,"start":6745,"enrollment":2649,"conditions":9476,"interventions":9478},"NCT03287388","MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy",[89],"2019-12",[9477,1879],"Neuromuscular Block",[9457,9457],{"intervention":9480,"totalTrials":132,"cells":9481},"Antihypertensive Agents",{"EARLY_PHASE1":9482,"PHASE1":9484,"PHASE2":9486,"PHASE3":9488,"PHASE4":9490,"NA":9492},{"trials":9483,"activeCount":97},[],{"trials":9485,"activeCount":97},[],{"trials":9487,"activeCount":97},[],{"trials":9489,"activeCount":97},[],{"trials":9491,"activeCount":97},[],{"trials":9493,"activeCount":97},[9494],{"nctId":9495,"briefTitle":9496,"status":103,"phases":9497,"primaryCompletion":9498,"completion":9498,"start":9499,"enrollment":21,"conditions":9500,"interventions":9506},"NCT05529147","The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly",[],"2023-07-18","2022-09-05",[1364,9501,9502,9503,9504,9505],"Frailty","Old Age; Dementia","Orthostatic Intolerance","Orthostatic Hypotension","Cerebral Hypoperfusion",[9480],{"intervention":9508,"totalTrials":132,"cells":9509},"Fluenz",{"EARLY_PHASE1":9510,"PHASE1":9512,"PHASE2":9514,"PHASE3":9516,"PHASE4":9518,"NA":9520},{"trials":9511,"activeCount":97},[],{"trials":9513,"activeCount":97},[],{"trials":9515,"activeCount":97},[],{"trials":9517,"activeCount":97},[],{"trials":9519,"activeCount":97},[],{"trials":9521,"activeCount":97},[9522],{"nctId":9523,"briefTitle":9524,"status":103,"phases":9525,"primaryCompletion":164,"completion":9526,"start":534,"enrollment":637,"conditions":9527,"interventions":9529},"NCT02642237","The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response",[89],"2018-02",[8182,9528],"Immune Tolerance",[9508],{"intervention":9531,"totalTrials":132,"cells":9532},"GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]",{"EARLY_PHASE1":9533,"PHASE1":9535,"PHASE2":9537,"PHASE3":9539,"PHASE4":9541,"NA":9543},{"trials":9534,"activeCount":97},[],{"trials":9536,"activeCount":97},[],{"trials":9538,"activeCount":97},[],{"trials":9540,"activeCount":97},[],{"trials":9542,"activeCount":97},[],{"trials":9544,"activeCount":97},[9545],{"nctId":9546,"briefTitle":9547,"status":103,"phases":9548,"primaryCompletion":2972,"completion":1787,"start":7310,"enrollment":512,"conditions":9549,"interventions":9551},"NCT00783068","Anti-inflammatory Effects of GTS-21 After LPS",[89],[17,33,9550],"Vagal Activity",[9531,9552],"Lipopolysaccharide E. Coli 113:H 10:K negative",{"intervention":9552,"totalTrials":132,"cells":9554},{"EARLY_PHASE1":9555,"PHASE1":9557,"PHASE2":9559,"PHASE3":9561,"PHASE4":9563,"NA":9565},{"trials":9556,"activeCount":97},[],{"trials":9558,"activeCount":97},[],{"trials":9560,"activeCount":97},[],{"trials":9562,"activeCount":97},[],{"trials":9564,"activeCount":97},[],{"trials":9566,"activeCount":97},[9567],{"nctId":9546,"briefTitle":9547,"status":103,"phases":9568,"primaryCompletion":2972,"completion":1787,"start":7310,"enrollment":512,"conditions":9569,"interventions":9570},[89],[17,33,9550],[9531,9552],{"intervention":9572,"totalTrials":132,"cells":9573},"Methotrexate 15 mg\u002Fweek for 12 weeks",{"EARLY_PHASE1":9574,"PHASE1":9576,"PHASE2":9578,"PHASE3":9580,"PHASE4":9582,"NA":9584},{"trials":9575,"activeCount":97},[],{"trials":9577,"activeCount":97},[],{"trials":9579,"activeCount":97},[],{"trials":9581,"activeCount":97},[],{"trials":9583,"activeCount":97},[],{"trials":9585,"activeCount":97},[9586],{"nctId":9587,"briefTitle":9588,"status":103,"phases":9589,"completion":7333,"start":7522,"enrollment":1102,"conditions":9590,"interventions":9592},"NCT00184886","The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans",[89],[6126,9591],"Vasodilation",[9572],{"intervention":9594,"totalTrials":132,"cells":9595},"systemic administration of 99mTc-HYNIC-Annexin A5",{"EARLY_PHASE1":9596,"PHASE1":9598,"PHASE2":9600,"PHASE3":9602,"PHASE4":9604,"NA":9606},{"trials":9597,"activeCount":97},[],{"trials":9599,"activeCount":97},[],{"trials":9601,"activeCount":97},[],{"trials":9603,"activeCount":97},[],{"trials":9605,"activeCount":97},[],{"trials":9607,"activeCount":97},[9608],{"nctId":9609,"briefTitle":9610,"status":103,"phases":9611,"primaryCompletion":5274,"completion":5274,"start":5989,"enrollment":26,"conditions":9612,"interventions":9615},"NCT00319059","The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance",[89],[9613,9614],"AMPD","Ischemic Tolerance",[9594],{"intervention":9617,"totalTrials":132,"cells":9618},"algeldrate\u002Fmagnesium oxide",{"EARLY_PHASE1":9619,"PHASE1":9621,"PHASE2":9623,"PHASE3":9625,"PHASE4":9627,"NA":9629},{"trials":9620,"activeCount":97},[],{"trials":9622,"activeCount":97},[],{"trials":9624,"activeCount":97},[],{"trials":9626,"activeCount":97},[],{"trials":9628,"activeCount":97},[],{"trials":9630,"activeCount":97},[9631],{"nctId":9632,"briefTitle":9633,"status":103,"phases":9634,"completion":5250,"start":9635,"enrollment":9636,"conditions":9637,"interventions":9640},"NCT00247715","Comparison of a \"Step-Up\" Versus a \"Step-Down\" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)",[89],"2003-10",664,[9638,9639],"Dyspepsia","Gastrointestinal Diseases",[9617,9641,9642],"ranitidine","pantoprazole",{"intervention":9641,"totalTrials":132,"cells":9644},{"EARLY_PHASE1":9645,"PHASE1":9647,"PHASE2":9649,"PHASE3":9651,"PHASE4":9653,"NA":9655},{"trials":9646,"activeCount":97},[],{"trials":9648,"activeCount":97},[],{"trials":9650,"activeCount":97},[],{"trials":9652,"activeCount":97},[],{"trials":9654,"activeCount":97},[],{"trials":9656,"activeCount":97},[9657],{"nctId":9632,"briefTitle":9633,"status":103,"phases":9658,"completion":5250,"start":9635,"enrollment":9636,"conditions":9659,"interventions":9660},[89],[9638,9639],[9617,9641,9642],{"intervention":9642,"totalTrials":132,"cells":9662},{"EARLY_PHASE1":9663,"PHASE1":9665,"PHASE2":9667,"PHASE3":9669,"PHASE4":9671,"NA":9673},{"trials":9664,"activeCount":97},[],{"trials":9666,"activeCount":97},[],{"trials":9668,"activeCount":97},[],{"trials":9670,"activeCount":97},[],{"trials":9672,"activeCount":97},[],{"trials":9674,"activeCount":97},[9675],{"nctId":9632,"briefTitle":9633,"status":103,"phases":9676,"completion":5250,"start":9635,"enrollment":9636,"conditions":9677,"interventions":9678},[89],[9638,9639],[9617,9641,9642],{"intervention":8274,"totalTrials":132,"cells":9680},{"EARLY_PHASE1":9681,"PHASE1":9683,"PHASE2":9685,"PHASE3":9687,"PHASE4":9689,"NA":9691},{"trials":9682,"activeCount":97},[],{"trials":9684,"activeCount":97},[],{"trials":9686,"activeCount":97},[],{"trials":9688,"activeCount":97},[],{"trials":9690,"activeCount":97},[],{"trials":9692,"activeCount":97},[9693],{"nctId":8269,"briefTitle":8270,"status":103,"phases":9694,"primaryCompletion":106,"completion":106,"start":594,"enrollment":1392,"conditions":9695,"interventions":9696},[89],[3313],[8233,8265,8274,8266,8255],{"intervention":9698,"totalTrials":132,"cells":9699},"vitamin C",{"EARLY_PHASE1":9700,"PHASE1":9702,"PHASE2":9704,"PHASE3":9706,"PHASE4":9708,"NA":9710},{"trials":9701,"activeCount":97},[],{"trials":9703,"activeCount":97},[],{"trials":9705,"activeCount":97},[],{"trials":9707,"activeCount":97},[],{"trials":9709,"activeCount":97},[],{"trials":9711,"activeCount":97},[9712],{"nctId":9713,"briefTitle":9714,"status":103,"phases":9715,"completion":8042,"start":203,"conditions":9716,"interventions":9718},"NCT00550121","Does Ascorbic Acid Reduce Sympathoexcitation in CHF?",[89],[9717],"Heart Failure",[9698],{"intervention":8231,"totalTrials":132,"cells":9720},{"EARLY_PHASE1":9721,"PHASE1":9723,"PHASE2":9725,"PHASE3":9727,"PHASE4":9729,"NA":9731},{"trials":9722,"activeCount":97},[],{"trials":9724,"activeCount":97},[],{"trials":9726,"activeCount":97},[],{"trials":9728,"activeCount":97},[],{"trials":9730,"activeCount":97},[],{"trials":9732,"activeCount":97},[9733],{"nctId":8225,"briefTitle":8226,"status":103,"phases":9734,"primaryCompletion":509,"completion":4857,"start":3893,"enrollment":637,"conditions":9735,"interventions":9736},[89],[17,753,8229,33],[113,8231],{"intervention":9738,"totalTrials":132,"cells":9739},"Evolocumab 140 MG\u002FML [Repatha]",{"EARLY_PHASE1":9740,"PHASE1":9742,"PHASE2":9744,"PHASE3":9746,"PHASE4":9748,"NA":9750},{"trials":9741,"activeCount":97},[],{"trials":9743,"activeCount":97},[],{"trials":9745,"activeCount":97},[],{"trials":9747,"activeCount":97},[],{"trials":9749,"activeCount":97},[],{"trials":9751,"activeCount":97},[9752],{"nctId":9753,"briefTitle":9754,"status":103,"phases":9755,"primaryCompletion":3705,"completion":3705,"start":9756,"enrollment":748,"conditions":9757,"interventions":9759},"NCT04141579","Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody",[89],"2020-11-10",[1977,9758],"Atherosclerosis of Coronary Artery",[9738],{"intervention":8474,"totalTrials":132,"cells":9761},{"EARLY_PHASE1":9762,"PHASE1":9764,"PHASE2":9766,"PHASE3":9768,"PHASE4":9770,"NA":9772},{"trials":9763,"activeCount":97},[],{"trials":9765,"activeCount":97},[],{"trials":9767,"activeCount":97},[],{"trials":9769,"activeCount":97},[],{"trials":9771,"activeCount":97},[],{"trials":9773,"activeCount":97},[9774],{"nctId":8469,"briefTitle":8470,"status":103,"phases":9775,"primaryCompletion":553,"completion":2697,"start":2315,"enrollment":165,"conditions":9776,"interventions":9777},[89],[3313,5688],[8340,8474,8341,8253,8475],{"intervention":8475,"totalTrials":132,"cells":9779},{"EARLY_PHASE1":9780,"PHASE1":9782,"PHASE2":9784,"PHASE3":9786,"PHASE4":9788,"NA":9790},{"trials":9781,"activeCount":97},[],{"trials":9783,"activeCount":97},[],{"trials":9785,"activeCount":97},[],{"trials":9787,"activeCount":97},[],{"trials":9789,"activeCount":97},[],{"trials":9791,"activeCount":97},[9792],{"nctId":8469,"briefTitle":8470,"status":103,"phases":9793,"primaryCompletion":553,"completion":2697,"start":2315,"enrollment":165,"conditions":9794,"interventions":9795},[89],[3313,5688],[8340,8474,8341,8253,8475],{"intervention":9797,"totalTrials":132,"cells":9798},"Influvac Tetra",{"EARLY_PHASE1":9799,"PHASE1":9801,"PHASE2":9803,"PHASE3":9805,"PHASE4":9807,"NA":9809},{"trials":9800,"activeCount":97},[],{"trials":9802,"activeCount":97},[],{"trials":9804,"activeCount":97},[],{"trials":9806,"activeCount":97},[],{"trials":9808,"activeCount":97},[],{"trials":9810,"activeCount":97},[9811],{"nctId":9812,"briefTitle":9813,"status":161,"phases":9814,"primaryCompletion":9815,"completion":9815,"start":4869,"enrollment":637,"conditions":9816,"interventions":9818},"NCT03630523","Response of Immune System to Flu Vaccination in PHTS",[89],"2019-01",[9817],"PTEN Hamartoma Tumor Syndrome",[9797],{"intervention":9820,"totalTrials":132,"cells":9821},"Optimal Medical Care",{"EARLY_PHASE1":9822,"PHASE1":9824,"PHASE2":9826,"PHASE3":9828,"PHASE4":9830,"NA":9832},{"trials":9823,"activeCount":97},[],{"trials":9825,"activeCount":97},[],{"trials":9827,"activeCount":97},[],{"trials":9829,"activeCount":97},[],{"trials":9831,"activeCount":97},[],{"trials":9833,"activeCount":97},[9834],{"nctId":9835,"briefTitle":9836,"status":103,"phases":9837,"primaryCompletion":2806,"completion":2806,"start":3893,"enrollment":9838,"conditions":9839,"interventions":9840},"NCT00928980","Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression",[89],317,[2134],[9820],{"intervention":9842,"totalTrials":132,"cells":9843},"atorvastatin 80 mg",{"EARLY_PHASE1":9844,"PHASE1":9846,"PHASE2":9848,"PHASE3":9850,"PHASE4":9852,"NA":9854},{"trials":9845,"activeCount":97},[],{"trials":9847,"activeCount":97},[],{"trials":9849,"activeCount":97},[],{"trials":9851,"activeCount":97},[],{"trials":9853,"activeCount":97},[],{"trials":9855,"activeCount":97},[9856],{"nctId":9857,"briefTitle":9858,"status":103,"phases":9859,"completion":2039,"start":9860,"enrollment":31,"conditions":9861,"interventions":9862},"NCT00497016","Does Statin Therapy Reduce Sympathoexcitation in Hypertension?",[89],"2007-05",[1364],[9842],{"intervention":9864,"totalTrials":132,"cells":9865},"Sp_6B",{"EARLY_PHASE1":9866,"PHASE1":9868,"PHASE2":9870,"PHASE3":9872,"PHASE4":9874,"NA":9876},{"trials":9867,"activeCount":97},[],{"trials":9869,"activeCount":97},[],{"trials":9871,"activeCount":97},[],{"trials":9873,"activeCount":97},[],{"trials":9875,"activeCount":97},[],{"trials":9877,"activeCount":97},[9878],{"nctId":9879,"briefTitle":9880,"status":103,"phases":9881,"primaryCompletion":9882,"completion":9882,"start":9883,"enrollment":165,"conditions":9884,"interventions":9886},"NCT05361499","A Controlled Human Pneumococcal Infection Model (PIM) Study",[89],"2023-02-16","2022-05-31",[9885],"Streptococcus Pneumoniae Infection",[9864,9887],"Amoxicillin 500 mg",{"intervention":9887,"totalTrials":132,"cells":9889},{"EARLY_PHASE1":9890,"PHASE1":9892,"PHASE2":9894,"PHASE3":9896,"PHASE4":9898,"NA":9900},{"trials":9891,"activeCount":97},[],{"trials":9893,"activeCount":97},[],{"trials":9895,"activeCount":97},[],{"trials":9897,"activeCount":97},[],{"trials":9899,"activeCount":97},[],{"trials":9901,"activeCount":97},[9902],{"nctId":9879,"briefTitle":9880,"status":103,"phases":9903,"primaryCompletion":9882,"completion":9882,"start":9883,"enrollment":165,"conditions":9904,"interventions":9905},[89],[9885],[9864,9887],{"intervention":9907,"totalTrials":132,"cells":9908},"BCG vaccine SSI",{"EARLY_PHASE1":9909,"PHASE1":9911,"PHASE2":9913,"PHASE3":9915,"PHASE4":9917,"NA":9919},{"trials":9910,"activeCount":97},[],{"trials":9912,"activeCount":97},[],{"trials":9914,"activeCount":97},[],{"trials":9916,"activeCount":97},[],{"trials":9918,"activeCount":97},[],{"trials":9920,"activeCount":97},[9921],{"nctId":9922,"briefTitle":9923,"status":103,"phases":9924,"primaryCompletion":1828,"completion":1655,"start":2696,"enrollment":21,"conditions":9925,"interventions":9926},"NCT02259608","γ-irradiated BCG to Train Innate Immunity",[89],[8182],[9907],{"intervention":9928,"totalTrials":132,"cells":9929},"Electromagnetic navigation",{"EARLY_PHASE1":9930,"PHASE1":9932,"PHASE2":9934,"PHASE3":9936,"PHASE4":9938,"NA":9940},{"trials":9931,"activeCount":97},[],{"trials":9933,"activeCount":97},[],{"trials":9935,"activeCount":97},[],{"trials":9937,"activeCount":97},[],{"trials":9939,"activeCount":97},[],{"trials":9941,"activeCount":97},[9942],{"nctId":9943,"briefTitle":9944,"status":103,"phases":9945,"primaryCompletion":8791,"completion":5115,"start":9946,"enrollment":1392,"conditions":9947,"interventions":9949},"NCT03355586","CT-Controlled Advanced Navigation Techniques for Transbronchial Pulmonary Lesion Access; Evaluation of Electromagnetic Navigation Based Diagnostic Yield",[],"2017-12-21",[9948],"Lung Cancer",[9928],{"intervention":9951,"totalTrials":132,"cells":9952},"5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin",{"EARLY_PHASE1":9953,"PHASE1":9955,"PHASE2":9957,"PHASE3":9959,"PHASE4":9961,"NA":9963},{"trials":9954,"activeCount":97},[],{"trials":9956,"activeCount":97},[],{"trials":9958,"activeCount":97},[],{"trials":9960,"activeCount":97},[],{"trials":9962,"activeCount":97},[],{"trials":9964,"activeCount":97},[9965],{"nctId":9966,"briefTitle":9967,"status":103,"phases":9968,"completion":3101,"start":9969,"enrollment":9970,"conditions":9971,"interventions":9974},"NCT00314990","VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis",[89],"1996-01",620,[9972,9973],"Deep-Vein Thrombosis","Pulmonary Embolism",[9951],{"intervention":9976,"totalTrials":132,"cells":9977},"Plenvu",{"EARLY_PHASE1":9978,"PHASE1":9980,"PHASE2":9982,"PHASE3":9984,"PHASE4":9986,"NA":9988},{"trials":9979,"activeCount":97},[],{"trials":9981,"activeCount":97},[],{"trials":9983,"activeCount":97},[],{"trials":9985,"activeCount":97},[],{"trials":9987,"activeCount":97},[],{"trials":9989,"activeCount":97},[9990],{"nctId":9991,"briefTitle":9992,"status":103,"phases":9993,"primaryCompletion":9994,"completion":9995,"start":9996,"enrollment":9997,"conditions":9998,"interventions":10000},"NCT05242562","Effect of Low-volume (1L) vs Intermediate-volume (2L) Bowel Preparation on Cost-effectiveness and Quality of Life",[89],"2023-02-27","2023-03-02","2022-05-16",509,[23,9999],"Colonic Polyp",[9976,10001],"Moviprep",{"intervention":10001,"totalTrials":132,"cells":10003},{"EARLY_PHASE1":10004,"PHASE1":10006,"PHASE2":10008,"PHASE3":10010,"PHASE4":10012,"NA":10014},{"trials":10005,"activeCount":97},[],{"trials":10007,"activeCount":97},[],{"trials":10009,"activeCount":97},[],{"trials":10011,"activeCount":97},[],{"trials":10013,"activeCount":97},[],{"trials":10015,"activeCount":97},[10016],{"nctId":9991,"briefTitle":9992,"status":103,"phases":10017,"primaryCompletion":9994,"completion":9995,"start":9996,"enrollment":9997,"conditions":10018,"interventions":10019},[89],[23,9999],[9976,10001],{"intervention":10021,"totalTrials":132,"cells":10022},"Exposure to 5 P. falciparum infected mosquitoes",{"EARLY_PHASE1":10023,"PHASE1":10025,"PHASE2":10027,"PHASE3":10029,"PHASE4":10031,"NA":10033},{"trials":10024,"activeCount":97},[],{"trials":10026,"activeCount":97},[],{"trials":10028,"activeCount":97},[],{"trials":10030,"activeCount":97},[],{"trials":10032,"activeCount":97},[],{"trials":10034,"activeCount":97},[10035],{"nctId":10036,"briefTitle":10037,"status":103,"phases":10038,"primaryCompletion":1787,"completion":1787,"start":1774,"enrollment":21,"conditions":10039,"interventions":10041},"NCT00757887","Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites",[89],[10040],"P. Falciparum Malaria",[10021],{"intervention":10043,"totalTrials":132,"cells":10044},"Enzalutamide, 160mg, 40 mg soft capsules, once daily",{"EARLY_PHASE1":10045,"PHASE1":10047,"PHASE2":10049,"PHASE3":10051,"PHASE4":10053,"NA":10055},{"trials":10046,"activeCount":97},[],{"trials":10048,"activeCount":97},[],{"trials":10050,"activeCount":97},[],{"trials":10052,"activeCount":97},[],{"trials":10054,"activeCount":97},[],{"trials":10056,"activeCount":97},[10057],{"nctId":10058,"briefTitle":10059,"status":103,"phases":10060,"primaryCompletion":10061,"completion":3563,"start":636,"enrollment":1392,"conditions":10062,"interventions":10064},"NCT02471469","Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response",[],"2019-02-13",[10063],"Metastatic Castration Resistant Prostate Cancer",[10043],{"intervention":10066,"totalTrials":132,"cells":10067},"Seasonal influenza vaccination",{"EARLY_PHASE1":10068,"PHASE1":10070,"PHASE2":10072,"PHASE3":10074,"PHASE4":10076,"NA":10078},{"trials":10069,"activeCount":97},[],{"trials":10071,"activeCount":97},[],{"trials":10073,"activeCount":97},[],{"trials":10075,"activeCount":97},[],{"trials":10077,"activeCount":97},[],{"trials":10079,"activeCount":97},[10080],{"nctId":10081,"briefTitle":10082,"status":103,"phases":10083,"primaryCompletion":1678,"completion":4765,"start":595,"enrollment":10084,"conditions":10085,"interventions":10087},"NCT01651754","Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome",[89],72,[10086,538],"Postcancer Fatigue",[10066],{"intervention":10089,"totalTrials":132,"cells":10090},"Sulphadoxine-pyrimethamine",{"EARLY_PHASE1":10091,"PHASE1":10093,"PHASE2":10095,"PHASE3":10097,"PHASE4":10099,"NA":10101},{"trials":10092,"activeCount":97},[],{"trials":10094,"activeCount":97},[],{"trials":10096,"activeCount":97},[],{"trials":10098,"activeCount":97},[],{"trials":10100,"activeCount":97},[],{"trials":10102,"activeCount":97},[10103],{"nctId":10104,"briefTitle":10105,"status":103,"phases":10106,"primaryCompletion":7310,"completion":7310,"start":1687,"enrollment":10107,"conditions":10108,"interventions":10109},"NCT00509015","Mass-Drug Administration to Reduce Malaria Transmission",[89],6000,[6838],[10089,10110,10111],"Artesunate","Primaquine-base",{"intervention":10110,"totalTrials":132,"cells":10113},{"EARLY_PHASE1":10114,"PHASE1":10116,"PHASE2":10118,"PHASE3":10120,"PHASE4":10122,"NA":10124},{"trials":10115,"activeCount":97},[],{"trials":10117,"activeCount":97},[],{"trials":10119,"activeCount":97},[],{"trials":10121,"activeCount":97},[],{"trials":10123,"activeCount":97},[],{"trials":10125,"activeCount":97},[10126],{"nctId":10104,"briefTitle":10105,"status":103,"phases":10127,"primaryCompletion":7310,"completion":7310,"start":1687,"enrollment":10107,"conditions":10128,"interventions":10129},[89],[6838],[10089,10110,10111],{"intervention":10111,"totalTrials":132,"cells":10131},{"EARLY_PHASE1":10132,"PHASE1":10134,"PHASE2":10136,"PHASE3":10138,"PHASE4":10140,"NA":10142},{"trials":10133,"activeCount":97},[],{"trials":10135,"activeCount":97},[],{"trials":10137,"activeCount":97},[],{"trials":10139,"activeCount":97},[],{"trials":10141,"activeCount":97},[],{"trials":10143,"activeCount":97},[10144],{"nctId":10104,"briefTitle":10105,"status":103,"phases":10145,"primaryCompletion":7310,"completion":7310,"start":1687,"enrollment":10107,"conditions":10146,"interventions":10147},[89],[6838],[10089,10110,10111],{"intervention":10149,"totalTrials":132,"cells":10150},"Rosiglitazone versus placebo",{"EARLY_PHASE1":10151,"PHASE1":10153,"PHASE2":10155,"PHASE3":10157,"PHASE4":10159,"NA":10161},{"trials":10152,"activeCount":97},[],{"trials":10154,"activeCount":97},[],{"trials":10156,"activeCount":97},[],{"trials":10158,"activeCount":97},[],{"trials":10160,"activeCount":97},[],{"trials":10162,"activeCount":97},[10163],{"nctId":10164,"briefTitle":10165,"status":103,"phases":10166,"primaryCompletion":1925,"completion":10167,"start":4511,"enrollment":31,"conditions":10168,"interventions":10169},"NCT00285805","The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride",[89],"2006-11",[515],[10149,10170,10171],"response (sodium excretion) to amiloride","response (sodium excretion) to furosemide",{"intervention":10170,"totalTrials":132,"cells":10173},{"EARLY_PHASE1":10174,"PHASE1":10176,"PHASE2":10178,"PHASE3":10180,"PHASE4":10182,"NA":10184},{"trials":10175,"activeCount":97},[],{"trials":10177,"activeCount":97},[],{"trials":10179,"activeCount":97},[],{"trials":10181,"activeCount":97},[],{"trials":10183,"activeCount":97},[],{"trials":10185,"activeCount":97},[10186],{"nctId":10164,"briefTitle":10165,"status":103,"phases":10187,"primaryCompletion":1925,"completion":10167,"start":4511,"enrollment":31,"conditions":10188,"interventions":10189},[89],[515],[10149,10170,10171],{"intervention":10171,"totalTrials":132,"cells":10191},{"EARLY_PHASE1":10192,"PHASE1":10194,"PHASE2":10196,"PHASE3":10198,"PHASE4":10200,"NA":10202},{"trials":10193,"activeCount":97},[],{"trials":10195,"activeCount":97},[],{"trials":10197,"activeCount":97},[],{"trials":10199,"activeCount":97},[],{"trials":10201,"activeCount":97},[],{"trials":10203,"activeCount":97},[10204],{"nctId":10164,"briefTitle":10165,"status":103,"phases":10205,"primaryCompletion":1925,"completion":10167,"start":4511,"enrollment":31,"conditions":10206,"interventions":10207},[89],[515],[10149,10170,10171],{"intervention":10209,"totalTrials":132,"cells":10210},"WES",{"EARLY_PHASE1":10211,"PHASE1":10213,"PHASE2":10215,"PHASE3":10217,"PHASE4":10219,"NA":10221},{"trials":10212,"activeCount":97},[],{"trials":10214,"activeCount":97},[],{"trials":10216,"activeCount":97},[],{"trials":10218,"activeCount":97},[],{"trials":10220,"activeCount":97},[],{"trials":10222,"activeCount":97},[10223],{"nctId":10224,"briefTitle":10225,"status":161,"phases":10226,"primaryCompletion":7932,"completion":5922,"start":10227,"enrollment":10228,"conditions":10229,"interventions":10231},"NCT03347591","Rare Bleeding Disorders in the Netherlands",[],"2017-11-07",300,[10230],"Rare Bleeding Disorders",[10209],{"intervention":1368,"totalTrials":132,"cells":10233},{"EARLY_PHASE1":10234,"PHASE1":10236,"PHASE2":10238,"PHASE3":10240,"PHASE4":10242,"NA":10244},{"trials":10235,"activeCount":97},[],{"trials":10237,"activeCount":97},[],{"trials":10239,"activeCount":97},[],{"trials":10241,"activeCount":97},[],{"trials":10243,"activeCount":97},[],{"trials":10245,"activeCount":97},[10246],{"nctId":1356,"briefTitle":1357,"status":103,"phases":10247,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":10248,"interventions":10249},[89],[1364,20,1365],[1367,1368,1332],{"intervention":10251,"totalTrials":132,"cells":10252},"GM-CSF",{"EARLY_PHASE1":10253,"PHASE1":10255,"PHASE2":10257,"PHASE3":10259,"PHASE4":10261,"NA":10263},{"trials":10254,"activeCount":97},[],{"trials":10256,"activeCount":97},[],{"trials":10258,"activeCount":97},[],{"trials":10260,"activeCount":97},[],{"trials":10262,"activeCount":97},[],{"trials":10264,"activeCount":97},[10265],{"nctId":10266,"briefTitle":10267,"status":103,"phases":10268,"primaryCompletion":1360,"completion":1360,"start":2065,"enrollment":18,"conditions":10269,"interventions":10270},"NCT01374711","The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia",[89],[17,753,8229,33],[10251,10271],"IFN-Y",{"intervention":10271,"totalTrials":132,"cells":10273},{"EARLY_PHASE1":10274,"PHASE1":10276,"PHASE2":10278,"PHASE3":10280,"PHASE4":10282,"NA":10284},{"trials":10275,"activeCount":97},[],{"trials":10277,"activeCount":97},[],{"trials":10279,"activeCount":97},[],{"trials":10281,"activeCount":97},[],{"trials":10283,"activeCount":97},[],{"trials":10285,"activeCount":97},[10286],{"nctId":10266,"briefTitle":10267,"status":103,"phases":10287,"primaryCompletion":1360,"completion":1360,"start":2065,"enrollment":18,"conditions":10288,"interventions":10289},[89],[17,753,8229,33],[10251,10271],{"intervention":10291,"totalTrials":132,"cells":10292},"Clearfil Protect Bond",{"EARLY_PHASE1":10293,"PHASE1":10295,"PHASE2":10297,"PHASE3":10299,"PHASE4":10301,"NA":10303},{"trials":10294,"activeCount":97},[],{"trials":10296,"activeCount":97},[],{"trials":10298,"activeCount":97},[],{"trials":10300,"activeCount":97},[],{"trials":10302,"activeCount":97},[],{"trials":10304,"activeCount":97},[10305],{"nctId":10306,"briefTitle":10307,"status":103,"phases":10308,"primaryCompletion":10309,"completion":10309,"start":10310,"enrollment":10311,"conditions":10312,"interventions":10314},"NCT05118100","Effectiveness of Adhesive Containing MDPB",[],"2021-06-30","2015-01-01",5102,[10313],"Secondary Caries",[10291,10315],"Clearfil SE Bond",{"intervention":10315,"totalTrials":132,"cells":10317},{"EARLY_PHASE1":10318,"PHASE1":10320,"PHASE2":10322,"PHASE3":10324,"PHASE4":10326,"NA":10328},{"trials":10319,"activeCount":97},[],{"trials":10321,"activeCount":97},[],{"trials":10323,"activeCount":97},[],{"trials":10325,"activeCount":97},[],{"trials":10327,"activeCount":97},[],{"trials":10329,"activeCount":97},[10330],{"nctId":10306,"briefTitle":10307,"status":103,"phases":10331,"primaryCompletion":10309,"completion":10309,"start":10310,"enrollment":10311,"conditions":10332,"interventions":10333},[],[10313],[10291,10315],{"intervention":10335,"totalTrials":132,"cells":10336},"111In-DTPA-exendin-4",{"EARLY_PHASE1":10337,"PHASE1":10339,"PHASE2":10341,"PHASE3":10343,"PHASE4":10345,"NA":10347},{"trials":10338,"activeCount":97},[],{"trials":10340,"activeCount":97},[],{"trials":10342,"activeCount":97},[],{"trials":10344,"activeCount":97},[],{"trials":10346,"activeCount":97},[],{"trials":10348,"activeCount":97},[10349],{"nctId":10350,"briefTitle":10351,"status":161,"phases":10352,"primaryCompletion":5947,"completion":10353,"start":5115,"enrollment":4726,"conditions":10354,"interventions":10355},"NCT04733508","Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes",[89],"2022-12-01",[1722,514],[10335,10356],"IRDye800CW-exendin-4",{"intervention":10356,"totalTrials":132,"cells":10358},{"EARLY_PHASE1":10359,"PHASE1":10361,"PHASE2":10363,"PHASE3":10365,"PHASE4":10367,"NA":10369},{"trials":10360,"activeCount":97},[],{"trials":10362,"activeCount":97},[],{"trials":10364,"activeCount":97},[],{"trials":10366,"activeCount":97},[],{"trials":10368,"activeCount":97},[],{"trials":10370,"activeCount":97},[10371],{"nctId":10350,"briefTitle":10351,"status":161,"phases":10372,"primaryCompletion":5947,"completion":10353,"start":5115,"enrollment":4726,"conditions":10373,"interventions":10374},[89],[1722,514],[10335,10356],{"intervention":10376,"totalTrials":132,"cells":10377},"Flucloxacillin",{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10384,"PHASE4":10386,"NA":10388},{"trials":10379,"activeCount":97},[],{"trials":10381,"activeCount":97},[],{"trials":10383,"activeCount":97},[],{"trials":10385,"activeCount":97},[],{"trials":10387,"activeCount":97},[],{"trials":10389,"activeCount":97},[10390],{"nctId":10391,"briefTitle":10392,"status":103,"phases":10393,"primaryCompletion":10394,"completion":2400,"start":10395,"enrollment":637,"conditions":10396,"interventions":10397},"NCT02993575","Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients",[],"2018-03-01","2017-06-01",[473],[10376],{"intervention":10399,"totalTrials":132,"cells":10400},"Exposure to Plasmodium falciparum infected mosquitoes",{"EARLY_PHASE1":10401,"PHASE1":10403,"PHASE2":10405,"PHASE3":10407,"PHASE4":10409,"NA":10411},{"trials":10402,"activeCount":97},[],{"trials":10404,"activeCount":97},[],{"trials":10406,"activeCount":97},[],{"trials":10408,"activeCount":97},[],{"trials":10410,"activeCount":97},[],{"trials":10412,"activeCount":97},[10413],{"nctId":10414,"briefTitle":10415,"status":103,"phases":10416,"primaryCompletion":5443,"completion":5443,"start":2073,"enrollment":21,"conditions":10417,"interventions":10418},"NCT01002833","Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection",[89],[5688,3313],[10399],{"intervention":8342,"totalTrials":132,"cells":10420},{"EARLY_PHASE1":10421,"PHASE1":10423,"PHASE2":10425,"PHASE3":10427,"PHASE4":10429,"NA":10431},{"trials":10422,"activeCount":97},[],{"trials":10424,"activeCount":97},[],{"trials":10426,"activeCount":97},[],{"trials":10428,"activeCount":97},[],{"trials":10430,"activeCount":97},[],{"trials":10432,"activeCount":97},[10433],{"nctId":8334,"briefTitle":8335,"status":103,"phases":10434,"primaryCompletion":2315,"completion":552,"start":578,"enrollment":637,"conditions":10435,"interventions":10436},[89],[8338],[8340,8341,8342,8312],{"intervention":10438,"totalTrials":132,"cells":10439},"statin treatment",{"EARLY_PHASE1":10440,"PHASE1":10442,"PHASE2":10444,"PHASE3":10446,"PHASE4":10448,"NA":10450},{"trials":10441,"activeCount":97},[],{"trials":10443,"activeCount":97},[],{"trials":10445,"activeCount":97},[],{"trials":10447,"activeCount":97},[],{"trials":10449,"activeCount":97},[],{"trials":10451,"activeCount":97},[10452],{"nctId":10453,"briefTitle":10454,"status":103,"phases":10455,"primaryCompletion":9097,"completion":1473,"start":1840,"enrollment":7688,"conditions":10456,"interventions":10457},"NCT03354156","The Effect of Statin Treatment on Trained Innate Immunity",[],[8033],[10438],{"intervention":10459,"totalTrials":132,"cells":10460},"Piperacillin\u002Ftazobactam",{"EARLY_PHASE1":10461,"PHASE1":10463,"PHASE2":10465,"PHASE3":10467,"PHASE4":10469,"NA":10471},{"trials":10462,"activeCount":97},[],{"trials":10464,"activeCount":97},[],{"trials":10466,"activeCount":97},[],{"trials":10468,"activeCount":97},[],{"trials":10470,"activeCount":97},[],{"trials":10472,"activeCount":97},[10473],{"nctId":10474,"briefTitle":10475,"status":103,"phases":10476,"primaryCompletion":3564,"completion":10477,"start":2097,"enrollment":1392,"conditions":10478,"interventions":10479},"NCT03738683","Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients",[],"2019-10-01",[473],[10459],{"intervention":8924,"totalTrials":132,"cells":10481},{"EARLY_PHASE1":10482,"PHASE1":10484,"PHASE2":10486,"PHASE3":10488,"PHASE4":10490,"NA":10492},{"trials":10483,"activeCount":97},[],{"trials":10485,"activeCount":97},[],{"trials":10487,"activeCount":97},[],{"trials":10489,"activeCount":97},[],{"trials":10491,"activeCount":97},[],{"trials":10493,"activeCount":97},[10494],{"nctId":8917,"briefTitle":8918,"status":103,"phases":10495,"completion":1926,"start":8920,"enrollment":165,"conditions":10496,"interventions":10497},[],[8922,6017],[8924,8925,8140],{"intervention":8925,"totalTrials":132,"cells":10499},{"EARLY_PHASE1":10500,"PHASE1":10502,"PHASE2":10504,"PHASE3":10506,"PHASE4":10508,"NA":10510},{"trials":10501,"activeCount":97},[],{"trials":10503,"activeCount":97},[],{"trials":10505,"activeCount":97},[],{"trials":10507,"activeCount":97},[],{"trials":10509,"activeCount":97},[],{"trials":10511,"activeCount":97},[10512],{"nctId":8917,"briefTitle":8918,"status":103,"phases":10513,"completion":1926,"start":8920,"enrollment":165,"conditions":10514,"interventions":10515},[],[8922,6017],[8924,8925,8140],{"intervention":10517,"totalTrials":132,"cells":10518},"daily interruption of sedatives",{"EARLY_PHASE1":10519,"PHASE1":10521,"PHASE2":10523,"PHASE3":10525,"PHASE4":10527,"NA":10529},{"trials":10520,"activeCount":97},[],{"trials":10522,"activeCount":97},[],{"trials":10524,"activeCount":97},[],{"trials":10526,"activeCount":97},[],{"trials":10528,"activeCount":97},[],{"trials":10530,"activeCount":97},[10531],{"nctId":10532,"briefTitle":10533,"status":103,"phases":10534,"primaryCompletion":4571,"completion":8099,"start":5990,"enrollment":637,"conditions":10535,"interventions":10537},"NCT00441506","Effects of Daily Interruption of Sedatives in Critically Ill Children",[89],[10536],"Critical Illness",[10517],{"intervention":1410,"totalTrials":132,"cells":10539},{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10546,"PHASE4":10548,"NA":10550},{"trials":10541,"activeCount":97},[],{"trials":10543,"activeCount":97},[],{"trials":10545,"activeCount":97},[],{"trials":10547,"activeCount":97},[],{"trials":10549,"activeCount":97},[],{"trials":10551,"activeCount":97},[10552],{"nctId":1402,"briefTitle":1403,"status":103,"phases":10553,"primaryCompletion":1405,"completion":106,"start":1406,"enrollment":637,"conditions":10554,"interventions":10555},[89],[1408],[39,1410],{"intervention":9039,"totalTrials":132,"cells":10557},{"EARLY_PHASE1":10558,"PHASE1":10560,"PHASE2":10562,"PHASE3":10564,"PHASE4":10566,"NA":10568},{"trials":10559,"activeCount":97},[],{"trials":10561,"activeCount":97},[],{"trials":10563,"activeCount":97},[],{"trials":10565,"activeCount":97},[],{"trials":10567,"activeCount":97},[],{"trials":10569,"activeCount":97},[10570],{"nctId":9030,"briefTitle":9031,"status":103,"phases":10571,"primaryCompletion":9033,"completion":9033,"start":9034,"enrollment":9035,"conditions":10572,"interventions":10573},[89],[9037],[9039,9040],{"intervention":10575,"totalTrials":132,"cells":10576},"Artemether-Lumefantrine",{"EARLY_PHASE1":10577,"PHASE1":10579,"PHASE2":10581,"PHASE3":10583,"PHASE4":10585,"NA":10587},{"trials":10578,"activeCount":97},[],{"trials":10580,"activeCount":97},[],{"trials":10582,"activeCount":97},[],{"trials":10584,"activeCount":97},[],{"trials":10586,"activeCount":97},[],{"trials":10588,"activeCount":97},[10589],{"nctId":10590,"briefTitle":10591,"status":103,"phases":10592,"primaryCompletion":5089,"completion":5089,"start":4510,"enrollment":10593,"conditions":10594,"interventions":10596},"NCT00868465","Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)",[89],600,[10595],"Uncomplicated Malaria",[10575,10597],"Dihydroartemisinin-piperaquine",{"intervention":10597,"totalTrials":132,"cells":10599},{"EARLY_PHASE1":10600,"PHASE1":10602,"PHASE2":10604,"PHASE3":10606,"PHASE4":10608,"NA":10610},{"trials":10601,"activeCount":97},[],{"trials":10603,"activeCount":97},[],{"trials":10605,"activeCount":97},[],{"trials":10607,"activeCount":97},[],{"trials":10609,"activeCount":97},[],{"trials":10611,"activeCount":97},[10612],{"nctId":10590,"briefTitle":10591,"status":103,"phases":10613,"primaryCompletion":5089,"completion":5089,"start":4510,"enrollment":10593,"conditions":10614,"interventions":10615},[89],[10595],[10575,10597],{"intervention":9065,"totalTrials":132,"cells":10617},{"EARLY_PHASE1":10618,"PHASE1":10620,"PHASE2":10622,"PHASE3":10624,"PHASE4":10626,"NA":10628},{"trials":10619,"activeCount":97},[],{"trials":10621,"activeCount":97},[],{"trials":10623,"activeCount":97},[],{"trials":10625,"activeCount":97},[],{"trials":10627,"activeCount":97},[],{"trials":10629,"activeCount":97},[10630],{"nctId":9060,"briefTitle":9061,"status":103,"phases":10631,"primaryCompletion":3244,"completion":6790,"start":4020,"enrollment":165,"conditions":10632,"interventions":10633},[89],[17,753,8229],[8184,9065],{"intervention":9091,"totalTrials":132,"cells":10635},{"EARLY_PHASE1":10636,"PHASE1":10638,"PHASE2":10640,"PHASE3":10642,"PHASE4":10644,"NA":10646},{"trials":10637,"activeCount":97},[],{"trials":10639,"activeCount":97},[],{"trials":10641,"activeCount":97},[],{"trials":10643,"activeCount":97},[],{"trials":10645,"activeCount":97},[],{"trials":10647,"activeCount":97},[10648],{"nctId":9082,"briefTitle":9083,"status":161,"phases":10649,"primaryCompletion":9085,"completion":9086,"start":9087,"enrollment":1102,"conditions":10650,"interventions":10651},[89],[9089,6700],[9067,9091],{"intervention":9101,"totalTrials":132,"cells":10653},{"EARLY_PHASE1":10654,"PHASE1":10656,"PHASE2":10658,"PHASE3":10660,"PHASE4":10662,"NA":10664},{"trials":10655,"activeCount":97},[],{"trials":10657,"activeCount":97},[],{"trials":10659,"activeCount":97},[],{"trials":10661,"activeCount":97},[],{"trials":10663,"activeCount":97},[],{"trials":10665,"activeCount":97},[10666],{"nctId":9093,"briefTitle":9094,"status":103,"phases":10667,"primaryCompletion":6674,"completion":9096,"start":9097,"enrollment":1298,"conditions":10668,"interventions":10669},[89],[9099],[9101,9067],{"intervention":8196,"totalTrials":132,"cells":10671},{"EARLY_PHASE1":10672,"PHASE1":10674,"PHASE2":10676,"PHASE3":10678,"PHASE4":10680,"NA":10682},{"trials":10673,"activeCount":97},[],{"trials":10675,"activeCount":97},[],{"trials":10677,"activeCount":97},[],{"trials":10679,"activeCount":97},[],{"trials":10681,"activeCount":97},[],{"trials":10683,"activeCount":97},[10684],{"nctId":8190,"briefTitle":8191,"status":103,"phases":10685,"primaryCompletion":5089,"completion":595,"start":3039,"enrollment":637,"conditions":10686,"interventions":10687},[89],[8194,4448],[8196,8197,7336],{"intervention":8197,"totalTrials":132,"cells":10689},{"EARLY_PHASE1":10690,"PHASE1":10692,"PHASE2":10694,"PHASE3":10696,"PHASE4":10698,"NA":10700},{"trials":10691,"activeCount":97},[],{"trials":10693,"activeCount":97},[],{"trials":10695,"activeCount":97},[],{"trials":10697,"activeCount":97},[],{"trials":10699,"activeCount":97},[],{"trials":10701,"activeCount":97},[10702],{"nctId":8190,"briefTitle":8191,"status":103,"phases":10703,"primaryCompletion":5089,"completion":595,"start":3039,"enrollment":637,"conditions":10704,"interventions":10705},[89],[8194,4448],[8196,8197,7336],{"intervention":8874,"totalTrials":132,"cells":10707},{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10712,"PHASE3":10714,"PHASE4":10716,"NA":10718},{"trials":10709,"activeCount":97},[],{"trials":10711,"activeCount":97},[],{"trials":10713,"activeCount":97},[],{"trials":10715,"activeCount":97},[],{"trials":10717,"activeCount":97},[],{"trials":10719,"activeCount":97},[10720],{"nctId":8864,"briefTitle":8865,"status":103,"phases":10721,"primaryCompletion":8867,"completion":8868,"start":8869,"enrollment":1362,"conditions":10722,"interventions":10723},[89],[4925,8871,8253,8872],[5772,5772,8874,8875],{"intervention":8875,"totalTrials":132,"cells":10725},{"EARLY_PHASE1":10726,"PHASE1":10728,"PHASE2":10730,"PHASE3":10732,"PHASE4":10734,"NA":10736},{"trials":10727,"activeCount":97},[],{"trials":10729,"activeCount":97},[],{"trials":10731,"activeCount":97},[],{"trials":10733,"activeCount":97},[],{"trials":10735,"activeCount":97},[],{"trials":10737,"activeCount":97},[10738],{"nctId":8864,"briefTitle":8865,"status":103,"phases":10739,"primaryCompletion":8867,"completion":8868,"start":8869,"enrollment":1362,"conditions":10740,"interventions":10741},[89],[4925,8871,8253,8872],[5772,5772,8874,8875],{"intervention":10743,"totalTrials":132,"cells":10744},"ICG",{"EARLY_PHASE1":10745,"PHASE1":10747,"PHASE2":10749,"PHASE3":10751,"PHASE4":10753,"NA":10755},{"trials":10746,"activeCount":97},[],{"trials":10748,"activeCount":97},[],{"trials":10750,"activeCount":97},[],{"trials":10752,"activeCount":97},[],{"trials":10754,"activeCount":97},[],{"trials":10756,"activeCount":97},[10757],{"nctId":10758,"briefTitle":10759,"status":103,"phases":10760,"primaryCompletion":10761,"completion":10761,"start":10762,"enrollment":10084,"conditions":10763,"interventions":10765},"NCT05555199","Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC",[89],"2024-10-31","2022-10-03",[10764],"Early-stage Lung Cancer",[10743],{"intervention":10767,"totalTrials":132,"cells":10768},"caspofungin",{"EARLY_PHASE1":10769,"PHASE1":10771,"PHASE2":10773,"PHASE3":10775,"PHASE4":10777,"NA":10779},{"trials":10770,"activeCount":97},[],{"trials":10772,"activeCount":97},[],{"trials":10774,"activeCount":97},[],{"trials":10776,"activeCount":97},[],{"trials":10778,"activeCount":97},[],{"trials":10780,"activeCount":97},[10781],{"nctId":10782,"briefTitle":10783,"status":103,"phases":10784,"primaryCompletion":1349,"completion":2806,"start":2315,"enrollment":165,"conditions":10785,"interventions":10786},"NCT01533558","Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates",[],[8583],[10767],{"intervention":8973,"totalTrials":132,"cells":10788},{"EARLY_PHASE1":10789,"PHASE1":10791,"PHASE2":10793,"PHASE3":10795,"PHASE4":10797,"NA":10799},{"trials":10790,"activeCount":97},[],{"trials":10792,"activeCount":97},[],{"trials":10794,"activeCount":97},[],{"trials":10796,"activeCount":97},[],{"trials":10798,"activeCount":97},[],{"trials":10800,"activeCount":97},[10801],{"nctId":8967,"briefTitle":8968,"status":103,"phases":10802,"primaryCompletion":1734,"completion":4765,"start":6438,"enrollment":1150,"conditions":10803,"interventions":10804},[89],[8971],[3898,8973,8974],{"intervention":8974,"totalTrials":132,"cells":10806},{"EARLY_PHASE1":10807,"PHASE1":10809,"PHASE2":10811,"PHASE3":10813,"PHASE4":10815,"NA":10817},{"trials":10808,"activeCount":97},[],{"trials":10810,"activeCount":97},[],{"trials":10812,"activeCount":97},[],{"trials":10814,"activeCount":97},[],{"trials":10816,"activeCount":97},[],{"trials":10818,"activeCount":97},[10819],{"nctId":8967,"briefTitle":8968,"status":103,"phases":10820,"primaryCompletion":1734,"completion":4765,"start":6438,"enrollment":1150,"conditions":10821,"interventions":10822},[89],[8971],[3898,8973,8974],{"intervention":8838,"totalTrials":132,"cells":10824},{"EARLY_PHASE1":10825,"PHASE1":10827,"PHASE2":10829,"PHASE3":10831,"PHASE4":10833,"NA":10835},{"trials":10826,"activeCount":97},[],{"trials":10828,"activeCount":97},[],{"trials":10830,"activeCount":97},[],{"trials":10832,"activeCount":97},[],{"trials":10834,"activeCount":97},[],{"trials":10836,"activeCount":97},[10837],{"nctId":8832,"briefTitle":8833,"status":103,"phases":10838,"primaryCompletion":8835,"completion":8835,"start":8836,"enrollment":5663,"conditions":10839,"interventions":10840},[],[8838,8839,8840,8841,8842],[8838,5666,8844],{"intervention":8844,"totalTrials":132,"cells":10842},{"EARLY_PHASE1":10843,"PHASE1":10845,"PHASE2":10847,"PHASE3":10849,"PHASE4":10851,"NA":10853},{"trials":10844,"activeCount":97},[],{"trials":10846,"activeCount":97},[],{"trials":10848,"activeCount":97},[],{"trials":10850,"activeCount":97},[],{"trials":10852,"activeCount":97},[],{"trials":10854,"activeCount":97},[10855],{"nctId":8832,"briefTitle":8833,"status":103,"phases":10856,"primaryCompletion":8835,"completion":8835,"start":8836,"enrollment":5663,"conditions":10857,"interventions":10858},[],[8838,8839,8840,8841,8842],[8838,5666,8844],{"intervention":1449,"totalTrials":132,"cells":10860},{"EARLY_PHASE1":10861,"PHASE1":10863,"PHASE2":10865,"PHASE3":10867,"PHASE4":10869,"NA":10871},{"trials":10862,"activeCount":97},[],{"trials":10864,"activeCount":97},[],{"trials":10866,"activeCount":97},[],{"trials":10868,"activeCount":97},[],{"trials":10870,"activeCount":97},[],{"trials":10872,"activeCount":97},[10873],{"nctId":1443,"briefTitle":1444,"status":103,"phases":10874,"primaryCompletion":534,"completion":534,"start":636,"enrollment":1392,"conditions":10875,"interventions":10876},[89],[17],[1448,1449,1450],{"intervention":1450,"totalTrials":132,"cells":10878},{"EARLY_PHASE1":10879,"PHASE1":10881,"PHASE2":10883,"PHASE3":10885,"PHASE4":10887,"NA":10889},{"trials":10880,"activeCount":97},[],{"trials":10882,"activeCount":97},[],{"trials":10884,"activeCount":97},[],{"trials":10886,"activeCount":97},[],{"trials":10888,"activeCount":97},[],{"trials":10890,"activeCount":97},[10891],{"nctId":1443,"briefTitle":1444,"status":103,"phases":10892,"primaryCompletion":534,"completion":534,"start":636,"enrollment":1392,"conditions":10893,"interventions":10894},[89],[17],[1448,1449,1450],{"intervention":10896,"totalTrials":132,"cells":10897},"Augmented fluoroscopy",{"EARLY_PHASE1":10898,"PHASE1":10900,"PHASE2":10902,"PHASE3":10904,"PHASE4":10906,"NA":10908},{"trials":10899,"activeCount":97},[],{"trials":10901,"activeCount":97},[],{"trials":10903,"activeCount":97},[],{"trials":10905,"activeCount":97},[],{"trials":10907,"activeCount":97},[],{"trials":10909,"activeCount":97},[10910],{"nctId":10911,"briefTitle":10912,"status":103,"phases":10913,"primaryCompletion":8791,"completion":5115,"start":9946,"enrollment":10914,"conditions":10915,"interventions":10916},"NCT03274609","CT-controlled Advanced Navigation Techniques for Transbronchial Pulmonary Lesion Access; Evaluation of Augmented Fluoroscopy Bronchoscopic Navigation Based Diagnostic Yield",[],47,[9948],[10896],{"intervention":2448,"totalTrials":132,"cells":10918},{"EARLY_PHASE1":10919,"PHASE1":10921,"PHASE2":10923,"PHASE3":10925,"PHASE4":10927,"NA":10929},{"trials":10920,"activeCount":97},[],{"trials":10922,"activeCount":97},[],{"trials":10924,"activeCount":97},[],{"trials":10926,"activeCount":97},[],{"trials":10928,"activeCount":97},[],{"trials":10930,"activeCount":97},[10931],{"nctId":10932,"briefTitle":10933,"status":161,"phases":10934,"primaryCompletion":10935,"completion":10936,"start":10937,"enrollment":1128,"conditions":10938,"interventions":10941},"NCT03248349","Population Pharmacokinetics of Antibiotics in Critically Ill Children (POPSICLE)",[],"2020-05-01","2020-10-01","2017-05-24",[10536,10939,10940],"Infectious Disease","Children",[2448],{"intervention":10943,"totalTrials":132,"cells":10944},"Iohexol Inj 300 MG\u002FML",{"EARLY_PHASE1":10945,"PHASE1":10947,"PHASE2":10949,"PHASE3":10951,"PHASE4":10953,"NA":10955},{"trials":10946,"activeCount":97},[],{"trials":10948,"activeCount":97},[],{"trials":10950,"activeCount":97},[],{"trials":10952,"activeCount":97},[],{"trials":10954,"activeCount":97},[],{"trials":10956,"activeCount":97},[10957],{"nctId":10958,"briefTitle":10959,"status":161,"phases":10960,"primaryCompletion":6512,"completion":6512,"start":10961,"enrollment":10962,"conditions":10963,"interventions":10966},"NCT03946345","Iohexol for Measuring Renal Function",[],"2019-05-01",105,[10964,10965],"Acute Kidney Injury","Critically Ill Children",[10943],{"intervention":10968,"totalTrials":132,"cells":10969},"Radium-223",{"EARLY_PHASE1":10970,"PHASE1":10972,"PHASE2":10974,"PHASE3":10976,"PHASE4":10978,"NA":10980},{"trials":10971,"activeCount":97},[],{"trials":10973,"activeCount":97},[],{"trials":10975,"activeCount":97},[],{"trials":10977,"activeCount":97},[],{"trials":10979,"activeCount":97},[],{"trials":10981,"activeCount":97},[10982],{"nctId":10983,"briefTitle":10984,"status":103,"phases":10985,"primaryCompletion":10986,"completion":10986,"start":10987,"enrollment":10988,"conditions":10989,"interventions":10992},"NCT04995614","Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223",[],"2020-06-29","2017-04-01",122,[10990,10991],"Castrate Resistant Prostate Cancer","Bone Metastases",[10968],{"intervention":10994,"totalTrials":132,"cells":10995},"venlafaxine",{"EARLY_PHASE1":10996,"PHASE1":10998,"PHASE2":11000,"PHASE3":11002,"PHASE4":11004,"NA":11006},{"trials":10997,"activeCount":97},[],{"trials":10999,"activeCount":97},[],{"trials":11001,"activeCount":97},[],{"trials":11003,"activeCount":97},[],{"trials":11005,"activeCount":97},[],{"trials":11007,"activeCount":97},[11008],{"nctId":11009,"briefTitle":11010,"status":103,"phases":11011,"completion":6438,"start":7072,"enrollment":10228,"conditions":11012,"interventions":11013},"NCT00115362","Serotonin Effect in Functional Dyspepsia",[89],[9638],[10994],{"intervention":616,"totalTrials":132,"cells":11015},{"EARLY_PHASE1":11016,"PHASE1":11018,"PHASE2":11020,"PHASE3":11022,"PHASE4":11024,"NA":11026},{"trials":11017,"activeCount":97},[],{"trials":11019,"activeCount":97},[],{"trials":11021,"activeCount":97},[],{"trials":11023,"activeCount":97},[],{"trials":11025,"activeCount":97},[],{"trials":11027,"activeCount":97},[11028],{"nctId":605,"briefTitle":606,"status":607,"phases":11029,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11030,"interventions":11031},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":617,"totalTrials":132,"cells":11033},{"EARLY_PHASE1":11034,"PHASE1":11036,"PHASE2":11038,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11035,"activeCount":97},[],{"trials":11037,"activeCount":97},[],{"trials":11039,"activeCount":97},[],{"trials":11041,"activeCount":97},[],{"trials":11043,"activeCount":97},[],{"trials":11045,"activeCount":97},[11046],{"nctId":605,"briefTitle":606,"status":607,"phases":11047,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11048,"interventions":11049},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":618,"totalTrials":132,"cells":11051},{"EARLY_PHASE1":11052,"PHASE1":11054,"PHASE2":11056,"PHASE3":11058,"PHASE4":11060,"NA":11062},{"trials":11053,"activeCount":97},[],{"trials":11055,"activeCount":97},[],{"trials":11057,"activeCount":97},[],{"trials":11059,"activeCount":97},[],{"trials":11061,"activeCount":97},[],{"trials":11063,"activeCount":97},[11064],{"nctId":605,"briefTitle":606,"status":607,"phases":11065,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11066,"interventions":11067},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":619,"totalTrials":132,"cells":11069},{"EARLY_PHASE1":11070,"PHASE1":11072,"PHASE2":11074,"PHASE3":11076,"PHASE4":11078,"NA":11080},{"trials":11071,"activeCount":97},[],{"trials":11073,"activeCount":97},[],{"trials":11075,"activeCount":97},[],{"trials":11077,"activeCount":97},[],{"trials":11079,"activeCount":97},[],{"trials":11081,"activeCount":97},[11082],{"nctId":605,"briefTitle":606,"status":607,"phases":11083,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11084,"interventions":11085},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":621,"totalTrials":132,"cells":11087},{"EARLY_PHASE1":11088,"PHASE1":11090,"PHASE2":11092,"PHASE3":11094,"PHASE4":11096,"NA":11098},{"trials":11089,"activeCount":97},[],{"trials":11091,"activeCount":97},[],{"trials":11093,"activeCount":97},[],{"trials":11095,"activeCount":97},[],{"trials":11097,"activeCount":97},[],{"trials":11099,"activeCount":97},[11100],{"nctId":605,"briefTitle":606,"status":607,"phases":11101,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11102,"interventions":11103},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":622,"totalTrials":132,"cells":11105},{"EARLY_PHASE1":11106,"PHASE1":11108,"PHASE2":11110,"PHASE3":11112,"PHASE4":11114,"NA":11116},{"trials":11107,"activeCount":97},[],{"trials":11109,"activeCount":97},[],{"trials":11111,"activeCount":97},[],{"trials":11113,"activeCount":97},[],{"trials":11115,"activeCount":97},[],{"trials":11117,"activeCount":97},[11118],{"nctId":605,"briefTitle":606,"status":607,"phases":11119,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11120,"interventions":11121},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":623,"totalTrials":132,"cells":11123},{"EARLY_PHASE1":11124,"PHASE1":11126,"PHASE2":11128,"PHASE3":11130,"PHASE4":11132,"NA":11134},{"trials":11125,"activeCount":97},[],{"trials":11127,"activeCount":97},[],{"trials":11129,"activeCount":97},[],{"trials":11131,"activeCount":97},[],{"trials":11133,"activeCount":97},[],{"trials":11135,"activeCount":97},[11136],{"nctId":605,"briefTitle":606,"status":607,"phases":11137,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11138,"interventions":11139},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":624,"totalTrials":132,"cells":11141},{"EARLY_PHASE1":11142,"PHASE1":11144,"PHASE2":11146,"PHASE3":11148,"PHASE4":11150,"NA":11152},{"trials":11143,"activeCount":97},[],{"trials":11145,"activeCount":97},[],{"trials":11147,"activeCount":97},[],{"trials":11149,"activeCount":97},[],{"trials":11151,"activeCount":97},[],{"trials":11153,"activeCount":97},[11154],{"nctId":605,"briefTitle":606,"status":607,"phases":11155,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11156,"interventions":11157},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":625,"totalTrials":132,"cells":11159},{"EARLY_PHASE1":11160,"PHASE1":11162,"PHASE2":11164,"PHASE3":11166,"PHASE4":11168,"NA":11170},{"trials":11161,"activeCount":97},[],{"trials":11163,"activeCount":97},[],{"trials":11165,"activeCount":97},[],{"trials":11167,"activeCount":97},[],{"trials":11169,"activeCount":97},[],{"trials":11171,"activeCount":97},[11172],{"nctId":605,"briefTitle":606,"status":607,"phases":11173,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":11174,"interventions":11175},[89],[613,614],[394,616,617,618,619,620,621,622,623,624,625],{"intervention":11177,"totalTrials":132,"cells":11178},"Antihypertensive medication withdrawal",{"EARLY_PHASE1":11179,"PHASE1":11181,"PHASE2":11183,"PHASE3":11185,"PHASE4":11187,"NA":11189},{"trials":11180,"activeCount":97},[],{"trials":11182,"activeCount":97},[],{"trials":11184,"activeCount":97},[],{"trials":11186,"activeCount":97},[],{"trials":11188,"activeCount":97},[],{"trials":11190,"activeCount":97},[11191],{"nctId":11192,"briefTitle":11193,"status":161,"phases":11194,"primaryCompletion":11195,"completion":11195,"start":11196,"enrollment":8,"conditions":11197,"interventions":11199},"NCT06175663","Hyperintense: Midlife Hypertension and the Brain",[],"2023-12-31","2021-07-06",[1364,11198],"Small Vessel Cerebrovascular Disease",[11177],{"intervention":11201,"totalTrials":132,"cells":11202},"Intravenous infusion of Intralipid\u002Fheparin",{"EARLY_PHASE1":11203,"PHASE1":11205,"PHASE2":11207,"PHASE3":11209,"PHASE4":11211,"NA":11213},{"trials":11204,"activeCount":97},[],{"trials":11206,"activeCount":97},[],{"trials":11208,"activeCount":97},[],{"trials":11210,"activeCount":97},[],{"trials":11212,"activeCount":97},[],{"trials":11214,"activeCount":97},[11215],{"nctId":11216,"briefTitle":11217,"status":103,"phases":11218,"completion":11219,"start":1503,"enrollment":165,"conditions":11220,"interventions":11222},"NCT00184899","The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids",[89],"2006-08",[3822,11221],"Metabolic Syndrome X",[11201,11223],"Intravenous infusion of Glycerol\u002Fheparin",{"intervention":11223,"totalTrials":132,"cells":11225},{"EARLY_PHASE1":11226,"PHASE1":11228,"PHASE2":11230,"PHASE3":11232,"PHASE4":11234,"NA":11236},{"trials":11227,"activeCount":97},[],{"trials":11229,"activeCount":97},[],{"trials":11231,"activeCount":97},[],{"trials":11233,"activeCount":97},[],{"trials":11235,"activeCount":97},[],{"trials":11237,"activeCount":97},[11238],{"nctId":11216,"briefTitle":11217,"status":103,"phases":11239,"completion":11219,"start":1503,"enrollment":165,"conditions":11240,"interventions":11241},[89],[3822,11221],[11201,11223],{"intervention":11243,"totalTrials":132,"cells":11244},"Statin",{"EARLY_PHASE1":11245,"PHASE1":11247,"PHASE2":11249,"PHASE3":11251,"PHASE4":11253,"NA":11255},{"trials":11246,"activeCount":97},[],{"trials":11248,"activeCount":97},[],{"trials":11250,"activeCount":97},[],{"trials":11252,"activeCount":97},[],{"trials":11254,"activeCount":97},[],{"trials":11256,"activeCount":97},[11257],{"nctId":11258,"briefTitle":11259,"status":103,"phases":11260,"primaryCompletion":1473,"completion":10395,"start":3873,"enrollment":7688,"conditions":11261,"interventions":11262},"NCT02817230","Effect of Statins on Trained Immunity",[],[8033],[11243],{"intervention":11264,"totalTrials":132,"cells":11265},"liraglutide",{"EARLY_PHASE1":11266,"PHASE1":11268,"PHASE2":11270,"PHASE3":11272,"PHASE4":11274,"NA":11276},{"trials":11267,"activeCount":97},[],{"trials":11269,"activeCount":97},[],{"trials":11271,"activeCount":97},[],{"trials":11273,"activeCount":97},[],{"trials":11275,"activeCount":97},[],{"trials":11277,"activeCount":97},[11278],{"nctId":11279,"briefTitle":11280,"status":161,"phases":11281,"primaryCompletion":1391,"completion":1391,"start":7474,"enrollment":390,"conditions":11282,"interventions":11283},"NCT01392898","Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes",[89],[2067],[11264,11284],"Insulin",{"intervention":11284,"totalTrials":132,"cells":11286},{"EARLY_PHASE1":11287,"PHASE1":11289,"PHASE2":11291,"PHASE3":11293,"PHASE4":11295,"NA":11297},{"trials":11288,"activeCount":97},[],{"trials":11290,"activeCount":97},[],{"trials":11292,"activeCount":97},[],{"trials":11294,"activeCount":97},[],{"trials":11296,"activeCount":97},[],{"trials":11298,"activeCount":97},[11299],{"nctId":11279,"briefTitle":11280,"status":161,"phases":11300,"primaryCompletion":1391,"completion":1391,"start":7474,"enrollment":390,"conditions":11301,"interventions":11302},[89],[2067],[11264,11284],{"intervention":11304,"totalTrials":132,"cells":11305},"fluconazole",{"EARLY_PHASE1":11306,"PHASE1":11308,"PHASE2":11310,"PHASE3":11312,"PHASE4":11314,"NA":11316},{"trials":11307,"activeCount":97},[],{"trials":11309,"activeCount":97},[],{"trials":11311,"activeCount":97},[],{"trials":11313,"activeCount":97},[],{"trials":11315,"activeCount":97},[],{"trials":11317,"activeCount":97},[11318],{"nctId":11319,"briefTitle":11320,"status":103,"phases":11321,"primaryCompletion":635,"completion":635,"start":2206,"enrollment":165,"conditions":11322,"interventions":11323},"NCT02666716","Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients",[],[3820],[11304],{"intervention":8349,"totalTrials":132,"cells":11325},{"EARLY_PHASE1":11326,"PHASE1":11328,"PHASE2":11330,"PHASE3":11332,"PHASE4":11334,"NA":11336},{"trials":11327,"activeCount":97},[],{"trials":11329,"activeCount":97},[],{"trials":11331,"activeCount":97},[],{"trials":11333,"activeCount":97},[],{"trials":11335,"activeCount":97},[],{"trials":11337,"activeCount":97},[11338],{"nctId":8344,"briefTitle":8345,"status":103,"phases":11339,"primaryCompletion":4765,"completion":4765,"start":578,"enrollment":1034,"conditions":11340,"interventions":11341},[89],[8338],[8340,8341,8349,8350,8312],{"intervention":8350,"totalTrials":132,"cells":11343},{"EARLY_PHASE1":11344,"PHASE1":11346,"PHASE2":11348,"PHASE3":11350,"PHASE4":11352,"NA":11354},{"trials":11345,"activeCount":97},[],{"trials":11347,"activeCount":97},[],{"trials":11349,"activeCount":97},[],{"trials":11351,"activeCount":97},[],{"trials":11353,"activeCount":97},[],{"trials":11355,"activeCount":97},[11356],{"nctId":8344,"briefTitle":8345,"status":103,"phases":11357,"primaryCompletion":4765,"completion":4765,"start":578,"enrollment":1034,"conditions":11358,"interventions":11359},[89],[8338],[8340,8341,8349,8350,8312],{"intervention":11361,"totalTrials":132,"cells":11362},"Intra-arterial infusion of adenosine",{"EARLY_PHASE1":11363,"PHASE1":11365,"PHASE2":11367,"PHASE3":11369,"PHASE4":11371,"NA":11373},{"trials":11364,"activeCount":97},[],{"trials":11366,"activeCount":97},[],{"trials":11368,"activeCount":97},[],{"trials":11370,"activeCount":97},[],{"trials":11372,"activeCount":97},[],{"trials":11374,"activeCount":97},[11375],{"nctId":11376,"briefTitle":11377,"status":103,"phases":11378,"completion":4511,"start":11379,"enrollment":363,"conditions":11380,"interventions":11382},"NCT00253929","Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia",[89],"2005-11",[11381],"Blood Flow in Healthy Volunteers",[11361,11383,11384,11385],"intra-arterial infusion of caffeine","intra-arterial infusion of acetylcholine","intra-arterial infusion of sodium nitroprusside",{"intervention":11383,"totalTrials":132,"cells":11387},{"EARLY_PHASE1":11388,"PHASE1":11390,"PHASE2":11392,"PHASE3":11394,"PHASE4":11396,"NA":11398},{"trials":11389,"activeCount":97},[],{"trials":11391,"activeCount":97},[],{"trials":11393,"activeCount":97},[],{"trials":11395,"activeCount":97},[],{"trials":11397,"activeCount":97},[],{"trials":11399,"activeCount":97},[11400],{"nctId":11376,"briefTitle":11377,"status":103,"phases":11401,"completion":4511,"start":11379,"enrollment":363,"conditions":11402,"interventions":11403},[89],[11381],[11361,11383,11384,11385],{"intervention":11384,"totalTrials":132,"cells":11405},{"EARLY_PHASE1":11406,"PHASE1":11408,"PHASE2":11410,"PHASE3":11412,"PHASE4":11414,"NA":11416},{"trials":11407,"activeCount":97},[],{"trials":11409,"activeCount":97},[],{"trials":11411,"activeCount":97},[],{"trials":11413,"activeCount":97},[],{"trials":11415,"activeCount":97},[],{"trials":11417,"activeCount":97},[11418],{"nctId":11376,"briefTitle":11377,"status":103,"phases":11419,"completion":4511,"start":11379,"enrollment":363,"conditions":11420,"interventions":11421},[89],[11381],[11361,11383,11384,11385],{"intervention":11385,"totalTrials":132,"cells":11423},{"EARLY_PHASE1":11424,"PHASE1":11426,"PHASE2":11428,"PHASE3":11430,"PHASE4":11432,"NA":11434},{"trials":11425,"activeCount":97},[],{"trials":11427,"activeCount":97},[],{"trials":11429,"activeCount":97},[],{"trials":11431,"activeCount":97},[],{"trials":11433,"activeCount":97},[],{"trials":11435,"activeCount":97},[11436],{"nctId":11376,"briefTitle":11377,"status":103,"phases":11437,"completion":4511,"start":11379,"enrollment":363,"conditions":11438,"interventions":11439},[89],[11381],[11361,11383,11384,11385]]